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vWHAt is A Witness seminAr?
The Witness Seminar is a specialized form of oral history, where several 
individuals associated with a particular set of circumstances or events are invited 
to meet together to discuss, debate, and agree or disagree about their memories. 
The meeting is recorded, transcribed and edited for publication. 
This format was first devised and used by the Wellcome Trust’s History of 
Twentieth Century Medicine Group in 1993 to address issues associated with 
the discovery of monoclonal antibodies. We developed this approach after 
holding a conventional seminar, given by a medical historian, on the discovery 
of interferon.  Many members of the invited audience were scientists or 
others involved in that work, and the detailed and revealing discussion session 
afterwards alerted us to the importance of recording ‘communal’ eyewitness 
testimonies. We learned that the Institute for Contemporary British History 
held meetings to examine modern political, diplomatic and economic history, 
which they called Witness Seminars, and this seemed a suitable title for us to 
use also. 
The unexpected success of our first Witness Seminar, as assessed by the 
willingness of the participants to attend, speak frankly, agree and disagree, and 
also by many requests for its transcript, encouraged us to develop the Witness 
Seminar model into a full programme, and since then more than 50 meetings 
have been held and published on a wide array of biomedical topics.1 These 
seminars have proved an ideal way to bring together clinicians, scientists, and 
others interested in contemporary medical history to share their memories. We 
are not seeking a consensus, but are providing the opportunity to hear an array 
of voices, many little known, of individuals who were ‘there at the time’ and 
thus able to question, ratify or disagree with others’ accounts – a form of open 
peer-review. The material records of the meeting also create archival sources for 
present and future use.
The History of Twentieth Century Medicine Group became a part of the 
Wellcome Trust’s Centre for the History of Medicine at UCL in October 
2000 until September 2010. It has been part of the School of History, Queen 
Mary, University of London, since October 2010, as the History of Modern 
Biomedicine Research Group, which the Wellcome Trust funds principally 
1 See pages 203–208 for a full list of Witness Seminars held, details of the published volumes and other 
related publications.
vi
under a Strategic Award entitled ‘The Makers of Modern Biomedicine’. The 
Witness Seminar format continues to be a major part of that programme, 
although now the subjects are largely focused on areas of strategic importance 
to the Wellcome Trust, including the neurosciences, clinical genetics, and 
medical technology.2
Once an appropriate topic has been agreed, usually after discussion with 
a specialist adviser, suitable participants are identified and invited. As the 
organization of the seminar progresses and the participants’ list is compiled, a 
flexible outline plan for the meeting is devised, with assistance from the meeting’s 
designated chairman/moderator. Each participant is sent an attendance list and 
a copy of this programme before the meeting.  Seminars last for about four 
hours; occasionally full-day meetings have been held. After each meeting the raw 
transcript is sent to every participant, each of whom is asked to check his or her 
own contribution and to provide brief biographical details for an appendix. The 
editors incorporate participants’ minor corrections and turn the transcript into 
readable text, with footnotes, appendices and a bibliography. Extensive research 
and liaison with the participants is conducted to produce the final script, which 
is then sent to every contributor for approval and to assign copyright to the 
Wellcome Trust. Copies of the original, and edited, transcripts and additional 
correspondence generated by the editorial process are all deposited with the 
records of each meeting in the Wellcome Library, London (archival reference 
GC/253) and are available for study.
For all our volumes, we hope that, even if the precise details of the more 
technical sections are not clear to the non-specialist, the sense and significance 
of the events will be understandable to all readers. Our aim is that the volumes 
inform those with a general interest in the history of modern medicine and 
medical science; provide historians with new insights, fresh material for study, 
and further themes for research; and emphasize to the participants that their 
own working lives are of proper and necessary concern to historians.
2 See our Group’s website at http://www.history.qmul.ac.uk/research/modbiomed  (visited 13 August 
2013).
vii
AcknOWLeDgements
The topic of ‘Drugs affecting 5-HT systems’ was suggested as a Witness Seminar 
by Professor Paul Andrews and Professor Gareth Sanger and we are grateful for 
their assistance over several months in planning the meeting. Our thanks also go to 
Professor Rod Flower for his excellent chairing of the occasion, and to Dr Patrick 
Humphrey for providing images and documents to illustrate the volume.
As with all our meetings, we depend a great deal on Wellcome Trust staff to ensure 
their smooth running: the Audiovisual Department, Catering, Reception, Security 
and Wellcome Images. We are also grateful to Mr Akio Morishima for the design 
and production of this volume; the indexer Ms Liza Furnival; Mrs Lois Reynolds 
and Ms Fiona Plowman for proof reading; Mrs Deborah Gee for transcribing the 
seminar; Mr Adam Wilkinson for assisting in the organization of the meeting and 
also Ms Emma Jones and Mr Alan Yabsley for help with running the seminar. 
Finally, we thank the Wellcome Trust for supporting this programme. 
Tilli Tansey
Caroline Overy
School of History, Queen Mary, University of London

ix
iLLustrAtiOns AnD creDits*
figure 1 Professor Rod Flower and Professor Tilli Tansey 3
figure 2 Dr Mick Bakhle 6
figure 3 Professor David Wallis 9
figure 4 Dr Patrick Humphrey 14
figure 5 Professor David Clarke, Professor Daniel Hoyer, 
Professor Richard Green and Dr Tom Blackburn 16
figure 6 Professor Gareth Sanger 19
figure 7 Professor Merton Sandler and Professor Charles 
Marsden 21
figure 8 Dr Tom Blackburn 23
figure 9 Professor David Clarke 35
figure 10 Some members of the 5-HT meeting held on Heron 
Island, Australia, indicating the number of 5-HT 
receptor subtypes they believed existed. Photograph 
provided by Dr Patrick Humphrey 36
figure 11 Professor Gavin Reynolds 40
figure 12 Classification of peripheral 5-HT (serotonin-S) 
receptors. Glaxo Group Research Report, 1983, 
authored by Dr Patrick Humphrey 42
figure 13 Poster advertising the 5-HT meeting held on Heron 
Island, Queensland, Australia, in September 1987. 
Poster provided by Dr Patrick Humphrey 44
figure 14 Professor Gavin Reynolds and Professor Charles 
Marsden 54
figure 15 Mr Wesley Miner 60
* Unless otherwise stated, all photographs were taken by David Sayer, Wellcome
Trust, and reproduced courtesy of the Wellcome Library, London.
figure 16 Professor Paul Andrews 62
figure 17 Professor Paul Andrews and Dr Mike Tyers 66
figure 18 Professor David Clarke and Professor  
Alberto Kaumann 69
figure 19 Dr Colin Dourish 75
figure 20 Dr Jackie Hunter 76
figure 21 Professor Gerald Curzon 78
figure 22 Dr Jeffrey Aronson 92
figure 23 Professor Helen Cox 98
figure 24 Professor Phillip Cowen 116
figure 25 Participants at the Witness Seminar 137
 
table 1 Outline programme for ‘Drugs affecting 5-HT 
Systems’ Witness Seminar 5
table 2 A summary of the organization of clinical trials. 
Adapted from: www.clinicaltrials.gov/ct2/info/
glossary (visited 5 June 2013), and reprinted from 
Reynolds and Tansey (eds) (2008), page 10. 111
table 3 The top psychiatric medicines prescribed in 2011 
using information from the British National 
Formulary and 2011 prescription data from Lindsley 
(2012), page 631. 126
xi
5-H1AA 5-Hydroxyindoleacetic acid
5-HT 5-hydroxytryptamine
5-HTP 5-Hydroxytryptophan 
BDNF Brain-derived neurotrophic factor 
BPS British Pharmacological Society
cAMP Cyclic adenosine monophosphate / cyclic AMP
CNS Central Nervous System
COPD Chronic obstructive pulmonary disease
DHE Dihydroergotamine 
EEG Electroencephalography
FDA Food and Drug Administration, US
GABA Gamma-aminobutyric acid
GI Gastrointestinal 
GPCR G protein-coupled receptor
GSK GlaxoSmithKline
hERG Human Ether-à-go-go-Related Gene
HGS Human Genome Sciences
HPLC High-performance liquid chromatography 
HTS High throughput screening
IBS Irritable bowel syndrome 
IP Intellectual property
IUPHAR International Union of Basic and Clinical Pharmacology
LSD Lysergic Acid Diethylamide
MAO Monoamine oxidase
MAOI Monoamine oxidase inhibitor
ABBreViAtiOns
MDMA 3,4-Methylenedioxymethamphetamine (ecstasy)
MRC Medical Research Council
NCE New chemical entities 
NIH National Institutes of Health
NMDA N-methyl D-aspartate
NPY Neuropeptide Y
OCD Obsessive compulsive disorder
PBG Phenylbiguanide 
PDG Phenyldiguanide 
PET Positron emission tomography 
PK Pharmacokinetics 
PPI Proton pump inhibitor
PTSD Post-traumatic stress disorder 
SMW Small molecular weight 
SNRI Serotonin and norepinephrine reuptake inhibitor
SSRI Selective serotonin reuptake inhibitor
WHO World Health Organization
xiii
AnciLLAry guiDes 
There are several reliable websites giving further details on drugs and 
pharmacological techniques mentioned in the text. See for example:
The DrugBank database  
www.drugbank.ca/ (visited 16 September 2013)
Medicines Information from NICE  
www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-
information (visited 16 September 2013)
The PubChem project  
http://pubchem.ncbi.nlm.nih.gov/ (visited 18 September 2013)
The IUPHAR / BPS Guide to Pharmacology 
www.guidetopharmacology.org/ (visited 21 October 2013)
Glossary of Terms and Symbols Used in Pharmacology (Boston University 
School of Medicine: Pharmacology and Experimental Therapeutics)  
www.bumc.bu.edu/busm-pm/academics/resources/glossary (visited 
21 October 2013)

xv
intrODuctiOn
It was in the very early hours of a February morning in 1977 that I first 
looked down the microscope and saw yellow fluorescence, characteristic of 
5-hydroxytryptamine (5-HT) in frozen sections of Octopus brain. After struggling 
for two years with the capricious fluorescence histochemical technique to locate 
catecholamines and 5-HT, I finally had a successful result, and the PhD that 
had seemed a remote possibility for many months finally began to look feasible.1
Given the enormously important topic of this volume – the discovery and 
development of drugs affecting 5-HT systems – this small excursion into 
Octopus neurochemistry might seem irrelevant. However, cephalopod molluscs 
have played important roles in the history of 5-HT. More than 30 000 pairs of 
posterior salivary glands of Octopus vulgaris were used by Vittorio Erspamer, 
for the first extraction and identification of enteramine, which  was later shown 
to be identical to serotonin discovered by John Gaddum, and chemically 
characterized as 5-hydroxytryptamine.2 Other molluscs have provided some of 
the most sensitive bioassays for 5-HT, as Gaddum and Paasonen described in 
1955,3 and several participants in this Witness Seminar recollected either using 
such bioassays or investigating invertebrate pharmacology at the beginning of 
their careers. Many reflected, however, that invertebrate receptors seemed to 
be very different from those found in mammals; they had, as David Wallis 
put it, ‘a parallel pharmacology’.4 One Witness, Merton Sandler, remembered 
attending a lecture by Vittorio Erspamer in London in the early 1950s, and 
being intrigued enough to start work on the degradative enzyme monoamine 
oxidase, a field which became highly significant for the development of a whole 
class of therapeutic drugs: the monoamine oxidase inhibitors.5
Chairing Erspamer’s lecture had been Sir Henry Dale, who shared the Nobel 
Prize in 1936 for the discovery of chemical neurotransmission. One of the 
many young scientists he inspired was John Gaddum, who followed in his 
footsteps to the Wellcome Physiological Research Laboratories, and then to 
the National Institute for Medical Research in Hampstead in 1927. There he 
1 See, for example, Tansey (1980).
2 Erspamer (1948); Erspamer and Asero (1952).
3 Gaddum and Paasonen (1955).
4 See, for example, comments by Wallis, pages 9 and 78; and by Humphrey, page 79.
5 Sandler, page 10.
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joined Dale’s lab, and became immersed in work that would demonstrate the 
neurotransmitter function of acetylcholine (for which Dale coined the word 
‘cholinergic’ in 1934). Gaddum also began investigations into a wide range 
of physiologically active, naturally occurring chemicals, including Substance P 
and what was later recognized to be 5-HT. In the late 1950s, he was also one of 
the first to make a direct link between the brain and 5-HT from his work on the 
interactions of 5-HT and LSD, at a time when newly discovered psychoactive 
drugs such as chlorpromazine stimulated such work.6 In 1957 Gaddum’s work 
with Picarelli demonstrated two different 5-HT receptors: the D receptor on 
smooth muscle, and the M receptor on nerves. The resulting publication was 
a seminal paper cited by several participants as a major influence on their later 
work on 5-HT receptors and drug development.7
There was however a substantial delay between that publication and the work 
discussed at this Witness Seminar. Science is largely a social activity, and meeting 
like-minded, sometimes unlike-minded, people is an important part of the 
creative process.  Widespread interest in 5-HT was slow in developing.  Strange 
as it may seem nowadays, even neuroscience was not the dominant discipline 
it has since become. For example, my own exciting histochemical discoveries 
(well, I was excited) were first transmitted to the Sheffield branch of the Brain 
Research Association (now the British Neuroscience Association), which then 
comprised a couple of zoologists and biochemists, a few more physiologists and 
psychologists and a stray psychiatrist who was the only clinician to attend. For 
those intrigued by the actions of 5-HT, it took some time to create a critical 
mass. In 1957, for example, when Gaddum and Picarelli’s work was published, 
an international bibliography of psychopharmacology lists only 17 publications 
on serotonin.8
Pat Humphrey, who started working on 5-HT receptors in the early 1970s, 
recalled giving a communication to the British Pharmacological Society (BPS) 
in 1976 that ‘went down like a lead balloon’, there was so little interest.9 Two 
years later he had discovered ‘kindred spirits’ in Birmingham, Philip Bradley 
6 Gaddum and Hameed (1954); Gaddum (1957). See also the Witness Seminar on drugs in psychiatric 
practice (Tansey, Christie and Reynolds (eds) (1998)). 
7 Gaddum and Picarelli (1957). See also the Witness Seminar on platinum compounds (Christie and 
Tansey (eds) (2007)). 
8 Caldwell (1958).
9 Humphrey, page 41. 
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and also Richard Green, who was feeling somewhat isolated himself.10 A major 
turning point was a 1984 meeting of the BPS in Birmingham, when several 
individuals with similar interests finally met each other, discussed results, ideas 
and future projects. The subsequent formation of the Serotonin Club in 1987 
created an important international organization that anyone interested in 
5-HT research could attend. That same year, when the International Congress 
of Pharmacology (later IUPHAR) met in Sydney, Australia, a 5-HT satellite 
meeting on Heron Island, Queensland addressed the vexed questions of how 
many 5-HT receptors there might be, and how to standardize and define their 
terminology. From that meeting, an international nomenclature committee 
was established, four members of which contributed to this Witness Seminar. 
That committee produced the definitive paper on 5-HT receptor classification 
in 1994 (one of the earliest attempts to sort out the classification of complex 
receptor systems), which has continued to inform the field ever since.11 Further 
increasingly sophisticated analyses and understanding of 5-HT receptors, 
the development of precisely (and not so precisely) targeted drugs for these 
receptors, and their clinical management and utility, provided much of the 
engaging and frank discussion in this volume.
Meetings of the BPS, the Serotonin Club and IUPHAR were, and still are, 
regularly attended by industrial, academic and clinical researchers. Many 
of the Witness Seminar participants commented on the collaborations, the 
potentials and the tensions engendered by this mix, and the shifting priorities 
within universities and industrial labs from the 1970s through to the first 
decade of the twenty-first century (a theme that has arisen in several previous 
Witness Seminars).12 Whilst industrial organizations were frequently praised 
for promoting research in their own labs and for providing travel funds, 
studentships and project grants to academics,13 the downside of commercial 
expectations, especially from marketing departments, was also acknowledged.14 
Scientists working in industry were not immune from similar pressures as Wes 
Miner graphically illustrates with his account of a particularly tense meeting 
10 Humphrey, page 43; Green, page 45.
11 Hoyer et al. (1994)
12 See, for example, the Witness Seminars on clinical pharmacology (Reynolds and Tansey (eds) (2008 a 
and b)) and platinum compounds (Christie and Tansey (eds) (2007)).
13 See comments by Bakhle, page 88, and Green, page 90.
14 See, for example, Curzon, pages 129–31. 
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with Beechams’ management.15 However a major, and repeatedly accredited, 
debt to the pharmaceutical industry was the free distribution of experimental 
compounds. This facilitated a wide range of innovative research, especially in 
understanding basic physiological control mechanisms in health and disease, 
much of which might not have been conducted in a solely industrial lab (for 
example, in the development of the 5-HT
3
 receptor antagonists).16 As Mike 
Tyers emphasizes, these exchanges were not only between academe and industry, 
but also between industry and industry.17
The work described by the participants at this meeting has contributed to the 
development of some of the most frequently prescribed, and most profitable, 
medicinal compounds in the world. Migraine, emesis, psychiatric and GI 
disorders, amongst others, all have therapeutic, and in some cases prophylactic, 
treatments based on their effectiveness on 5-HT systems.  There was nothing 
inevitable about their development. The stories told here emphasize the 
importance of serendipity, collaboration and communication across many 
disciplines and several institutional locations; and they illustrate some of the 
false starts, disappointments and frustrations as well as the satisfactions and 
rewards of such research, for researchers, companies and ultimately for patients.
e m tansey 
Queen Mary, University of London 
15 Miner, pages 59–60.
16 Miner, page 88; see also the Witness Seminar on platinum compounds (Christie and Tansey (eds) 
(2007)). 
17 Tyers, page 83. 
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figure 1: Professor rod flower and Professor tilli tansey.
Professor tilli tansey:  Can I begin by welcoming everybody to this full-day 
meeting on Drugs Affecting 5-HT Systems.1 The purpose of this meeting is to 
find out what really happened. These Witness Seminars are meetings where we ask 
clinicians and scientists to tell us how ideas developed, how projects developed, 
who were the drivers, what the brakes were; to go behind the scientific papers. 
This meeting came out of an earlier meeting we had on platinum compounds2 
which ended up talking about 5-HT receptor antagonists and it seems that 
looking at drugs affecting 5-HT systems was going to be a very profitable, rich 
area for us to work on. Paul Andrews and Gareth Sanger, who worked with me 
on this meeting, and I have been talking for some time about doing a meeting 
on 5-HT and a Strategic Award grant from the Wellcome Trust has enabled 
us to develop and continue our programme and, indeed, this is one of the 
first meetings under that new Strategic Award. Our purpose today is to record 
all the discussions, all the debates, disagreements, if there are any, differences 
of opinion; this is the stuff of history. It will be transcribed and edited for 
publication. Everything is made freely available on the web to download. But let 
me stress that nothing will be published without your permission. You will have 
plenty of opportunity to amend the record, to add footnotes and you will be 
asked to assign copyright to the Wellcome Trust. So nothing will be published 
without your express permission. 
1 For consistency the term ‘5-HT’ has been used throughout and in most cases, the term ‘serotonin’ has 
been changed to 5-HT. 
2 Christie and Tansey (eds) (2007).
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As we were planning this meeting and we’d set it up, I received a letter from 
David Wallis asking if I would consider a meeting on 5-HT because he was 
writing a book on the history of 5-HT.3 This was a very useful confluence of 
ideas and different perspectives, so David has also been involved with Gareth 
and Paul and me in setting up the meeting. A key part of any meeting is selecting 
the chairman and I’m delighted that we’ve persuaded Rod Flower to chair this 
Witness Seminar. Rod is an old hand; he’s already chaired two of these meetings 
for us. So without further ado I’ll hand over to Rod Flower.
Professor rod flower:  Thanks very much Tilli and good morning everyone. 
Actually the discovery that defibrinated or clotted blood contained a 
vasoconstrictor substance was made over a century ago but it remained in the 
literature as an isolated observation for many years. 
John Gaddum, in an early edition of his pharmacology textbook, called it Spätgift 
and elsewhere refers to the substance(s) as vasotonins.4 He evidently thought there 
was more than one. He also pointed out, in what I thought was a very prescient 
comment at the time, that this factor could be removed from the blood during 
a passage through the lungs. In 1948 this substance was isolated in a pure form 
from serum by a group at the Cleveland Clinic and was given the name ‘serotonin’ 
because it was a serum-derived substance that had an effect on vascular tone. 
Meanwhile Vittorio Erspamer in Italy had identified a substance from 
enterochromaffin cells that contracted the intestine and which he called 
‘enteramine’.5 It wasn’t until 1952 that it was realized that serotonin and enteramine, 
as well as many other substances with similar names such as vasoconstrictine, 
vasotonin, thromocytin and thromobotin, were identical and it was renamed 
5-HT – although we still adhere to the old nomenclature sometimes.6
Gaddum and Picarelli did the pioneering experiments on 5-HT receptors 
suggesting that there were two types, which they termed D and M.7 Later, of 
course, this notion was overthrown by the radio ligand binding data. We now 
3 Wallis (in preparation).
4 Gaddum (1948), page 250. For biographical details of Gaddum see page 147.
5 See, for example, Erspamer (1948); Erspamer and Ghiretti (1951). For biographical details of Erspamer 
see pages 145–6. 
6 Erspamer and Asero (1952). 
7 Gaddum and Picarelli (1957). 
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know we have at least 14 5-HT receptors and one additional receptor in the 
mouse. Most of these are G-protein coupled receptors but there is one ligand-
gated ion channel. 
These discoveries initiated a very fertile era of drug discovery across a wide 
range of diseases. There are drugs that affect mood, nausea and vomiting and, of 
course, migraine. Indeed, I think there are currently about 11 drugs for treating 
migraine on the market.8 
So how we got from those early observations of vasoactive factors in clotted 
blood to the current situation where we have some 14 receptors and a clutch of 
highly successful drugs, is what we’re here to find out about (Table 1). Let’s go 
back to the beginning of the story. As I’ve said there were a variety of substances 
reported in the literature in the 1940s and 1950s. Can anyone remember back 
that far and remember the sorts of discussions that went on? I noticed that 
Gaddum’s pharmacology book, which I referred to, was published in 1948. I 
think it was his third edition. So Mick did you read that book when you were 
at Oxford?
Before the 1970s
Metabolism, distribution, synthesis
Techniques of investigation
Binding sites
Receptor classification
the ‘heady days’
Scientific communication 
1984 Serotonin Receptors Symposium, Birmingham
1987 The Serotonin Club
5-HT receptors and their classification
from theoretical pharmacology to practical use
Funding
Industry and academe – tensions and collaborations
Specific drugs
Impact
table 1: Outline Programme for ‘Drugs affecting 5-Ht systems’ Witness seminar
8 The 11 drugs include both therapeutic and prophylaxis, see the British National Formulary.
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Dr mick Bakhle:  I have to admit I don’t think I ever read Gaddum’s Pharmacology. 
But my contact with 5-HT was at the end of the 1960s, 1968–70, something 
like that, at the Royal College of Surgeons, as a part of the work we were doing 
on metabolism of vasoactive materials, endogenous vasoactive substances, in 
the pulmonary circulation. It came after some work John Vane had done in vivo 
and Val Alabaster and I took that on a stage further to look at what happened 
in a perfused lung.9 5-HT was one of the things that was cleared very effectively 
by a single passage through the pulmonary circulation, which was, perhaps, why 
I always thought you got right-sided cardiac lesions in the carcinoid syndrome 
and not left-sided lesions, because all the 5-HT had gone.10 It had been secreted 
into the intestinal circulation, come up the venous side, and essentially been 
cleared on passage through the pulmonary circulation. So, maybe arterial blood 
was relatively free of 5-HT whereas the venous blood had been fairly thick 
with 5-HT. Anyway, that’s what we did and it seemed very clear from our work 
that there was an uptake system in the lung, which was very like the uptake 
system already shown by Les Iversen for catecholamines.11 There was also a 
9 Thomas and Vane (1967); Alabaster and Bakhle (1970). For Sir John Vane see page 135, note 353 and 
biographical details on pages 157–8.
10 Professor Merton Sandler added: ‘See Goble, Hay and Sandler (1955) and Gobel et al. (1956) for the 
first formulation of this concept in the scientific literature.’ Note on draft transcript, 12 February 2013.
11 Iversen (1967); see also biographical details on pages 150–1. 
figure 2: Dr mick Bakhle.
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monoamine oxidase (MAO) activity because none of that 5-HT which went 
into the lung through the pulmonary circulation was retained; it all came out 
again as metabolite, in this case 5-HIAA (5Hydroxyindoleacetic acid). So it was 
a very rapid, and I thought very interesting, physiological clearance mechanism 
because, in a sense, you couldn’t overfill the lung with 5-HT because it was 
continuously cleared. So this was a continuous mechanism for clearing 5-HT 
from venous blood,12 apart from the platelets, which were doing it all the time. 
Later on, of course, we found out that the clearance was taking place in the 
endothelial cells. The only important thing, I think, about the pulmonary 
circulation is that it is one of the two circulations that take the entire cardiac 
output. So this was a highly effective clearance mechanism. The only other 
comment I’d like to make on this point is that about ten years after we did 
this work, a PhD student (Marie-Anne Pilot) came to us from the London 
Hospital Medical School, where she was studying the secretion of acid in the 
isolated blood-perfused stomach of a dog, and said: ‘We can’t do it. It won’t 
work.’ Then we found out that it was already known that the isolated dog 
stomach, perfused with blood, won’t secrete acid, but if you then cross-perfuse 
that isolated stomach with blood from another dog, it will secrete acid. And 
this all turned out to be due to the fact that there was a lung in circuit, so that 
you had the dog’s own pulmonary circulation still in the circuit but it was then 
pump perfused through the stomach and the stomach then secreted acid very 
well.13 The failure to secrete acid was methysergide-sensitive, which I thought 
was a very nice way to show that this lung clearance was relevant. That was my 
early exposure to 5-HT. 
Professor richard green:  John Vane had actually published a method for 
bioassay in about 1957.14 I’m not very convinced about the lung story in that 
normally, if platelets are harvested intact and not damaged (as so easily can 
be done by taking the blood), you will find essentially no 5-HT at all because 
platelets are not full of 5-HT and they take it up very avidly. Going back, 
Reginald Stacey, at Tommy’s [St Thomas’ Hospital, London], was one of the 
very first people together with Mike Rand to actually show that platelets contain 
12 Professor Merton Sandler wrote: ‘There was even speculation about the possible role of this in the 
pathogenesis of migraine, Sandler (1972).’ Note on draft transcript, 12 February 2013.
13 Pilot (1979).
14 Vane (1957).
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5-HT.15 I think they’re the real mechanism for getting rid of excess. With David 
Grahame-Smith, we used to look at the carcinoid syndrome because it was one 
of his big interests,16 and the only time you could find 5-HT in the plasma was 
really when the condition was so severe that the platelets were loaded up and 
they just couldn’t take up any more.
Professor merton sandler:  I love hearing all these pharmacologists speculate. 
[Laughter] But you know I came in from the clinical side and let me mention 
the name straight away of Michael Pare, with whom I worked for donkey’s 
years.17 Back then, Mike and I were in the army together pottering around and 
trying to do significant things with amino acids because we were bored out of 
our minds with military duties. So we built some chromatography equipment 
and came up with some semi-quantitative observations of interest. When I came 
out of the army in 1953, I went to work at the Brompton and teamed up with 
a couple of bright Antipodeans, Alan Goble and David Hay. They soon went to 
work down the road at the National Heart Hospital and promptly encountered 
one of the first cases of carcinoid syndrome to hit the headlines, which we 
investigated to the hilt!18 David Hay and Alan Goble astutely recognized this 
new syndrome, previously described in only two or three places in the literature. 
Carcinoid syndrome and its bizarre clinical presentation, of course, was what 
led me down the monoamine avenue, where I’ve remained ever since. I was 
still at the Brompton, so daily, 24-hour samples of urine and blood obtained 
by cardiac catheter from various sites used to come to me. We detected massive 
amounts of 5-HT and, of course, of urinary 5hydroxyindoleacetic acid, which 
is still the way you make the diagnosis clinically. So I became a bit of a carcinoid 
expert.19 Fred Lembeck in Austria was actually the first to identify enteramine – 
which is what Erspamer first called 5-HT at that time – in small semi-malignant 
15 Reginald Stacey (1905–1974) was at the time Reader in Pharmacology and Therapeutics at St Thomas’ 
Hospital; he was Professor there from 1958 to 1970. Michael Rand (1927–2002) held the Chair of 
Pharmacology at the University of Melbourne from 1965 to 1992. See Rand and Reid (1951); Hardisty 
and Stacey (1955). 
16 Grahame-Smith (1968). David Grahame-Smith (1933–2011) was Rhodes Professor of Clinical 
Pharmacology at the University of Oxford from 1972 to 2000. See further biographical details on page 147.
17 See page 20 and note 277.
18 Goble, Hay and Sandler (1955); Gobel et al. (1956)
19 Williams and Sandler (1963).
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carcinoid tumours of the small intestine.20 Little ‘semi-benign’ carcinoids in 
the gut that he had somehow picked up and good luck to him; Fred should be 
remembered as setting up this major signpost.21 
flower:  Before we move on I want to try to capture as much as possible about 
those very early days when we didn’t really understand 5-HT metabolism or 
removal. David, have you got a comment on that?
Professor David Wallis:  Yes, I was going to say, there’s a kind of parallel 
pharmacology with 5-HT in invertebrates; in fact someone just mentioned 
John Vane’s sensitive assay, which I think was rat’s stomach strip.22 But before 
that, John Gaddum had used an invertebrate heart preparation in 1953 that 
was very highly sensitive to 5-HT23 and, of course, the work by Erspamer to 
20 Lembeck (1953). Fred Lembeck (b. 1922) worked as an assistant in the Institute of Physiology in Graz. 
He later became the Director of the Institute for Experimental and Clinical Pharmacology at the University 
of Graz. 
21 Professor Merton Sandler wrote: ‘It led directly to the direct quantification of the 5-hydroxyindole 
pathway by Udenfriend and his team at Bethesda.’ Note on draft transcript, 12 February 2013. See 
Bowman, Caulfield and Udenfriend (1955); Bogdanski et al. (1956). 
22 Vane (1957).
23 Gaddum and Paasonen (1955). 
figure 3: Professor David Wallis.
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some extent concentrated on invertebrate mechanisms. And I think there was 
a kind of lag where the physiology and pharmacology of 5-HT in invertebrates 
took ages to catch up; the receptors were peculiar, they didn’t seem to fit in with 
schemes from the mammalian classification. This parallel history finally did 
catch up but it’s an interesting aspect of the story.24
flower:  Has anyone else got any comments on the very early days? 
sandler:  Erspamer came to London to give a special University of London lecture 
and he was obviously thought to be important at that time because they put Sir 
Henry Dale in the chair of that meeting! When Erspamer spoke nobody could 
understand a word of what he said. From my point of view it was a bit of a damp 
squib; monoamine oxidase had never really impinged on my consciousness at 
the time but still I came away from that lecture thinking: ‘We must measure 
monoamine oxidase.’ Indeed I teamed up with Alan Davison at Queen Square 
and we were the first to identify human monoamine oxidase using the Warburg 
apparatus, which dated from the Middle Ages of biochemistry!25 Erspamer was 
a nice man who rarely travelled and hardly ever moved in scientific circles. We 
gathered that this was one of the few times that he’d ever been to England – or 
anywhere in Europe for that matter – because he couldn’t speak anything but 
what sounded like broken Italian!
flower:  David, were you at the lecture as well?
Wallis:  No, just that the early discovery by Maurice Rapport was very quickly 
followed by the synthesis by Abbott Laboratories and Upjohn, and they 
distributed samples of 5-HT worldwide as far as I can see.26 So a lot of the 
early observations depended on this largesse; I think John Gaddum got his 
5-HT from one of those two firms27 and one of the earliest electrophysiological 
observations of actions in the mammalian nervous system was by A S Paintal. 
24 Professor Paul Andrews wrote: ‘5-HT is also found in plants. Stinging nettle contains 5-HT as well as 
ACh and histamine (Collier and Chesher (1956)). There is a nice experiment (Brittain and Collier (1957)) 
showing that contraction of a range of smooth muscle tissues in vitro was reduced by dock leaf extract.’ Note 
on draft transcript, 7 January 2013.
25 Davison and Sandler (1956).
26 Maurice Rapport (1919–2011) was working at the Cleveland Clinic, see pages 12–13. For further 
biographical information see page 154.
27 See page 12 and note 35.
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He got his 5-HT from one of the two drugs firms as well.28 I think these firms 
did quite a lot to promote investigating actions by people who previously had 
not got access to the pure material. 
flower:  I’d like to say that when drug companies do this sort of altruistic 
thing it makes a huge difference to the field. The same thing happened with 
the prostaglandins: if it hadn’t been for Upjohn distributing free samples of 
standardized materials the field would never have got anywhere. 
Bakhle:  The only further point I would make about the metabolism and the 
clearance in lung is that, to me, the big difference between the system that 
appears to be now in the endothelial cell and the other systems, for instance in 
nerves or indeed in the platelets, is that in nerves and in platelets the amine is 
taken up and stored in vesicles. It’s preserved for whatever purpose; you could say 
for later release. Whereas in the endothelial cell, and therefore in the pulmonary 
circulation, it is a true clearance: it goes in, is metabolized and then is spat 
out again as metabolite. So it’s just a clearance mechanism.29 It isn’t a storage 
mechanism and, as far as I know, nobody has suggested that the amines that 
might be taken up by the endothelium are then ‘releasable’, as they might be 
neurons or from platelets. So the lung endothelium operates in a different way 
from nerves or platelets – I used to call it ‘physio-pharmacokinetic’; essentially 
that is what was happening in the lung and it wasn’t in any sense a neuronal or 
a functional way of protecting 5-HT, or any other amine, for further release. 
Professor charles marsden:  Just to bring the Erspamer story a bit more up to 
date. I was invited to give a talk in June 2009 at the 100th anniversary of his 
birth. The event was held at Sapienza University of Rome and was organized 
by the Italian Society of Histochemistry.30 His wife, Giulianna, who is also a 
scientist, was there and the event was of interest to me because my first links 
28 Professor Paul Andrews wrote: ‘Paintal and others (especially John Widdicombe and Ainsley Iggo) used 
phenyl bi/di guanide (PBG / PDG) to activate vagal afferents. Most of the relevant papers are in the Journal 
of Physiology. PBG turns out to be a 5-HT
3
 receptor agonist and together with the more potent m-chloro 
PBG is still used today. The use of PDG seems to have originated with von Bezold at the end of the 
nineteenth century, and, of course, the von Bezold-Jarish reflex played an important role in identification 
of the 5-HT antagonist effect of metoclopramide identified by Fozard and which in turn made a major 
contribution to identification of selective 5-HT
3
 receptor antagonists.’ Note on draft transcript, 7 January 
2013.
29 See note 9.
30 For Erspamer, see notes 5 and 6.
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with 5-HT were with invertebrates and, of course, the majority of Erspamer’s 
work was invertebrate based, particularly with the molluscs, which were the 
invertebrates that I began my career working on.31 
flower:  Before we leave this, you mentioned a group at the Cleveland Clinic, 
Maurice Rapport, Arda Green and Irvine Page. Does anyone have any memories 
of them because obviously that was a very important step forward in the history 
of 5-HT?32
sandler:  I remember them very well. There were a lot of meetings at that time, 
some in England and some in the United States, that one was lucky as a very 
young worker, as a youth really, to get involved in. But Page was sort of a 
business man as I remember it. He had a decent team around him. I hope I’m 
not slandering him. He was alright; a nice enough man.
green:  Well, Maurice Rapport only died a couple of years ago and used to 
come to the Serotonin Club meetings.33 A delightful gentleman. The interesting 
history is that, whilst he worked as a post doc under Page and they isolated 
the substance, it was Maurice Rapport alone who actually did the structural 
identity.34 I think he ticked off Irvine Page quite seriously in publishing it and 
going and telling him that after submission. Again just to link what we were 
talking about Abbott and Upjohn: the very first substance was actually made at 
Columbia University. Maurice Rapport got them to do it and they then passed 
it on and asked these two companies to make it. I handed a letter over to the 
Royal Society Archives that Maurice Rapport gave me, in which John Gaddum 
thanks Maurice Rapport for a sample of a very few milligrams as I remember, 
and which Gaddum still managed to put into his bioassay system. He later got 
25mg, which I suspect he then got because Abbott and Upjohn were making 
this freely available.35 But as a memory of Maurice Rapport, he did say to me 
that he’d tried to keep up with this interesting new substance that he’d been 
31 For example, Marsden and Kerkut (1969, 1970).
32 Irvine H Page (1901–1990), director of the Research Division in the Cleveland Clinic, worked with 
Maurice Rapport (1919–2011) and Arda A Green (1899–1958) to isolate and characterize 5-HT. Rapport, 
Green and Page (1948). For biographical information, see pages 147–8 and 153–4.
33 See page 51 and note 165.
34 Rapport (1949). 
35 This letter in fact thanks Maurice Rapport for the 25mg sample in 1951 not the earlier 0.65mg sample. 
It is reproduced in Green (2008), page 1586.
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involved with for several years, but by the later 1950s, when I think papers were 
coming out at a rate of several hundred a year, he gave up feeling that he could 
in any way keep up with all the material being published.
Wallis:  On the same topic: in that speech he gave to the Serotonin Club he gave 
an amusing anecdote of how the discovery process went on when he was trying 
to identify samples from fluids and blood and so on. They were all tested on the 
perfused rabbit ear vein, of which Arda Green was in charge, and Maurice was 
very much the junior partner in the set up. So it came about that during the 
course of the day, Arda would set up an ear preparation, test a number of things, 
but Maurice Rapport’s sample had to be last. And it frequently happened that 
that was applied and the ear stopped responding and Arda Green said: ‘The ear 
didn’t like that; that’s it for today.’ 36 [Laughter]
flower:  Merton actually introduced the topic of monoamine oxidase so maybe 
this is a good point to move on a bit to the first studies into the synthesis and 
metabolism of 5-HT?37 
Dr Patrick Humphrey:  I just want to finish off what we were talking about. 
I didn’t know Erspamer or Page or any of these men, but when I started 
working on 5-HT in 1972, it was their books that I was reading. And I always 
remember that Erspamer’s books and articles were great fun; you could sit there 
for days reading them because there was so much data in there but it was very 
difficult to get much medically relevant specifics from it because it was just 
huge numbers of experiments that had been done on a multiplicity of animals 
and tissues and so on, but one was struck by the fact that molluscan hearts 
were incredibly sensitive, 10pM to -10nM. You had the feeling that 5-HT was 
really a potent neurotransmitter, just like adrenaline and noradrenaline, which 
I think was quite an exciting concept to people who were starting in the field, 
but you couldn’t make much of it. And I think Irvine Page was maligned. I 
was going to ask when we were going to mention Page, because he wrote two 
reviews in Physiological Reviews, which for me was the eye opener because there 
he was starting to look at physiology and showing that 5-HT was not only a 
constrictor but it was also a vasodilator and, of course, we’ve already talked 
about the chronotropic effect, the multiplicity of physiological effects that he 
36 See, for example, Rapport (1997).
37 Professor Merton Sandler wrote: ‘The situation in those early days came under careful scrutiny at a large 
meeting in the mid-1960s (Costa and Sandler (1968)).’ Note on draft transcript, 12 February 2013.
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studied and referred to, which certainly tweaked my interest.38 So, Page was 
an important person, certainly for me, because he set me on the road to think 
seriously about 5-HT. I want to read something from a book I bought about 
15 years ago and never even looked at – Irvine Page’s last thoughts on 5-HT. 
As I was coming to this meeting, I thought I’d better look at it. I still haven’t 
really read it, but I read the beginning and I read the end and there is a rather 
nice note here, well two things. He says: ‘There are already ample reviews and 
excellent books, large and extensively documented’, that tell you about what 
they saw; they are not really trying to analyse. ‘What seems lacking is briefer 
and more intimate discussions by one or two authors, discussions that represent 
a single point of view to provide possibly unity to a field that is becoming 
chaotic.’ And, of course, once we opened Pandora’s box another decade or 
two later, it became even more chaotic. Finally, at the end of the book, he’s 
summing up his thoughts and he makes the point that: ‘Serotonin has added yet 
another facet to the equilibrated system which controls many bodily functions. 
In disease states, it and its derivatives will be detected and measured because of 
their abnormal amounts, but in normal circumstances it seems to take its part 
with other substances in an orderly fashion, scarcely displaying the multiplicity 
of actions that so delight the pharmacologist and the biochemist.’39 I think he 
38 Page (1954, 1958).
39 Page (1968), pages S1, 116.
figure 4: Dr Patrick Humphrey.
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was working on this in the 1950s and Erspamer was in that sort of period, even 
earlier. All this was written up, waiting to be explored. So I think they certainly 
played a massive role in my start in the field, and of many others, I’m sure. 
flower:  You’ve brought up an important point: when did researchers begin to 
realize that 5-HT was important in the brain as well as in platelets and the gut, 
because this must have been a tipping point in the development of the field? 
Professor Daniel Hoyer:  The answer is very early on, in 1943, when LSD was 
found, except that we had no proof that it was going to be for 5-HT or primarily 
through 5-HT receptors (they were not known at the time), but this was actually 
what started the Sandoz efforts in the field because LSD had such a potent 
effect on people’s behaviour.40 They clearly knew that the effects were centrally 
mediated. Sandoz at the time started looking into compounds like these, the 
next in the series was psilocybin. Originally, when Hofmann synthesized LSD 
the first time in 1938, they didn’t know what the compound was all about; it 
was rediscovered in 1943 (the famous bike trip);41 we had a 50th anniversary 
for LSD/5-HT (a small closed meeting in Ticino, Switzerland) which was not 
supported very much by Sandoz. But this was the start of 5-HT research even 
before 5-HT was known. Several points can be made: 1) LSD had very potent 
effects in the brain; 2) it started the whole chemistry around ergot natural 
products again; the whole ergotamine chemistry developed and lots of Novartis 
chemistry was based on the indoles (the indole synthesis was then published in 
the early 1950s); and the indole ring is one of the major components in all these 
molecules (5-HT, LSD, ergolines, ergopeptides). By the time we found out that 
ergotamine and dihydroergotamine (DHE) were working in migraine, this is 
also primarily mediated by 5-HT receptors.42 It took some time to make the 
link between ergotamine and migraine and internally we had some quite heated 
discussions, but eventually it was by reconciling the incredible number of 
receptors and their pharmacological signatures that got things going. We sorted 
out the mess that was created initially when people were describing all kinds of 
40 Professor Daniel Hoyer wrote: ‘Albert Hofmann investigated extracts of many mushrooms in/from 
Central and South America known to cause hallucinations.’ Note on draft transcript, 16 January 2013.
41 Albert Hofmann (1906–2008), was a Swiss research chemist at the Sandoz Laboratories in Basle. Having 
previously, inadvertently, experienced the effects of LSD, Hofmann carried out a self-experiment on 19 April 
1943 to examine the effects by taking 0.25mg. He later had to be taken home on his bicycle accompanied 
by his lab assistant. ‘Bicycle day’ is detailed in his autobiography (Hofmann (1979)). For a general account 
of psychedelic drugs, see Snyder (1986), Chapter 7.
42 See, for example, Hoyer, Schoeffter and Gray (1989).
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effects of 5-HT in the most varied tissues and sometimes 5-HT was extremely 
potent. John Vane’s fundus preparation is probably the most sensitive one in 
vertebrates; 5-HT has an incredible affinity for this 5-HT
2
 (5-HT
2B
 receptor 
as characterized much later), which was unexpected, as 5-HT
2
 receptors were 
thought to have low affinity for 5-HT. But this is when things started moving; 
5-HT compounds largely evolved from the old LSD/ergot derivatives chemistry 
(at least at Sandoz, Eli Lilly and a few other pharmaceutical companies). 
Humphrey:  But again in Erspamer’s reviews and work, he described 5-HT levels 
in just about every organ going, so you knew there was lots of 5-HT in the 
brain, the gut and the heart, or rather platelets, and so on.43
green:  Adding to what Danny said, Gaddum, of course, used LSD in his 
preparation and suggested that since he’d found 5-HT in the brain, that it might 
have something to do with mood, based on the already existing human stuff on 
mood change.44 The Americans Woolley and Shaw, as I remember, saw the 
structural similarity between 5-HT and LSD and said: ‘You know, this probably 
43 See page 4, note 5.
44 See Green (2008).
figure 5: Left to right: Professor David clarke, Professor Daniel Hoyer,  
Professor richard green and Dr tom Blackburn.
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means there’s something going on in the brain with 5-HT and mood.’45 But I 
think the other major breakthrough was from B. B. Brodie’s lab, which was an 
absolute powerhouse in the later 1950s when, having developed a fluorescent 
method for actually analyzing 5-HT, because bioassay can’t do large numbers, 
they started putting every psychoactive drug they could think of into rats and 
measuring 5-HT concentrations.46 Drugs like reserpine and MAO inhibitors, 
and by the late 1950s everyone got most interested in 5-HT in the brain. 
Bakhle:  Where does ergotamine fit into this? Obviously, they would clearly have 
seen central effects from ergot ingestion for centuries – St Anthony’s Fire and all 
that sort of stuff.47 The question I’m really asking is: when was ergot and LSD 
connected with 5-HT? 
green:  If you really want to go back over a period, one of the interests of Henry 
Dale in about 1910 was the ergots, and in the Wellcome Labs, he and Patrick 
Laidlaw were looking at tryptamine and ergot compounds in about 1912.48 
I think that’s why Gaddum wanted to look at LSD in the system because 
tryptamine is so structurally related, that’s where he linked the two. That’s clever 
pharmacology.
Hoyer:  I think it was Pat who made the link and he should say something to this 
effect because, by the time we figured out that sumatriptan was working, by and 
large, on similar receptors to ergotamine and DHE,49 then the link was made. It 
wasn’t obvious at the beginning because we thought that ergotamine and DHE 
were working on a very specific combination of receptors in some vascular tissue 
(probably more adrenergic than 5-HT-like, as was the saphenous vein) and, 
at the time, we could never figure out the target because these compounds 
are working on adrenoreceptors (and dopamine receptors as well). It was a bit 
45 Woolley and Shaw (1954).
46 Bernard Brodie (1907–1989) was Head of the Laboratory for Clinical Pharmacology at the National 
Institutes of Health in Bethesda. See note 21 and Costa, Karczmar and Vesell (1989).
47 Poisoning from the consumption of ergot (ergotism) is characterized by convulsions and burning 
gangrene in feet, hands and limbs from its vasoconstrictive properties; it is known as St Anthony’s Fire after 
the Order of Antonite monks who established hospitals for sufferers of ergotism around 1100 AD. See, for 
example, the discussion in Tansey (2001).
48 Henry Dale was at the Wellcome Physiological Research Laboratories at Herne Hill from 1904 to 1914. 
For Dale’s scientific work on ergot and publications with Laidlaw, see various papers in Dale (1953).
49 See Hoyer, Schoeffter and Gray (1989).
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messy, but by the time we had sorted out the receptors things became clear, but 
I think some people (Pat) knew before that the link was there, although the 
target was called 5-HT
1
-like at the time.50
Humphrey:  Thank you very much Danny; it’s very kind of you. I think this is 
another discussion; we could have a whole day on migraine,51 but suffice to say 
that when I did start on the migraine project, 5-HT had already been infused 
into people and shown to abort an attack, which is clearly not a therapeutic 
strategy because of all its undesirable effects. We knew ergotamine worked 
and, again, preferably if it was given parenterally rather than orally. Strangely, 
my good friend James Lance in Australia, a brilliant clinician, had found that 
methysergide was also acutely active in some of his patients even though it was 
given normally prophylactically and was purported to be a 5-HT antagonist.52 
We worked out that it was probably an agonist when it was working acutely. And 
so, what was the common denominator between 5-HT, ergot and methysergide? 
Well, it turned out to be the 5-HT
1B
 receptor, but obviously it took us a while to 
get to that point, but we actually made another compound, sumatriptan, which 
mimicked the desirable effect (selective cranial vasoconstriction) and was an 
agonist for that receptor.53 So ultimately it all came full circle and became very 
clear. To finish on that point: every one of those four compounds I mentioned, 
they’re all indoles, so chemically they’re highly related.
Professor gareth sanger:  I just want to throw another molecule in, synthesized 
by the Delagrange company in 1964, and it’s called metoclopramide.54 It 
was made to improve on the anti-arrhythmic actions of procainamide, but 
was found to inhibit vomiting, antagonize at the dopamine D2 receptor and 
stimulate gastric motility; later research into the mechanisms of action of this 
drug then gave birth to 5-HT
4
 receptors and greatly helped clarify the role of 
50 Professor Daniel Hoyer wrote: ‘i.e. sumatriptan was acting selectively on 5-HT
1B
/5-HT
1D
 receptors as we 
reported in second messenger systems’. Note on draft transcript, 16 January 2013.
51 A Witness Seminar ‘Migraine: Diagnosis, Treatment and Understanding c.1960–2010’ was held on 28 
May 2013, and will be published in 2014.
52 Curran and Lance (1964). James Lance was Professor of Neurology at the University of New South 
Wales from 1975 to 1992 and since then, Professor Emeritus. He has published widely on headaches and 
migraine. See page 100. 
53 See Humphrey, Ferrari and Olesen (eds) (2001).
54 See, for example, Justin-Besancon and Laville (1964 a and b).
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the 5-HT
3
 receptor in the mechanisms of severe vomiting. It was a molecule 
that was circulating around at the time in exactly the same manner in the others 
we’ve discovered – again, in the 1960s and 1970s.
Dr tom Blackburn:  While we’re on the tryptamine story, at about the time 
that Pat Humphrey was referring to, we were seeing the development of 
histofluorescent assay technology developed by Falck and Hillarp in the early 
1960s in Sweden that revolutionized the study of monoamines in the central 
nervous system (CNS).55 They were able to identify serotoninergic pathways 
and cell bodies along with tryptaminergic pathways system that tryptamine-
like drugs such as LSD were thought to act at. Perhaps Charles Marsden can 
talk more about this during his post-doctoral years at the Karolinska56 and 
the tremendous amount of important histofluorescent/histological studies of 
the brain, mapping out these different 5-HT pathways from the raphe cell 
bodies, which created an enormous amount of interest in the role of the raphe 
serotoninergic system within psychiatry and neurology.57
55 See Falck et al. (1962); Carlsson, Falck and Hillarp (1962).
56 Professor Charles Marsden wrote: ‘I was not at the Karolinska but in Bergen, though I had important 
research connections at the Karolinska particularly with Urban Ungerstedt and the development of 
microdialysis.’ Email to Ms Caroline Overy, 21 June 2013. 
57 See Murphy, Campbell and Costa (1978). 
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sandler:  In the early 1950s when Mike Pare and I came out of the army, I played 
about in a lab at the Brompton and he went to work at the Maudsley. In fact, 
the Maudsley talked about nothing else but 5-HT in the brain and monoamine 
oxidase, and monoamine oxidase had just about come in. Does anybody here 
remember Nate Kline? 58 He was a big operator – he had his photograph on 
the front of Fortune Magazine as one of the ten best-known men in America; 
not ten best-known psychiatrists, best-known men in America. He was a grand 
phoney actually. [Laughter] Well, a showman at any rate! I had the good fortune 
of going every year to a meeting in the Caribbean that he organized through 
the generosity of one of his patients. And there was a nucleus of people that you 
would all be familiar with, like Arvid Carlsson.59 5-HT was all the rage at that 
time and so were monoamine oxidase inhibitors (MAOI). Nate Kline had really 
stumbled over the action of iproniazid in particular in depressive illness.60 And 
also Gaddum had been publicizing the fact that LSD was a 5-HT antagonist.61 
We decided to try to test this hypothesis in vivo – in man – and we got six or 
eight volunteers, registrars at the Maudsley, and we gave them LSD, a rather 
dangerous thing to do. But we knew no better in those days. We gave them 
LSD and we also gave them 5-hydroxytryptophan (5-HTP) to try to modify 
the LSD reaction. The thing that upset us was the fact that one of the registrar 
volunteers, after receiving LSD, became psychotic, clinically schizophrenic, for 
about six months. He had to be controlled by several large Maudsley attendants 
before he could be calmed. Mike Pare and I were responsible for tentatively 
suggesting that 5-HT might be involved in schizophrenia.62 
58 Nathan S Kline (1916–1983), best known for his work with psychopharmacologic drugs, was the 
founder and Director of the Rockland Research Institute (now the Nathan S Kline Institute for Psychiatric 
Research). Professor Merton Sandler wrote: ‘He introduced the MAO inhibitor, iproniazid, to psychiatric 
practice to treat depressive illness.’ Note on draft transcript, 12 February 2013. For further comments by 
Professor Sandler on Nathan Kline, see Tansey, Christie and Reynolds (eds) (1998), page 144.
59 Professor Arvid Carlsson (b. 1923) is a Swedish pharmacologist best known for his research on the 
neurotransmitter, dopamine. He was jointly awarded (with Paul Greengard and Eric Kandel) the Nobel 
Prize in Physiology or Medicine in 2000 ‘for their discoveries concerning signal transduction in the nervous 
system’. See www.nobelprize.org/nobel_prizes/medicine/laureates/2000/carlsson-autobio.html (visited 6 
March 2013).
60 Loomer, Saundera and Kline (1957); Kline (1958).
61 Gaddum and Hameed (1954); Gaddum (1957). 
62 Brengelmann, Pare and Sandler (1958, 1959). 
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flower:  Anybody else want to say anything about the first steps that we took to 
characterize the metabolic and synthetic pathways? 
green:  David Grahame-Smith, whom I worked with for many years, was the 
first person to identify tryptophan hydroxylase.63 Everyone had known that 
there was an hydroxylation step first, but they were not sure whether tryptophan 
hydroxylase and tyrosine hydroxylase were the same enzyme or not. David, 
again through the interest he gained at St Mary’s on the carcinoid syndrome, 
was actually able to identify and characterize the enzyme and show it was the 
rate-limiting enzyme. I think the point to really emphasize about this was that 
it was his PhD – he was already medically qualified. He did it on his own and 
when he first presented it in the States he remembers, famously, that some of 
Brodie’s lab who had been working on this for several years, came up to him and 
said: ‘How the hell did you manage to do this when we couldn’t?’ It’s really quite 
remarkable because the Brodie lab had people like Axelrod and Udenfriend,64 
and I could name many others in that lab, who were real experts in monoamines 
and he beat them. I think that’s worth commenting on very strongly.
flower:  David Grahame-Smith’s response is not recorded, I presume?
63 Grahame-Smith (1964, 1967).
64 For biographical details on Julius Axelrod (1912–2004) and Sydney Udenfriend (1918–1999), see pages 
141–2 and 157; see also note 21.
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green:  He didn’t tell me that. [Laughter]
sandler:  Around about the same time that David Grahame-Smith was able to 
characterize the hydroxylation, there was very similar Japanese input. 
flower:  Does anybody else want to talk about early attempts to characterize the 
synthesis and degradation of 5-HT?
Blackburn: There was one particular monoamine assay at the time, the Welch 
and Welch spectrofluorescent monoamine assay, which was one of the first 
neurochemical techniques we were using at ICI Pharmaceuticals in the 1970s.65 
Basically, the practice at the time was to dissect as many rat brain areas as 
possible and look at the levels of 5-HT, noradrenaline, dopamine and their 
metabolites, HVA, 5-HIAA and so on. This was the first time I can remember 
where we were starting to look at monoamine oxidase inhibitors and their effects 
on different monoamine metabolites. We were looking at action of tricyclic 
antidepressants, noradrenaline uptake inhibitors, and at the time I was working 
on a compound called viloxazine, Vivalan, a noradrenaline uptake inhibitor, 
which also increased 5-HT turnover. So the hypothesis at the time in Dr David 
Greenwood’s and Professor Brian Leonard’s lab was to try to understand the 
importance of 5-HT and its metabolites, looking at the areas associated with 
mood and emotion and other neurological psychiatric disorders, and trying to 
pinpoint which of these particular areas of the brain were important. One of 
the lovely memories I have is working with Brian Leonard.66 Professor Leonard 
at the time was being recorded for an Horizon television programme. He was 
dressed all in black with his long silver grey hair and he was demonstrating 
dissecting the brain of a rat to perform one of his experiments; he placed the 
brain on a block of dry ice in those days. There were rows and rows of frozen rat 
brains all ready for the biochemical assay – Welch and Welch assay. However, 
Brian was dissecting out one brain and it flipped out and went on the floor. He 
then followed the brain on to the floor with a spatula with the camera looking 
on all the time. I was really hoping this would be captured on the Horizon 
programme and it actually was – it just showed him going out of camera shot! 
However, this was one of the classical bioassay systems being used at the time. 
65 Welch and Welch (1969).
66 Professor Brian Leonard was a lecturer in pharmacology in the School of Pharmacy, Nottingham 
University before joining ICI in 1968 and subsequently moving to Organon International in Holland. 
From 1974 until his retirement in 1999, he was Professor and Head of Department of Pharmacology at the 
National University of Ireland, Galway.
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We were trying to understand which areas of the brain were important and 
being modulated by drugs, but in those days it was like looking at 101 different 
areas with a 101 different compounds to try to understand their mode of action 
– it was a nightmare. 
flower:  What techniques were you using in those days? Paper chromatography 
or something like that?
Blackburn:  Spectrofluorometric assays.
flower:  Just spectrofluorometric?
Blackburn:  Yes, for biochemical assays.
Professor David clarke:  When we come to talking about the clearance and 
metabolism of 5-HT, we cannot forget Ray Fuller and David Wong at Eli Lilly 
in the United States (discoverers of Prozac).67 It was Ray Fuller’s work that really 
characterized the type of monoamine oxidase that was involved in metabolism of 
5-HT and it was his work that really set out and defined the uptake mechanism 
67 Dr Ray Fuller (1935–1996) joined Eli Lilly in 1963 as a pharmacologist; Dr David Wong (b. 1935) 
joined the company in 1968 as a research biochemist; together with Dr Bryan Molloy, a senior organic 
chemist at Eli Lilly, they developed the compound fluoxetine, introduced into the market as Prozac in 
1988. See Fuller et al. (1974). See also page 28 and note 91. For further biographical details on Ray Fuller, 
see page 147.
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for 5-HT into neurological tissue. And you know there is a parallel here with 
the clearance of noradrenaline as depicted by Iversen’s Uptake 1 and Uptake 2.68 
However, we never found any evidence whatsoever for an Uptake 2 for 5-HT, 
it just seemed to go into the nerves. Ray Fuller was certainly a key figure in this 
field and actually I bear some sort of physical resemblance to him. In meetings, 
when it was rather dim and dark, I’d be sitting on my own and somebody would 
come up to me and sit next to me and say: ‘Ray, we did get that result. This 
is the way in which it works. It works like this ....’ And I just used to sit there 
and listen. This was fantastic. And then someone else would come up and say 
something about science and I’d turn round and say: ‘I’m afraid I’m not Ray; 
I’m Dave Clarke.’ And they’d say: ‘Who the hell are you?’ [Laughter]
green:  One hates to boast, but if we’re talking about assays, the first assay was 
actually native fluorescence, I mean chromatography first and then what was 
called native fluorescence in strong acid.69 Then I actually used a Snyder method 
in about 1966.70 But Gerald Curzon came to me – I was doing my PhD with 
him at the time – and said that there was a really interesting new method by 
Maickel, an American, where 5-HT was reacted with ortho phthaldialdehyde,71 
and he said: ‘This ought to be very sensitive. He says it is.’ And it was. Then 
he went on to say: ‘And when you’ve extracted the 5-HT the 5-HIAA ought to 
still be left behind. You should be able to extract that out and measure that.’ 
And that worked as well. In the end we published this in 1970 and it was, I 
think, the first method to measure in discrete brain regions both 5-HT and 
5-HIAA. I mention this because over the next ten years it was cited nearly a 
thousand times. It was three pages long in British Journal of Pharmacology and is 
the most cited paper I’ve ever had.72 So, it just shows you, a paper can be quite 
small and still be interesting. Then, of course, that was taken over very much by 
Charles Marsden’s new techniques of high-performance liquid chromatography 
(HPLC), where they could measure it in vivo.73 
68 Iversen (1967).
69 Bogdanski et al. (1956).
70 Snyder, Axelrod and Zweig (1965).
71 Maickel et al. (1968). 
72 Curzon and Green (1970).
73 Professor Charles Marsden wrote: ‘We could measure it in both in tissue and in vivo using microdialysis, 
Marsden (1981); Wright Upton and Marsden (1992).’ Note on draft transcript, 2 September 2013. 
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marsden:  I was going to go back to Tom’s point about the fluorescent 
histochemistry and what a major role that I think it played in the early 1960s. 
It was in 1964 that Dahlstrom and Fuxe first identified 5-HT pathways using 
fluorescence histochemistry.74 Of course, the difference between dopamine and 
5-HT was all in the colour; the dopamine was green and the 5-HT yellow. Hillarp 
in Sweden developed the fluorescence histochemical method and published it 
in 1962.75 I was still an undergraduate at that time and I was very impressed by 
a Pharmacological Reviews article by Kjell Fuxe that led me to completely give 
up becoming a zoologist and go into pharmacology.76 My first laboratory work 
was at Southampton with Gerald Kerkut, using the fluorescence histochemical 
method to map the 5-HT cells in snail brains. These were very large cells and 
were subsequently used a lot for the early pharmacological work identifying 
responses to 5-HT and related compounds and there is a continuum from the 
development of the tissue assay methods through to the cellular localization 
of 5-HT and its measurement in vivo using microdialysis.77 But I think that 
mapping of those pathways really spurred a lot of people’s interest, as we could 
now see where the 5-HT cells were in the brain and where they went to, so we 
knew which regions to concentrate on in future research.
sandler:  I just want to make sure that 5-HTP decarboxylase, the precursor 
enzyme responsible for the production of 5-HT, receives a mention and I must 
say that in the experiments that I mentioned before, about giving LSD and 
giving 5-HTP to modulate its action, it worked actually, but that’s another 
story.78 We collected urine samples from the subjects to whom we had given 
5-HTP and were surprised to find a very large increase of 5-HT itself in their 
urine, showing that substantial decarboxylation had almost certainly taken 
place in the kidney. To this day, peripheral, as opposed to central, decarboxylase 
inhibition forms part of Parkinson’s disease treatment.79
flower:  Let’s talk a bit about uptake. David [Clarke] introduced the subject. 
When were 5-HT transporters first characterized? I quoted a sentence from 
74 Dahlström and Fuxe (1964).
75 Carlsson, Falck and Hillarp (1962); Falck et al. (1962).
76 Hillarp, Fuxe and Dahlström (1966). 
77 Marsden and Kerkut (1970).
78 Brengelmann, Pare and Sandler (1958, 1959). See page 20.
79 Bartholini and Pletscher (1975).
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Gaddum’s book in 1948, mentioning that the biological activity of clotted 
blood could be removed by passing it through the lungs. How did this idea of 
uptake evolve?
clarke:  I’m not sure. This is a long time ago but I suspect and, I’m uncertain 
about this, that the work arose out of Axelrod’s lab originally where he was 
studying the uptake of noradrenaline and so forth.80 5-HT was used there as 
well. But I’m sure other people in the room will have a more precise idea about 
that.
green:  There was a very clever experiment, which many people probably 
don’t remember, by Archie Todrick who worked up at Dumfries. They were 
looking at human platelets and gave uptake inhibitors, and showed that the 
concentration of 5-HT in the platelets went down over the next week. They 
correctly interpreted this as the fact that the platelets could no longer take 
up 5-HT and that this might be how these tricyclic antidepressants work.81 
They also showed the corollary of that, which is if they gave MAO inhibitors 
then the concentration in the platelets went up. So they looked at two types 
of antidepressants and showed these different effects. But I suspect that you’re 
right, David, and that it was actually Les Iversen and his catecholamine affinity 
uptake systems that then made people interested in 5-HT uptake systems. But 
I don’t know more than that. 
clarke:  There was a lot of humour about blocking uptake of 5-HT into platelets 
and relating this to psychiatric illness.82 People were talking about psychotic 
platelets and so forth! It wasn’t really related to serotonergic nerves in the brain 
until later; but I think I may be right with Axelrod and Iversen.83
Bakhle:  That last comment reminds me, I think it was in Grahame-Smith’s 
Clinical Pharmacology Department in Oxford, David Boullin or somebody like 
that, was selling the idea of the platelet as a model for the brain?84 A neuronal 
model because of uptake and storage and, as you said, it developed into the 
psychotic platelet idea and so on.
80 For consistency, the term ‘norepinephrine’ has been replaced with ‘noradrenaline’. For a history of 
neurotransmitter transporters, see Iversen (2006a); for Axelrod’s lab, see Axelrod (1988), Iversen (1992).
81 Marshall et al. (1960).
82 See, for example, Marazziti et al. (2006).
83 See note 80.
84 See, for example, Boullin (1979). 
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green:  That was mainly in Brodie’s lab and Costa’s lab, before he went to Oxford. 
Bakhle:  Well, anyway, that model was certainly around but I think the origins of 
5-HT uptake must be with Iversen. I remember Hugh Blaschko coming back to 
Oxford and sitting down to lunch in the department – we used to have lunch all 
together in the department in those days – and he said: ‘Oh you know, there’s 
this amazing finding’; he’d just examined Les Iversen’s PhD in Cambridge and 
he was very, I suppose, excited. I’ve never really seen Blaschko excited but he was 
fairly excited. He really thought it was a lovely piece of work, the two uptake 
systems, and it was, I think, fairly clear. I don’t know whether Les ever ran 5-HT 
as an alternative substrate; if you look in his PhD thesis you’ll probably find out. 
I suspect he probably did, because you know it was a biogenic amine and maybe 
he ran histamine as well. I certainly would if I’d found out something about 
catecholamines, I’d throw every amine I could at it. 
green:  Les [Iversen] wrote a monograph as the result of his PhD.85 I bet few 
PhD students can have a monograph published on their PhD work. It’s on 
uptake and I don’t think there’s a mention of 5-HT in that. I think it’s only 
catecholamines.
Humphrey:  To add to that, Richard, he did actually look at 5-HT and I was always 
very struck by the fact that 5-HT had an affinity for Uptake 1 in mammalian 
hearts, rodents. But it was quite potent. It was about one fiftieth of the affinity 
of noradrenaline, so there you see 5-HT having a not grossly dissimilar affinity 
to that of noradrenaline, and that follows through on the receptors, that 5-HT 
will actually activate alpha adrenoreceptors if you give enough of it. I think that 
confused a lot of the pharmacology in the early days because there’s 5-HT activating 
alpha receptors because pharmacologists have given too big a concentration and 
stupidly thinking that they were studying a new 5-HT receptor.
clarke:  Someone in the room who’s an expert in CNS will probably recall when 
tricyclic antidepressants came out; drugs such as amitriptyline and imipramine 
and other related compounds.86 I think it was Axelrod who showed that 5-HT 
neuronal uptake was blocked by these drugs.87 Am I incorrect in saying this? 
85 Iversen (1967).
86 For an account of the development of tricyclic antidepressants, see Healy (1997), pages 152–5, and the 
discussion at the Witness Seminar on drugs in psychiatric practice, Tansey, Christie and Reynolds (eds) 
(1998).
87 See, for example, Axelrod and Inscoe (1963). 
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green:  Iversen and Horn certainly published in that area, but that was long 
after these drugs were available.88 That was in about the mid-1970s and a lot of 
the tricyclics had been around. It was the usual thing in the area of psychiatry, 
they were found to be clinically effective without really very much idea of how 
they worked. 
Blackburn:  When I came back from the States last year (2011), I brought 
back lots of the boxes that I had taken over there in 1999 and one of things 
I found recently, but haven’t read since then, was the Scrip’s Report from 
1988 and it discusses a lot of the different 5-HT post-synaptic, pre-synaptic 
uptake inhibitors.89 The first compound 5-HT reuptake inhibitor (SSRI) to be 
marketed was from Astra, Zimelidine, which was withdrawn for serious side 
effects (Guillian-Barré syndrome).90 But before that, as David quite rightly 
said, clomipramine, which is a very potent noradrenaline and 5-HT uptake 
inhibitor, was also very important in those days in trying to understand the 
5-HT reuptake mechanism. But it wasn’t until the work of the David Wong, 
Bryan Molloy and Ray Fuller and colleagues at Lilly, who played a key role in 
the development of fluoxetine, Prozac, in the 1980s, and the pioneering work 
of Arvid Carlsson and colleagues at the Karolinska that really started to put the 
5-HT reuptake mechanism on the map.91 
clarke:  I remember now that John Fozard and I did an experiment in pithed 
rats that were reserpinized. You could infuse noradrenaline into them and, of 
course, because the vesicles were inoperative one couldn’t subsequently get 
88 For an overview, see Iversen and Mackay (1979).
89 Scrip (1988).
90 See, for example, Fagius et al. (1985).
91 See pages 23-24 and note 67. Dr Tom Blackburn wrote: ‘In 1971 Bryan Molloy at Eli Lilly synthesized a 
range of new compounds, a group of phenoxyphenyl-propylamines from diphenhydramine, an antihistamine 
found to inhibit reuptake of the neurotransmitter “serotonin”. One of these compounds, Lilly 110140 (later 
in 1975 called fluoxetine), was found to be highly selective, affecting only the neurotransmitter serotonin. 
As the chemist who synthesized the new series of compounds, Molloy was in this literal sense Prozac’s 
creator. Years of development and testing finally led to approval of fluoxetine hydrochloride for marketing. 
In 1976 Eli Lilly begins clinical trials of fluoxetine. In 1983 Lilly applied to US FDA for approval to sell 
Prozac for treatment of depression. Fluoxetine was initially approved for treatment of depression in Belgium 
in 1986, and then Eli Lilly’s Prozac was approved by the FDA on 29 December 1987 and introduced in 
the United States at the beginning of 1988. It was the first of a new class of drugs, called selective serotonin 
reuptake inhibitors (SSRIs), to be approved for use in the United States.’ Email to Ms Caroline Overy, 
7 June 2013.
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a response to tyramine. But if one pretreated these reserpenized rats with a 
monoamine oxidase inhibitor you could infuse noradrenaline, give tyramine, 
and restore the tyramine response beautifully. So John and I said: ‘Well, let’s put 
in 5-HT’, and so we infused 5-HT into reserpenized rats, gave tyramine, and 
got no response. Put it into reserpenized rats pretreated with a MAO inhibitor 
– beautiful responses to 5-HT. So this was a clear-cut demonstration, measuring 
the vasoconstrictor response to 5-HT as a read out, of 5-HT being able to go 
up into noradrenergic nerves; peripheral noradrenergic nerves. The monoamine 
oxidase inhibitor that we used was an intraneuronal monoamine oxidase 
inhibitor, bretylium. It was taken up into the nerves, concentrated in the nerves, 
inhibited MAO and preserved noradrenaline when it was infused and taken up, 
and preserved 5-HT when it was infused and taken up. Now that was in the 
1960s; this is published in the Journal of Pharmacy and Pharmacology92 or the 
local newspaper in Bradford.93 [Laughter].
green:  That leads on easily to some of the major work that David Grahame-
Smith started which was giving a monoamine oxidase inhibitor and tryptophan, 
and the animals show a behavioural syndrome.94 He showed that if you just gave 
tryptophan, which increases the turnover of 5-HT, you didn’t get the behaviour. 
If you only gave an MAO inhibitor you didn’t get the behaviour, even though 
the 5-HT concentrations in the brain went up enormously. So he concluded 
that, in fact, intraneuronal metabolism was very important for controlling 
function. Again he showed that tricyclics brought the syndrome on earlier and 
quicker because MAO couldn’t be taken back up. Alec Coppen, who is one of 
the major people involved in the clinical pharmacology/psychiatry of 5-HT, 
had actually shown that he could potentiate an antidepressant effect in about 
1965/6.95 Giving tryptophan potentiated the antidepressant action of MAO 
inhibitors, so he’d done the same sort of thing in humans. I think that’s really an 
important thing. Then David and I used this 5-HT model of function to look at 
every drug we could think about during the 1970s. Moussa Youdim maintained 
92 Fozard and Clarke (1970).
93 This is a reference to the research group at Bradford with Professor Robert Naylor and Professor Brenda 
Costall’s work on a 5-HT
3
 receptor antagonist and Glaxo’s development of the anti-emetic drug ondansetron 
the expense of which was reported in the Bradford Telegraph and Argus. See comments by Professor Naylor 
in Christie and Tansey (eds) (2007), pages 59 and 61.
94 Grahame-Smith (1971).
95 Coppen, Shaw and Farrell (1963). Dr Alec Coppen attended the Witness Seminar on drugs in psychiatric 
practice; see Tansey, Christie and Reynolds (eds) (1998).
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that we just pulled down the Merck Index and then tried to find as many drugs 
as we could and publish on them. But it’s a nice behavioural functional model 
in animals, some of which has been applied to humans as well.
marsden:  This was about the selective 5-HT uptake inhibitors and when they 
first appeared. It was my feeling that actually Fuller and Wong synthesized and 
pharmacologically tested fluoxetine (Lilly 110140) quite early96 because when, 
with Ralph Adams, we were trying to develop the voltammetric method to 
electrochemical monitor 5-HT in vivo in Kansas, we used fluoxetine at that 
point.97 That was 1977/8 so it was available then as a selective compound but 
Lilly were not particularly interested in it as a clinical entity at that time, as 
the emphasis in the US was on noradrenaline and depression. But then, to our 
embarrassment, for years Ray Fuller always used our data showing an increase 
in the signal that we obtained, to provide evidence that extracellular 5-HT was 
increased by fluoxetine when, by that time, in fact, we had discovered that the 
signal we recorded wasn’t actually 5-HT but, most probably, ascorbic acid.98
Blackburn:  I had the privilege of meeting Ray Fuller on a number of occasions 
and one of the stories he told – and I think it’s very true to the whole of 5-HT 
research at the time – was that the mind-set of Lilly management wasn’t 
particularly favourable to 5-HT research. When I joined Beecham, they actually 
in-licensed paroxetine, a 5-HT uptake inhibitor, from Ferrosan in Holland. 
ICI had turned it down, and this was the same time that Ray was having his 
problems at Lilly with regard to the market size for SSRIs, which we now know 
was enormous. But, it was the mind-set of the management at that particular 
time that they were more comfortable with the noradrenaline reuptake inhibitors 
rather than the 5-HT drugs.
96 See note 67.
97 Conti et al. (1978); Marsden et al. (1979).
98 Professor Charles Marsden wrote: ‘The carbon electrodes we used to record the voltammetric signals 
were very sensitive at a similar potential not only to the amines but also their metabolites and ascorbic acid, 
the latter which was abundantly present in the brain and readily released. We were probably measuring the 
release of ascorbic acid and the metabolites of dopamine and 5-HT rather than the amines themselves (for 
example, Brazell and Marsden (1982)). This problem was subsequently overcome by using nafion-coated 
carbon fibre electrodes, which excluded ascorbic and uric acid from the electrode surface (for example, 
Crespi, Martin and Marsden (1988)) and this technique has been further refined and improved in recent 
years. The technique of in vivo microdialysis to measure 5-HT release has also had a major impact on our 
understanding of the role of 5-HT in both drug action and behaviour (for example, Wright, Upton and 
Marsden (1992)).’ Email to Ms Caroline Overy, 21 June 2013.
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marsden:  This demonstrates the point that, at that time, we were interested in 
serotonin or 5-HT on this side of the Atlantic and the Americans were more 
into noradrenaline (or norepinephrine, as they called it).99
flower:  Let’s edge our way towards the early receptor studies now. I can’t recall 
who the workers were, but there were early studies using radioactive 5-HT to 
identify binding sites. Does anyone want to say anything about these early 
experiments and maybe discuss Gaddum’s early experiments with ‘M’ and ‘D’ 
receptors?
Hoyer:  Everyone is citing Peroutka and Snyder,100 but actually the first to really 
perform 5-HT binding was a chap called Gilles Fillion at the Institut Pasteur, 
but the Institut Pasteur had little interest in this sort of thing.101 J P Changeux 
was there working on nicotinic receptors, neuropharmacology was rather 
prominent, and everyone considered that 5-HT was of rather less importance 
because of J P Changeux’s interest in cholinergic receptors. But Fillion did these 
things and, at the time, he used surprisingly strange material like horse brain; 
because the horse is fairly large, you can work on one brain for quite some time. 
So they started using 5-HT, but also LSD, and they were pretty close to saying 
that there was a relationship between 5-HT and LSD. He was also one of the 
first to start with second messenger studies, again in the brain (horse brain), 
and reported 5-HT-induced cyclic AMP (cAMP) accumulation.102 Inhibition 
of cAMP was not on the cards in those days because it was difficult in intact 
tissues, but clearly it was there as well. The nomenclatures were very bizarre; they 
were talking about S receptors, S1 and S2; and then a little later it was all sorted 
out when Peroutka and Snyder started using spiperone (spiroperidol), LSD and 
5-HT only to show that spiperone, on top of its known dopamine activity, was 
labelling something that was fairly common to what was labelled by LSD; but 
then LSD was also labelling a site that was common with 5-HT-labelled sites, 
so they introduced a distinction between 5-HT
1
 and 5-HT
2
 sites. 5-HT
1
 had 
high affinity for 5-HT and LSD, whereas 5-HT
2
 had high affinity for LSD 
and spiperone. This opened Pandora’s box because then came ketanserin and a 
number of other ligands with different levels of selectivity for different 5-HT 
99 For the use of the terms adrenaline and epinephrine, and also noradrenaline and norepinephrine, see 
Aronson (2000); see also note 80.
100 See, for example, Peroutka and Snyder (1979). 
101 See, for example, Fillion et al. (1978).
102 See Fillion et al. (1979).
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receptors.103 Again, many people had been doing binding studies with ligands 
that were totally exotic; in the different companies they were using tools like 
ergotamine, DHE, methysergide, and it was so complicated and dependent on 
the tissue you were working on, that it was a total mess. It was much later when 
the selective compounds started to come out. I’m probably the latest latecomer 
here; I started to work on 5-HT in 1983, and was only in 5-HT research for 
about nine years before I turned to neuropeptides. When I started, tritiated 
ketanserin, 5-HT, LSD, and spiperone were available; there had been some 
playing with iodinated LSD and one of the major contributions at the time was 
the discovery of 8-OH-DPAT, which was the first 5-HT
1
 (5-HT
1A
) selective 
ligand.104 Then we could slowly but surely unravel the mysteries of 5-HT 
receptor families and sub-families. We are going to go into subtypes later, but 
this was the beginning of the binding saga with Fillion, Peroutka and Snyder. 
Everyone remembers Peroutka and Snyder, when actually one of the major 
contributors was Fillion. This was in 1975/6 when the College de France had 
a very strong influence in the neurotransmitter field around Jacques Glowinski 
(although Fillion wasn’t at the College de France). Fillion published in 1976, 
but it was at the time when all these people were coming back from the United 
States having spent some time in Julie Axelrod’s and other labs at NIH.105 They 
looked at one receptor after the other; one ligand after the other. Lefkowitz did 
exactly the same thing at pretty much the same time; in 1977 he published on 
beta receptor binding with the beta blocker [3H] dihydroalprenolol (DHA).106 
Subsequently there was further work with [125I]HYP, (hydroxybenzylpindolol), 
[3H]propranolol, [3H]carazolol, and we developed [125I]CYP (cyanopindolol), 
which not only bound beta receptors but also 5-HT
1B
 receptors (at least in 
rodents).107 It was the time when it was still very difficult to get agonists to 
bind to these receptors (e.g. HBI, [3H]hydroxybenzylisoproterenol, was an 
exception), whereas antagonists would be binding much better; there was some 
confusion about high affinity antagonist binding sites and low affinity agonist 
103 Ketanserin, a 5-HT receptor antagonist used to lower blood pressure, developed by the Janssen 
pharmaceutical company in 1980, blocks 5-HT
2A
 receptors and alpha-1 adrenergic receptors. See Brunton, 
Chabner and Knollman (eds) (2011), page 350.
104 Hoyer, Engel and Kalkman (1985b).
105 Fillion et al. (1976).
106 Lefkowitz and Williams (1977).
107 See Engel et al. (1981); Hoyer, Engel and Kalkman (1985 a and b).
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binding, which turned out to be totally irrelevant. But 1976 is when it really 
started with binding and second messenger studies, primarily cAMP. Inositol 
phosphates and calcium would come a few years later.
flower:  I want to come back at the end of this session to talk a bit about 
the ‘5-HT summit’ and the ensuing paper that you [Daniel Hoyer] published, 
together with others in this room, on 5-HT receptor classification, but at the 
moment I want to try and gather other reminiscences before the Pharmacological 
Reviews or the IUPHAR classification.
Bakhle:  Around 1970, someone asked me if I would write a chapter on 5-HT 
and bradykinin for a pharmacology textbook.108 And the reason they were 
grouped together was that, at that time, certainly from the outside, i.e. someone 
who hadn’t been studying 5-HT all their lives, both were transmitters without 
a function. Nobody knew what bradykinin was for; it was there, it did a lot of 
things but what on earth was it really doing? And 5-HT, the only thing I could 
think about 5-HT in those days as a physiological function was what Edith 
Bülbring had done to demonstrate that it was involved in the peristaltic reflex.109 
To me, that was the only physiological function of 5-HT. But it was there, all 
over the body, in enormous amounts. What on earth was it doing? Both 5-HT 
and bradykinin, as far as I was concerned, were transmitters without a function. 
Luckily I dallied so long about writing this chapter, because in a year, bingo! 
There were 53 receptors, well, no, [laughter] at least five or six. I thought, 
‘thank God’, because it would have been so embarrassing to publish this chapter 
about the ‘no-function transmitters’ and then it would have blown up in my 
face. So delay is quite a good idea from time to time.
flower:  When did we begin to get the first intimation that there were more 
than two receptors?
Humphrey:  That’s really the topic of the next session and I can tell you how I see 
it, but coming back to Gaddum and Picarelli, I always remember when I started 
108 Dr Mick Bakhle wrote: ‘I never actually got around to writing it [the chapter] … when I was asked, the 
topic was “do-able” but within a year or so the number of 5-HT receptors had increased dramatically and I 
would never have been able to do both in one chapter.’ Email to Ms Caroline Overy, 11 June 2013.
109 Bülbring and Crema (1958).
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in 1972 that it was the definitive paper.110 Everybody thought it important 
because, firstly it was Gaddum, and secondly, it had identified two separate 
receptor types. So everybody used to say: ‘Ah, there are two 5-HT receptors.’ 
And I told them: ‘There are at least two, yes. We know these two.’ But I wasn’t 
even convinced about those, because the two drugs used to characterize were 
really, really dirty. Here you have a guinea pig ileum that was contracted by 
5-HT, and clearly one response seemed to be a neuronally mediated contraction 
and the other a smooth muscle contraction, but the first drug used to block 
the neuronal contraction was morphine. Well, obviously, that was a functional 
antagonist and inhibited release of acetylcholine. Then dibenzyline was the 
dirtiest drug going. So you really hadn’t got very far when you’re dealing with 
those sorts of drugs. It was all to play for, even though Gaddum had published 
this paper that just about every pharmacologist or student of pharmacology 
knew about.
clarke:  May I just jump in on that. The Gaddum and Picarelli paper in 1957 
was seminal because we got two 5-HT receptor targets to aim at; one on nerve 
– the M receptor, and one on muscle – the D receptor.111 But the trouble was 
afterwards people couldn’t repeat the experiment. In fact it’s very difficult in 
guinea pig ileum to get a response to 5-HT that is mediated directly on the 
smooth muscle via the D receptor; it’s almost impossible. Margaret Day and 
John Vane failed to do it convincingly;112 Brownlee at King’s failed to do it 
convincingly.113 Much later, in 1985, Buchheit, using guinea pig ileum, had 
to use industrial doses of 5-HT to get a response at the D receptor.114 It’s quite 
clear that there’s a tremendous strain variation of 5-HT receptors within guinea 
pig gut and maybe young guinea pigs, which Gaddum used, did express the 
5-HTD, which is now the 5-HT
2
 receptor, but he was extremely lucky. I think 
this is an important point, that when you do make discoveries, often luck is 
on your side. It’s just lucky to get a piece of guinea pig ileum right next to the 
caecum that had a reasonable response to 5-HT. Then, as Pat said, he did use 
dibenzyline and what that did, of course, was to block muscarinic receptors 
but, in so doing, he wiped out the 5-HT
4
 receptor. He had to use very high 
110 Gaddum and Picarelli (1957).
111 For the equivalence of the M to the 5-HT
3
 receptor, see Craig and Clarke (1990).
112 Vane and Day (1963).
113 Brownlee and Johnson (1963).
114 Buchheit et al. (1985).
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concentrations of 5-HT and all he picked up was the neuronal M or 5-HT
3
 
receptor. He missed the high potency neuronal 5-HT
4
 receptor, which was at 
the foot of the dose-effect curve to 5-HT, because it was blocked at the level 
of the muscarinic receptor by dibenzyline. So it was a messy experiment, as 
Pat said, but he was lucky and he did pick out two receptors that subsequently 
appear to have played out.
Humphrey:  Just to add to that, those are the practical difficulties. What you 
haven’t mentioned is that there are other 5-HT receptors in those preps as well, 
on different sites; so you’ve got a relaxant receptor in there and you’ve probably 
got other receptors. I did think about trying to work them all out when we 
had better ligands but I didn’t think it was really worth it. It was a pretty messy 
situation but it was seminal in the sense that people thought: ‘There are two 
receptors and it’s a bit like the catecholamine story all over again. You know, 
we can use that and move on.’ In those days people didn’t think about multiple 
families of receptors; in fact I think a lot of people thought there were two 
receptors for every neurotransmitter, or later, that there were four for every 
transmitter. It turned out to be very different.
Wallis:  Dirty drugs or not, I still see that as a key historical point when more 
than two receptors, the S1 and the S2, and the 3 or the M as it was then, were 
subsequently firmly established in people’s minds.
figure 9: Professor David clarke.
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Hoyer:  Yes, 25 years ago we had the first 5-HT meeting in Heron Island115 
where some famous pharmacologists were present and were asked: ‘How many 
5-HT receptors do you think exist?’ And Pat raised his finger, his single finger, 
so in those days he still said: ‘One, only one.’116 
Humphrey:  Only one receptor but worth several billion dollars.117 [Laughter]
Hoyer:  That’s one thing. The other, more importantly, is that in those days 
people were not shy of using high concentrations of compounds. If you do this 
today people will say: ‘It’s totally unselective; what are you doing? You’re killing 
everything around.’ But, actually, you’re probably setting the right conditions 
to getting closer to what you want. Obviously, they have missed many of the 
115 The 5-HT meeting was held on Heron Island, Queensland, Australia, 4–6 September 1987. This was a 
satellite meeting of the International Union of Basic and Clinical Pharmacology (IUPHAR) congress held 
in Sydney, 23–28 August 1987.
116 Professor Daniel Hoyer wrote: ‘Others, such as. Ewan Mylecharane, were proposing up to ten.’ Note on 
draft transcript, 16 January 2013.
117 A reference to the numerous drugs affecting 5-HT systems; see also Table 3, page 126.
figure 10: some members of the 5-Ht meeting held on Heron island, Australia, indicating 
the number of 5-Ht receptor subtypes they believed existed. Pictured left to right: 
günter engel, toshiro shibano, Brian richardson, ewan mylecharane, stephen Peroutka, 
ralph Purdey, John fozard and Pat Humphrey. 
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high affinity receptors. We can talk about 5-HT
4
, 5-HT
7
, and who knows how 
many receptors lie in the guinea pig ileum? One of the issues in the ileum, and, 
I think Gareth should say something about this, is that the composition of the 
receptor environment in the gut keeps changing from top to bottom. It is very 
difficult to get a piece of tissue that is replicable, not even between species. In 
the same animal you will see that the composition of receptor populations, the 
same receptors, will vary. Also the multiple splice variants (for 5-HT
4
 receptors) 
are making the issue extremely complex. What do you think, Gareth?
sanger:  I completely agree. It depends on which part of the small intestine you 
study, and this is what most people study. From top of the gut to the bottom 
there are massive changes in cholinergic and other functions.
flower:  Is that the reason why no one could repeat Gaddum and Picarelli’s 
original data?118
sanger:  I don’t know is the short answer, but yes, I could easily envisage that. 
You talked about the terminal ileum next to the caecum, but that behaves more 
like a sphincter than the main part of the ileum. If you move away from that 
region you can get a completely different pharmacology to several different 
receptor ligands. So, yes, very easily; not understanding gastrointestinal (GI) 
physiology is a real issue.
green:  It’s worth mentioning Janssen Pharmaceuticals because they got involved 
in receptors very early on. You’ve mentioned ketanserin, but they had ritanserin 
and pirenperone. They went for what were then called 5-HT
2
 receptors. I went 
for a meeting there, I think in the very late 1970s, and remember that Paul 
Janssen, who sat there chain-smoking and grunting at various points, didn’t 
really believe the 5-HT
1
 story.119 Even with the existence of 8-OH-DPAT he 
thought the 5-HT
2
 receptor was the interesting and important one and that 
it was almost a silent receptor, until pathology took over. So, if there was a 
hemorrhage, the platelet receptors for 5-HT
2
 became active, and he felt the 
brain acted in the same way. There were these 5-HT
2
 receptors but they didn’t 
do anything very much unless there was something like psychiatric illness, in 
which case you should block them because 5-HT then became pathologically 
functionally active. That drove it. I think that some of the people like Josée 
Leysen didn’t totally believe this, but Paul was in charge of that company.
118 See page 34. 
119 Paul Janssen (1926–2003) was the founder of the Belgian pharmaceutical company Janssen Pharmaceutica 
(part of Johnson and Johnson since 1961); for further biographical information, see page 151.
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Humphrey:  Paul did push that hypothesis or at least the company did. I got a 
lot of stick from David Jack at Ware [Allen & Hanburys]120 saying: ‘Are you sure 
that 5-HT’s not involved in the aetiology of hypertension?’ And I said: ‘Yes, 
David, it’s not, because the fact is that ketanserin is an alpha blocker and that’s 
why it lowers blood pressure.’ 121 
green:  I went to a quick meeting with Janssen, who had a place down at 
Wantage, and again David Grahame-Smith was involved with this, and the 
Medical Director was sort of trying to pooh-pooh the alpha story, saying: ‘These 
drugs don’t do very much, even if you give them at high dose.’ And David just 
burst out laughing and said: ‘You know, your patients stand up and fall flat on 
their faces!’ Ketanserin wasn’t that great at high doses.
Blackburn:  Not to lose the M and D nomenclature, which really provided a 
very important roadmap for pharmacologists, as did Peroutka and Snyder’s (S1 
and S2) and Fillion’s work. All of this work and knowledge gave us sets of 
pharmacological data: where these sets of data came from, what part of the 
tissue or organ you’re trying to manipulate, its mechanism of action and its 
receptor subtype. What we tend to do is take these observations in isolation 
and we use this data to follow a road map, sometimes in the wrong direction, 
sometimes in the right direction, which may take a number of years to get to 
the actual receptor and mechanism of action. Jim Black122 gave an excellent talk 
several years ago in the States, where he showed pA
2
 values for histamine (H1) 
receptors and that you could get orders of magnitude differences in pA
2
s using 
perhaps the same tissue from the same part of the tissue from different labs – 
with the same drugs. So there are road maps, which pharmacologists follow, 
sometimes they lead us in the right direction and sometimes not, but certainly 
the M and D and the S1, S2 nomenclature provided a very valuable road map 
for us to move along with into the 1980s. 
flower:  We’re going to move on to talk about the way in which the field spread 
and come back to the topic of receptors and classification.
120 The pharmaceutical manufacturers Allen & Hanburys are now part of GlaxoSmithKline laboratories 
at Ware, Hertfordshire. For details of the pharmaceutical companies’ mergers, see Appendix 1, note 255.
121 Humphrey, Feniuk and Watts (1983).
122 Professor Sir James Black (1924–2010) was Professor of Analytical Pharmacology at King’s College 
Hospital Medical School, London, from 1984 to 1993. For further biographical details, see pages 142–3.
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sandler:  Before we move on, we should mention monoamine oxidase (MAO) 
which is present in two forms, quite different from each other.123 Only MAOB 
is present in human platelets, for instance.124 MAOA is distributed quite 
differently in rat brain and human brain. So this adds another level of compexity 
when you’re interpreting your data.125
clarke:  Merton is absolutely correct and I think I’m right in saying that 5-HT 
could be stored in platelets, because it isn’t a substrate for MAOB and it could 
not be stored in nerves unless it was in vesicles, because MAOA is inside the 
nerves. So that’s a very important distinction.
green:  Leading on from that, it is worth mentioning Ted Marley because it was 
known that the MAO inhibitors could cause this hypertensive crisis, the ‘cheese 
reaction’, and I think I’m right in that Ted was the first one who really linked 
this up on major papers.126 Would you disagree with that?
flower:  Do you want to say something about this, Merton, or do you just want 
to disagree?
sandler:  The whole situation is complex and species dependent: in rat brain, for 
instance, dopamine is metabolized by MAOA,127 but in the human brain it is an 
MAOB substrate.128 So we’ve got to think about this; there are a lot of factors.
flower:  While we’re on this topic, when did the association between 5-HT 
and the carcinoid syndrome become apparent? Was that obvious from the start 
or was it something that gradually dawned on clinical investigators such as 
yourself?
sandler:  I’m trying to remember actually. It all seemed to emerge at the 
beginning and middle of the 1950s. It was certainly known by the time that 
Mike Pare and I got immersed in this area.129 
123 Johnston (1968).
124 Collins and Sandler (1971).
125 Sandler (2004).
126 See, for example, Blackwell and Marley (1964, 1966).
127 Waldmeier, Delini-Stula and Maître (1976).
128 Glover et al. (1977).
129 Goble, Hay and Sandler (1955); Gobel et al. (1956). See page 8. 
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green:  I seem to remember that Gerald Curzon published a paper 
chromatography method showing huge excretion of 5-HIAA from carcinoid 
patients way back in about 1955, so, very early. 130
sandler:  Starting with Lembeck’s surprise observation of the presence of 5-HT 
in small ileal carcinoids.131 It was the people from Bethesda – Sid Udenfriend 
and Al Sjoerdsma and colleagues – who developed most of the 5-hydroxyindole 
methodology and particularly the method for 5-HIAA in the urine.132 They 
deserve a lot of the credit. 
Professor gavin reynolds:  Not a story, but a compelling question, perhaps to 
Merton: we mentioned Alec Coppen in the introduction of tryptophan as a 
treatment for depression,133 at what stage did we realize that we could actually 
manipulate 5-HT levels with tryptophan where we can’t, of course, manipulate 
dopamine with tyrosine?
130 Curzon (1955).
131 Lembeck (1953). See pages 8–9. 
132 See, for example, Sjoerdsma et al. (1960). Albert Sjoerdsma was head of the Experimental Therapeutics 
Branch of the National Heart Institute in Bethesda, see Sjoerdsma (2008). For Sydney Udenfriend, see 
page 157. 
133 See page 29 and note 95. For an interview with Alec Coppen, see Healy (1996), pages 265–86.
figure 11: Professor gavin reynolds.
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sandler:  I’m not sure when precisely, Alec was very smooth and very shrewd; he 
actually patented the tryptophan treatment of depression. He was a jolly bluff 
clinician with a foot in both clinical and biochemical camps; I’m sorry he’s not 
here today. 
tansey:  He sent his apologies for the meeting.
flower:  We want to move on to discuss the field as it was advancing: what was 
happening, what sort of people worked in the area, where people published, 
what 5-HT ‘clubs’ or societies were formed and how and why they were 
important. I want to start discussing the classification of 5-HT receptors. When 
did the increasing interest in 5-HT begin to impact on societies like the British 
Pharmacological Society (BPS) and the Physiological Society? 
Humphrey:  I’d like to answer this because it very much focused around myself, 
in the sense that I was asked to work on migraine at Ware. I joined in 1972 
and by 1976 we thought we’d discovered this new receptor, which I alluded to 
just now, the one that had the commonality between ergot, methysergide, and 
5-HT. It was a receptor mainly in cranial blood vessels and we thought that, if we 
could constrict them selectively, we would actually block the painful distension. 
At the time there was a theory about carotid arterial venous anastomoses and, 
funnily enough, although this receptor is in the blood vessels, predominantly 
cranial blood vessels, we discovered it in the dog saphenous vein. Luckily we 
had lots of dogs at the time that we used to work on, anaesthetized dogs, and I 
used to come along and whip out the veins and put them in a gut bath. I went 
to the BPS at Manchester, I think in 1976, to talk about this and there must 
have been 300 or 400 people in the audience – it was in the days when we had 
big audiences at BPS meetings. People said, ‘Pat, you’re not going to talk about 
5-HT again, are you?’, because they used to take the ‘Mick’ as nobody else 
was talking about 5-HT. I gave a talk about this new receptor we thought we’d 
discovered in the saphenous vein134 and I think it went down like a lead balloon 
except, as I walked up the steps from the podium, there was Michael Owen, 
who was Head of SmithKline pharmacology department, who had worked on 
migraine with Novartis. He knew the area well and said: ‘That’s going to be big.’ 
And it did turn out to be big, because then all we had to do was set about trying 
to find a selective agonist for this receptor. We knew there were more than two 
receptors because we had discovered a third, and there was some anticipation 
134 Feniuk, Humphrey and Levy (1977).
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that there would be others, so we had to get a selective compound. I had an in-
house classification in 1976 and I’ve got a piece of paper here from an internal 
report that shows it (Figure 12). 
I very reluctantly decided to call them S receptors because of 5-HT. I didn’t 
really want to become an American, I wanted it 5-HT but S just seemed a bit 
more modern, so in-house we had S1 for the Gaddum D receptor and S2 for 
our new receptor, and then S3 for the M receptor. Again, that was incredibly 
naive looking back on it; we were mixing up ion channel receptors and G 
protein-coupled receptors.135 But we went through with it, and by 1978 we had 
found that there was also a smooth muscle ‘relaxant’ receptor; having made a 
135 For G protein-coupled receptors, see Brunton, Chabner and Knollman (eds) (2011), pages 52–5.
figure 12: classification of peripheral 5-Ht (serotonin-s) receptors. glaxo group research 
report, 1983, authored and provided by Dr Patrick Humphrey. 
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compound we thought was going to be anti-migraine and when we put it in 
animals, it lowered blood pressure.136 On investigation we found that there is 
actually a receptor that, when activated, will relax smooth muscle rather than 
constrict it. So, by 1978 we had a classification in-house that went S1, S2, 
S3, which I’ve just described and then the ‘relaxant’ receptor we called S4. It 
was pretty obvious this was getting to be a bit of a mish-mash by now and it 
needed some resolution and I was quite keen to talk to other people. But I think 
the bomb really dropped for me when Peroutka and Snyder started publishing 
because they talked about S1 and S2 binding sites. The problem was that the S1 
binding site was our S2 receptor and vice versa, so it was obviously a complete 
mess. [Laughter] At the time I had a PhD student working with Philip Bradley, 
who was very keen on 5-HT, having worked with Richard Green, and he was 
always talking about Richard: ‘I know a man who knows about 5-HT.’ Suddenly 
I had kindred spirits to start talking with about 5-HT receptors and we had a 
student who was looking at platelet release and contraction of smooth muscle, 
and so on and so on. It was natural that we should start talking about things, so 
Philip Bradley set up a seminar at Birmingham.137 I think that the initial thing 
was probably just for students, but we agreed we would try to set this up at the 
BPS meeting in Birmingham in 1984 and Philip organized it. That was terrific 
because we did get people along who had different views about what these 
things should be called. They had had different experiences in the lab and had 
published different types of work. I can remember standing on the lawn outside 
and everybody having really good discussions from the offset. I think there was 
something unique about the 5-HT area that these guys were all very nice. Dave 
is still talking to me after years [laughter] and Daniel and I have had punch-
ups, but we still talk to each other and go off and have a beer. So I think for 
some reason, I don’t know what it was, experts came together from all disparate 
areas – Daniel didn’t know anything about pharmacology, he was a binder and 
grinder,138 I had to teach him some pharmacology [laughter] – and wanted to 
discuss and debate. We did eventually have a publication that came out from 
136 Dalton, Feniuk and Humphrey (1986).
137 See also pages 45–6. 
138 Binding and grinding is a somewhat dismissive label for those who work in vitro using biochemical 
techniques, including grinding up tissues and using radioactively labelled chemicals to bind to putative 
receptor sites. Whilst providing quantitative data about binding sites, such approaches give no information 
about the anatomical localization, or functionality of receptor sites. 
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the Birmingham meeting in Neuropharmacology139 and it is interesting to look 
at the names: Phillip Bradley, Gunter Engel, who couldn’t unfortunately be here 
today; Wasyl Feniuk, who is a very close colleague of mine and it’s a great shame 
he isn’t here today, because he did a lot of work with me on migraine; John 
Fozard, another very important person, and it’s a very great pity he can’t be here 
either; myself; Derek Middlemiss, again coming from a binding background 
from what I remember; Ewan Mylecharane, he’s an Aussie, we’ll forgive him 
for not being here; Brian Richardson, from Sandoz; and then Pramod Saxena, 
another very important man in the field of migraine research. So, that was quite 
a group. I think that after that Birmingham meeting everybody was talking 
regularly on the phone or at meetings and that was really the start of it. All of us 
realized, however, that we needed to bring it together into a more authoritative 
basis and, I suppose, that leads us up to Heron Island. 
For those of you who didn’t go, hard luck. [Laughter] This was the meeting that 
was in parallel with the International Union of Basic and Clinical Pharmacology 
(IUPHAR) meeting in Australia and everybody who was interested in 5-HT and 
could make it was there. Again, this sort of collegiate interaction was amazing. 
There was a lot of good, healthy discussion, some of it unhealthy as well, I 
suspect, but usually offline, and we could get agreement. I was very pleased with 
the book that came out of this meeting, because Brian Richardson and I wrote 
a chapter that said: ‘This is where we think we are at the moment with 5-HT 
139 Bradley et al. (1986). 
figure 13: Poster advertising the 5-Ht meeting held on Heron island, Queensland,  
Australia, 4–6 september 1987. 
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receptors.’140 It wasn’t just us, because it was a round table discussion – a bit 
like this meeting – people were jumping up and Brian and I led the discussion 
and finally collated all the thoughts and put it into a piece of prose. That was in 
September 1987 and at the same time I went to the IUPHAR meeting, to the 
vestigial IUPHAR receptor and nomenclature committee that Paul Vanhoutte 
had set up.141 Paul had also been very instrumental helping to set up the Heron 
Island meeting, but unfortunately he wasn’t able to make it in the end. But I 
went to the IUPHAR meeting to represent the 5-HT story so far and report 
back from Heron Island, and that was the formation of the Serotonin Receptor 
Nomenclature Committee under the auspices of IUPHAR.142 I remained 
chairman of that committee from 1987 to 1993. So that was the beginning. 
I think Heron Island really set things up because people were marooned on a 
desert island [laughter], we had days to talk to each other, and old friendships 
were established, if they hadn’t been established before. I think people could see 
that everybody had different opinions, that was good, but we were all interested 
in finally getting some sense out of the real mish-mash – there were people with 
different nomenclatures, 5-HT
1P
 and God knows what else. We got rid of that 
in the end. 
flower:  You mentioned giving a talk to BPS in 1976 or 1978. How many 
people were interested in 5-HT at the BPS meetings in those days? It sounds 
like hardly any.
Humphrey:  Virtually none.
green:  I remember working through the 1970s, a different era from Pat, 
and feeling there weren’t very many people interested in 5-HT at all. Then 
the Birmingham meeting was just amazing.143 Phil Bradley had very much 
organized this and being used to a great deal of indifference about 5-HT in the 
140 Humphrey and Richardson (1989).
141 Professor Paul Vanhoutte (b. 1940) was a consultant in the Departments of Physiology and Biophysics, 
and Department of Cardiovascular Medicine at the Mayo Clinic, Rochester, Minnesota, from 1981 to 
1989, and has been Director of the BioPharmaceutical Development Centre, University of Hong Kong, 
since 2003 and Chair Professor and Head of the Department of Pharmacology at the Li Ka Shing Faculty 
of Medicine, University of Hong Kong, since 2006.
142 The Serotonin Receptor Nomenclature Committee was established in 1990 as a subcommittee of the 
Serotonin Club, whose chair and members are appointed by its Executive Committee.
143 See pages 43–4. 
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brain at things like BPS meetings. I went to that meeting to give a talk and there 
was this huge lecture theatre, which was absolutely packed out.144 I said to Les 
Iversen, who of course had just moved then to Merck: ‘What’s all this about? 
Why are all these people interested?’ And Les, in his usual slightly hooded-
eyed manner, said: ‘I’ve no idea.’ Of course, he did have an idea because, as 
Pat said, the industry was abuzz then, but most of it hadn’t been published. It 
was all happening under the surface and there were huge numbers of industry 
people at that meeting all writing frantically, you could tell, and that really was 
a major turning point as far as I’m concerned, from a quiet time to suddenly it 
all happening.
Humphrey:  The meeting was called ‘5-HT, Peripheral and Central Receptors, 
and Functions’, but it was under the auspices of the BPS, and I suspect that may 
have been one of the reasons so many people came.145 
Wallis:  I didn’t go to the nomenclature meeting, but I remember reading a very 
adroit and complete description of it written by Paul Hartig and his key point 
was ‘fingerprint criteria’ for establishing the receptors.146 I want to ask Pat how 
important was that to the discussion?
Humphrey:  I think, again, this was interesting because Paul Hartig was coming 
very much from the second messenger angle, and he brought a lot of new thinking 
in there. But the concept of the fingerprints was something that was evolving 
throughout the pharmacological world and, in fact, that’s what the IUPHAR 
nomenclature group set out to do in the first instance: we had an international 
committee just to talk about the fingerprints you needed to characterize receptors 
almost as a blueprint147 before one went off into these different receptor areas. A 
lot of it was pioneered by the 5-HT group simply because we had so much data 
and then suddenly we had so many people prepared to have an input. In many 
ways the 5-HT group carried the thinking around receptor characterization in 
general anyway. Of course, we had the complexity too of all the molecular biology 
coming in and some of the molecular biologists were doing their own thing and 
giving their proteins names unilaterally, but towards the end they were coming 
144 Green (1984).
145 Some of the proceedings of this meeting were published in Neuropharmacology (1984) 23 (12B): 1465–
569. 
146 See, for example, Hartig (1994). 
147 Vanhoutte et al. (1994). 
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down the IUPHAR track. It was very interesting in the prostaglandin area: 
the functional characterization and nomenclature had been done long before 
Narumiya did all his wonderful molecular biology, and the molecular biologists 
had to go along with the functional nomenclature rather than the other way 
around.148 But anyway, I think by then we’d all realized that fingerprints needed 
everything: it needed second messenger, it needed functional data, it needed the 
molecular definitive recognition as well. 
Hoyer:  There are at least four different groups who were extremely important 
in this. Firstly, the Serotonin Club that was created 25 years ago; we have just 
celebrated 25 years of the Serotonin Club in Montpellier this summer (2012). 
The club was an amalgamation of people with very different expertise and 
horizons – academics, but also people from industry.149 I think for some reason 
at that time, there were probably more people from industry than academics. 
The second important contribution was the support that we got from the BPS 
from the start. When you look at many of these 5-HT meetings they were 
in conjunction with the BPS. Actually, the Serotonin Club used to have a 
lecture at every Christmas BPS meeting, sometimes in a Greek restaurant or at 
a Christmas party; no one could hear anything, but the whole point was to be 
there with friends and colleagues. Thirdly, IUPHAR was also important and it 
started pretty much at the same time. We established the 5-HT nomenclature 
committee in 1990, which had a leading role for setting the criteria for all the 
receptor nomenclature committees that were established afterwards, something 
like 90 committees. The Hartig paper that we published together in 1993 in 
Trends in Pharmacological Sciences, was the result of one of these meetings, it 
set the scene.150 So we said that there have to be four criteria for a receptor to 
be recognized including: a) it has to be relevant to the human situation; b) the 
pharmacological fingerprint or profile; c) structure, which was about to come 
because molecular biology was kicking in in the early 1990s; d) function – 
the function at that time could have been anything, but it was even better if 
you had a second messenger you could characterize. We haven’t talked about 
splice variants, and strange things like biased signalling at the time (quite often 
described as poor pharmacology). But we left it open for future adaptation. The 
good thing is that the group had enough flexibility to keep going. The fourth 
contribution that was important, I actually think it was probably the first one, 
148 Coleman et al. (1984); Coleman, Smith and Narumiya (1994).
149 See the Serotonin Club website at www.serotoninclub.org/ (visited 26 March 2013).
150 Humphrey, Hartig and Hoyer (1993).
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was the input of the pharmaceutical industry, where 5-HT research was very 
active, but often people did not know of it because much work in the industry 
was more underground and was not published immediately. What we knew, 
of course, was that Pat was working on these targets; similarly Sandoz, which 
has been a 5-HT company since the start (they worked on LSD),151 realized in 
1978 that 5-HT was important and so they asked Brian Richardson to set up a 
task force whose only remit was: ‘What is 5-HT? How many receptors? What 
do we know about 5-HT’s role? What is the link to the clinic and what can we 
do to make drugs, whatever the indication?’ They started to work on 5-HT
3
 
(Gaddum’s M receptor) and initial indications were pain, because the blister pain 
model using capsaicin, was sensitive to 5-HT
3
 antagonists, e.g. ICS 205,930. 
This was only the first indication. At some point they also considered migraine 
but, of course, 5-HT
3
 mechanisms in pain are more complex. Somewhat earlier 
John Fozard had started a group at Merrell Dow in Strasbourg, where they 
were working specifically on 5-HT. They discovered MDL 72,222, which died, 
as do many compounds because of toxicology reasons, but it was one of the 
first selective 5-HT
3
 antagonists.152 Mike Tyers and collaborators in Bradford 
(Brenda Costall and Robert Naylor, I don’t know how many collaborations 
they had altogether), reported on GR 38032 (ondansetron),153 the beauty was 
that industrial chemists were to design new, selective compounds. That was 
the difference before cloning, once you had the tools you could start working. 
Today everything is simple: clone and express the receptor and you throw any 
compound on it; you know it’s only mediated by that given receptor. But in 
those days, whether you used a guinea pig ileum or anything else, you would 
have to make sure that you had selective compounds, otherwise things were 
not going to fly. So the interesting part was that then some worked on 5-HT
1
, 
but others worked on 5-HT
2
 or 5-HT
3
 receptors. Paul Janssen was working on 
5-HT
2
 and there’s much to say about his influence in the field at that time.154 
151 For Sandoz and LSD see page 15 and Snyder (1986), pages 189–93.
152 Professor David Wallis wrote: ‘Between 1983 and 1985, John Fozard collaborated with David Wallis at 
Cardiff in experiments assessing the action of MDL 72222 on the 5-HT
3
 receptors on sympathetic neurons 
and on vagal afferent neurones, work funded by Merrell Dow.’ Note on draft transcript, 14 December 2012.
153 For a discussion of the use of ondansetron in a paediatric study, see Christie and Tansey (eds) (2007), 
pages 59–60. 
154 For Janssen, see note 119.
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Actually, there was some good influence and some rather bad influence.155 But it 
was the involvement of the chemists, by and large, that made the whole process 
of receptor characterization feasible, because they synthesized more and more 
selective compounds. Then, at some point, Fozard, Hamon and other colleagues 
published about 8-OH-DPAT being the first selective 5-HT
1A
 compound.156 
That’s when I jumped in and we just kept going, testing more compounds, 
more radioligands, more tissues and more species. I was supposed to be in 
cardiovascular research but actually my heart has always been in the brain. So 
I worked almost ‘undercover’ with Chema Palacios in CNS who had just come 
back from Mike Kuhar’s lab in Baltimore and we applied techniques that Pat 
would never use, not at that time; he changed later.157 We use a combination of 
binding, autoradiography and second messenger and chemicals, lots of ligands, 
to sort out the mess. This was how we discovered 5-HT
1A
 versus 5-HT
1B
 and the 
5-HT
1C
 that was renamed 5-HT
2C
. We looked at 5-HT
2
 receptors, of course, 
and then realized that a subtype of 5-HT
2
 receptors was in the stomach fundus 
(to become 5-HT
2B
). We started to work on 5-HT
3
 receptors, then realized 
there was something in the gut and in the brain that didn’t fit to any of these 
classifications, which was 5-HT
4
 at this point, and so on (there was still some 
confusion about 5-HT
3
, 5-HT
4
 and the M receptor in the late 1980s).158 New 
receptors came out one after the other. An interesting thing is that, shortly 
afterwards, molecular biology kicked in and we integrated all these cloning 
people in the ‘club’. The first interaction I had with Pat was at the BPS meeting 
in 1986. I think there were probably 600 people in the audience. Everything 
went well and I described the 5-HT
1A
 receptor mediated inhibition of cyclic 
AMP (cAMP) activity;159 nothing to write home about today, but at that time 
it was new. Then Pat got up and said: ‘This has nothing to do with physiology, 
you’re just talking about a second messenger. We don’t know what the second 
155 Professor Daniel Hoyer wrote: ‘There was a strong bias toward supporting ketanserin as an 
antihypertensive for several years, ignoring findings that showed that this had nothing to do with 5-HT
2
 
antagonism, as it was all explained by alpha 1 antagonism. Along the same lines, some of Paul’s senior 
collaborators were influencing the field by not recognizing at all 5-HT
1
 or 5-HT
3
 receptors.’ Email to Ms 
Caroline Overy, 1 July 2013.
156 Middlemiss and Fozard (1983); Gozlan et al. (1983). 
157 See for example, Palacios et al. (1990).
158 Hoyer (1990). 
159 See, for example, Markstein, Hoyer and Engel (1986); Schoeffter and Hoyer (1988). 
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messenger is doing.’ That was going back and forth. Then the chair of the 
session160 said: ‘Stop. Go to the bar. Sort it out. Then come back.’ [Laughter] 
This was the beginning of a friendship that resulted in the big nomenclature 
paper,161 I don’t know where the friendship will culminate as we keep seeing 
each other, even when we’re in different parts of the world, and we keep going. 
But this is what led to the spirit of the 1994 Pharmacological Reviews paper. It 
has been cited about 2500 times now, it keeps being cited, and I think you can 
re-read this paper, occasionally I do, and much of what we had written then 
and there is still pretty valid. It’s good, it integrates different backgrounds and 
when you look at it, you can clearly recognize the style of the different authors. 
John Fozard’s writing is different from my writing, which isn’t surprising given 
my background. I will try to improve. The good thing is that everyone’s views 
were accepted and, given that industry was playing a major role, what we tried 
to do was not to mislead people. That is, we could not give away all the secrets, 
but at least there was the understanding that if anyone was going on the wrong 
track we were telling them not to do that, not to mislead, just to be open. We 
could not say everything, but it worked, and I think it worked remarkably well. 
I’ve published papers with people from all over the place, maybe more from the 
‘competition’ than with Sandoz. That was remarkable. Again, it was because of 
the auspices of the BPS. It would not have happened in France and it would not 
have happened in the United States, that’s for sure.162
Humphrey:  I have a human perspective on what Daniel has said. Daniel and I 
took care of the editing of the consensus IUPHAR manuscript163 but, as Daniel 
said, all the authors wrote their own chunks and then we had to try to integrate 
it, which involved quite a lot of time and effort. I’d just like to mention that 
the authors were: Hoyer; Clarke, sitting there; Fozard; Paul Hartig; Graeme 
Martin, who unfortunately can’t be here today, who went on to take over from 
me as Chairman of the Nomenclature Committee after I moved onto other 
160 No one can now recall who was chairing this meeting.
161 Hoyer et al. (1994).
162 Professor Daniel Hoyer wrote: ‘The collegiality between researchers from academia and industry that 
was so obvious at the BPS was so very different from what was common standard in the other countries and 
was certainly not experienced between industrial scientists in other countries, for fear of competition and IP 
(intellectual property) issues.’ Email to Ms Caroline Overy, 1 July 2013.
163 Hoyer et al. (1994). 
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neurotransmitters; Ewan Mylecharane; Pramod Saxena and myself. So it’s 
difficult to know who wrote that paper because everybody had such a massive 
contribution and the fact that we got everybody to agree, in what was a very 
large tome. I think we made a rather trite statement at the beginning that, 
between them, all the authors had got 100 years or more experience in the 
5-HT field, but it was true.164
flower:  It was a landmark paper; no doubt about that. I want to step back for 
a second to ask if there were any other influential organizations apart from the 
BPS? 
green:  I think it was the BPS, more than anything else. Certainly not the 
Physiological Society. Some of these people that Pat and Danny have mentioned 
– Danny himself, Pramod Saxena – used to come to the BPS winter meetings, 
and it is notable that when Paul Vanhoutte wanted to set up the Serotonin 
Club, he had a meeting in December 1986 in London, actually at the School of 
Pharmacy.165 I don’t know who else was there, but Paul recognized that, as well 
as setting up the Serotonin Club in the States, coming to the UK in December, 
because that’s when these meetings were held, was another important step in 
setting up the Serotonin Club.
clarke:  A quick comment that classical pharmacology played an important 
role in the definition of 5-HT receptors, no doubt about that. Pat’s work was 
classical pharmacology; Fozard’s work was started in 1962. I taught him classical 
pharmacology at Bradford. Without any binding, without any structure, 
without any second messenger, Fozard defined the 5-HT
3
 receptor with cocaine 
and various isomers of cocaine and so forth.166 So classical pharmacology was 
the foundation, but it wasn’t enough, and as Daniel says, without the tools, 
classical pharmacology is quite impotent. But we did have one or two tools 
164 ‘It is the role of the biologist to define the receptors of interest and to define the type of ligand required 
for a particular therapeutic utility. It is for this reason that the authors of this review have spent more than a 
combined total of 100 years working on 5-HT receptors, to characterize them and to define their function 
and distribution.’ (Hoyer et al. (1994), page 159).
165 See Green (2004), page 3, in which he writes: ‘In 1986 I attended a “start up” meeting at the School 
of Pharmacy in London that Paul Vanhoutte had organised in order to get together scientists who were 
interested in forming a society that would incorporate anyone interested in serotonin research.’ The 
Serotonin Club was formally founded in 1987, see www.serotoninclub.org/newsletters/Nwsltr64.pdf 
(visited 8 May 2013).
166 See, for example, Fozard, Mobarok Ali and Newgrosh (1979).
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and classical pharmacology did lay an important foundation for binding and 
structure, which then led to cementing the whole field.
Blackburn:  Pat mentioned the screening cascades he was developing. In the 
1980s at ICI Pharmaceuticals, we were developing similar screening cascades 
based on the 5-HT M & D receptor classification and subsequently the S1 and 
S2 receptors. Around this time, ICI chemists Bob Pearce and Craig Thornber 
were synthesizing compounds, which were believed at the time to be selective 
S2 receptor antagonists.167 We didn’t understand then about 5-HT
2A
, 5-HT
2B
, 
5-HT
2C
 receptors, but we had inklings that the receptor from the fundus of 
the rat stomach was different from the classical 5-HT receptor pharmacology 
that we were working on at this time. I’ll come back to that later with regard to 
actually identifying selective compounds for the 5-HT
2B
 receptor at SmithKline 
Beecham. So, the industry was very good at the time in developing tools and 
ICI 169,369 and ICI 170,809 were some of the early 5-HT
2
-like compounds, 
used worldwide in trying to understand the physiology/pharmacology of the 
5-HT
2
 receptor. About this time, John Fozard and I were communicating on 
a selective 5-HT
1
 receptor agonist 8-OH-DPAT and it was clear that the ICI 
chemists’ sample of 8-OH-DPAT was more potent than John’s sample. So we 
were swapping actual compounds in those days. Those tools proved to be very 
valuable in our 5-HT research at the time. A number of these compounds did 
actually go into the clinic as they didn’t possess the alpha-1 receptor properties 
that the Janssen compound ketanserin possessed.168 For example, ICI 169,369 
went into a migraine prophylactic study and was shown to be active – it reduced 
the general symptoms of migraine by about 40–50 per cent. 
We also went into the clinic with ICI 170,809 in schizophrenia and depression 
but, unfortunately, the compound failed to show efficacy due to the studies 
being, in my opinion, underpowered. However, at that time ICI Pharmaceuticals 
acquired an American company, Stuart Pharmaceuticals, in 1972, which focused 
on CNS research. It was a little later, that Professor Barry Cox and I presented 
the Serotonin 2 (now 5-HT
2A
)/dopamine hypothesis to them in Wilmington, 
with regard to the importance in the basal ganglia area and in ameliorating the 
167 Blackburn et al. (1987).
168 See note 103.
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dyskinesias and psychotic-like side effects in schizophrenia.169 It was from this 
early work that the atypical antipsychotic Seroquel (quetiapine) was developed 
and became one of the biggest selling drugs for AstraZeneca. 
So, in those early days, we were providing compounds that allowed the science 
and the pharmacology of 5-HT to move forward, with a few of them still very 
successful in the clinic.170 If you look at the 2010 prescription sales, out of the 
top ten there are, I think, four or five compounds that are related to 5-HT 
research;171 we’re talking about billions of prescriptions, which highlights the 
impact that 5-HT research and development has had on industry and academia.
sanger:  I want to add a comment to David [Clarke’s] point because there are only 
really two occasions when I’ve wished my first degree was in pharmacology. The 
first was when my post doc supervisor asked me to define a pA
2
 first thing in the 
morning.172 [Laughter] The second was reading your [David Clarke] paper in 
which you used classical pharmacology to define the 5-HT
4
 receptor using ICS 
205,930, then known as a 5-HT
3
 receptor antagonist. But you protected the 
receptor and showed that this molecule in high concentrations could actually 
antagonize a response mediated by a different receptor, later called 5-HT
4
.173 
It was a wonderful piece of classical pharmacology and I think broke open the 
area of 5-HT
4
 receptor research. Until then we were talking about responses and 
maybe recognition sites – I certainly was. You actually defined it using that nice, 
classical piece of pharmacology. You were absolutely right.
marsden:  Just going back to that 1984 meeting. I think one of the interesting 
things for me and people like Richard and others who were involved in 
some of the behavioural functional read-outs, was that there was an interest 
in that aspect and that we needed to try to get things in order to be able 
to classify the receptors. The arrival of 8-OH-DPAT was very important 
169 Blackburn et al. (1980, 1981); Blackburn, Cox and Lee (1982).
170 See Scrip (1988) and also the comment by Dr Patrick Humphrey on page 36 and note 117.
171 See Table 3 on page 126.
172 Professor Gareth Sanger wrote: ‘This is a pharmacology term, defined as: “The negative logarithm to 
the base 10 of the molar concentration of antagonist that makes it necessary to double the concentration of 
agonist needed to elicit the original submaximal response” (Cammack et al. (eds) (2006)). It is a very useful 
way of quantifying and comparing the functional effects of the antagonist in different experiments.’ Email 
to Ms Caroline Overy, 16 July 2013.
173 Craig and Clarke (1990). 
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because you actually got a defined response, both the temperature response 
and the behavioural response, so it seemed possible that you could use these 
as behavioural outcomes. The other thing that occurred at that time, of 
course, was the expansion of molecular biology. That had an adverse effect, 
I think, particularly on academic research, because the Thatcher years were 
not the easiest for academic research and the Government at that time were 
very keen on having very short-term, quick responses, and molecular biology 
seemed to provide that opportunity.174 Those of us who were on the more 
functional end had quite a struggle at that time. I was extremely lucky because 
I was protected as I was supported by the Wellcome Trust on a long-term 
sponsorship. The other advance that occurred then was the development of 
both the in vitro and in vivo measurements of ‘release’ or, at least, transmitter 
overflow and measurement of extracellular levels.175 I think that the 
development of microdialysis, in particular, provided an alternative approach 
174 The mid-1980s saw the launch of the campaign ‘Save British Science’, which highlighted the difficulties 
in raising funds for scientific research in Britain. In 2005 this became the Campaign for Science and 
Engineering in the UK (CaSE); see www.sciencecampaign.org.uk/about/history/index.htm (visited 27 
March 2013). 
175 See note 98 and also Marsden (ed.) (1984). 
figure 14: Professor gavin reynolds and Professor charles marsden.
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that could be used to look for end points in terms of receptor responses.176 I 
do think, however, the very strong impact of molecular biology on research, 
while terribly important, did have, to some extent, a negative impact on the 
development of ways of understanding the role of 5-HT in disease and what 
the true functional consequences of 5-HT were in terms of behaviour. Now, 
of course, that has to some extent been reversed.177 
Dr mike tyers:  I want to have a chance to talk about the 5-HT
3
 receptor, 
since no one seems to be talking about it. It’s a sort of forgotten receptor, 
probably because it appears to have no subtypes and, as far as we know, 
it’s the only ligand-gated ion channel receptor. We started looking at the 
5-HT
3
 receptor at Glaxo Greenford in the early 1980s, a separate group 
from Pat’s at Allen & Hanburys at Ware. We started looking for a selective 
5-HT
3
 receptor antagonist. We knew that metoclopramide was a dopamine 
antagonist, but John Fozard had shown that, at higher concentrations, it was 
a 5-HT
3
 receptor antagonist as well.178 Several companies were looking at 
5-HT
3
 receptors at the time and were making compounds related to known 
molecules that had affinity for the receptor, like metoclopramide and cocaine. 
At Glaxo, we started with the neurotransmitter and synthesized lots of 
modified tryptamines and screened them in vitro against depolarization of the 
vagus nerve induced by 5-HT, and in vivo against the Bezold-Jarisch reflex 
bradycardia induced by intravenous injection of 5-HT or a 5-HT
3
 selective 
agonist in the chloralose in the anaesthetized cat.179 I remember that within 
a few weeks of starting the project in 1985, we discovered 2-methyl-5-HT, 
which was a selective 5-HT
3
 receptor agonist. Selective 5-HT
3
 antagonists 
soon followed by substituting the 5-OH group with bulk and a substituted 
-N imidazo group (the chemists involved were Dai Humber, Ian Coates, Alec 
Oxford and Colin Smith).180 Our screening test was depolarization of the rat 
isolated vagus nerve. The vagus nerve is smothered in 5-HT
3
 receptors and, 
176 For an overview, see Chefer et al. (2009).
177 Professor Charles Marsden added: ‘… by the need to have real understanding of the behavioural 
consequences of genetic manipulation in mice.’ Note on draft transcript, 5 February 2013.
178 Fozard and Mobarok Ali (1978).
179 See Ireland and Tyers (1987); Kilpatrick, Bunce and Tyers (1990). 
180 Brittain et al. (1987).
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being the Xth cranial nerve, arose in the brain stem in the region of the area 
postrema, also called the vomiting centre.181 Latterly we identified a 5-HT
3
 
radio-ligand binding site in the brain and used this as our preferred in vitro 
test.182 As the Department of Neurophamacology at Glaxo Research we were 
particularly interested in the central effects of 5-HT receptor-selective ligands. 
We set up academic collaborations with many groups around the world and 
gifted our selective compounds to them, asking them to test them in their 
particular assay systems. Our collaboration with the Bradford group – Brenda 
Costall, Bob Naylor and Annette Domeney – was particularly productive, 
leading us to start clinical trials in dementia, memory and anxiety.183 We soon 
found it virtually impossible for one company to do evaluation in more than 
one psychiatric disease because the error was so great, needing studies on 
many tens of thousands of patients for each arm of the study. Also, it wasn’t 
just one dose needed to produce the effects, but many – the amount of data 
and subsequent analysis was awesome, even for Glaxo!
Upjohn undertook eleven trials with Prozac to get FDA approval and onto the 
market, only two of which showed effects in depressed patients. Amazing! 
Inspired by John Fozard’s work with MDL 72,222 in migraine,184 we also 
undertook a trial with one of our selective 5-HT
3
 antagonists and found that, as 
in John’s study, the 5-HT
3
 antagonism had no effect on headache but did have 
a moderate effect on sickness. John didn’t actually report what effects MDL 
72,222 had on vomiting, but has subsequently said that there was a mild effect. 
Now, Dick Gralla, an oncologist in New York, had reported that high doses 
of metoclopramide were able to stop sickness in cisplatin-induced vomiting 
in his cancer patients better than other dopamine antagonists, which had no 
additional 5-HT
3
 actions.185 Putting two and two together, we postulated that 
181 For a detailed description and review of the anatomy of the central pathways for nausea and vomiting, 
see Hornby (2001); Onishi et al. (2007); Stern, Koch and Andrews (2011).
182 Kilpatrick, Jones and Tyers (1988).
183 For 5-HT and psychiatry, see Sandler, Coppen and Harnett (eds) (1991).
184 See for example, Loisy et al. (1985); see also Fozard (1990). 
185 See Gralla et al. (1981); Kris et al. (1983); Gralla (1983); see also the Witness Seminar on the discovery, 
use and impact of platinum salts as chemotherapy agents for cancer, at which Professor Richard Gralla was 
a participant; Christie and Tansey (eds) (2007).
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block of 5-HT
3
 receptors should be able to stop sickness induced by cancer 
chemotherapeutic drugs.186 Subsequent studies with a selective 5-HT
3
 antagonist 
by Robert Naylor in ferrets [100 per cent effective!]187 and then by John Smyth 
in Edinburgh in patients, showed this to be true.188 We went up to John Smyth 
in Edinburgh and asked him if he would test the compound in his patients. 
He said: ‘I’ve got very sick patients here,’ and so referred us to Bob Naylor at 
Bradford, who was doing experiments with dopamine antagonists, to do some 
tests in ferrets. I went up to Bob and said: ‘Would you test this compound 
against cisplatin in your ferrets?’ He said: ‘It’s not going to work, you know.’ 
Anyway he did test it, and two weeks later he said: ‘You know, it worked; 100 
per cent!’189 So we went back to John Smyth and said we had the data, and 
he gave it to one of his most refractory patients. He phoned up the next day, 
excited, and said: ‘This drug has worked effectively. The patient is sitting up 
in bed eating a hospital breakfast, looking pink and happy.’ This was possibly 
the anti-anxiety effect showing through as well. I think some clinicians started 
using it off label; one was a patient with bulimia, who said it was the best drug 
she had ever taken to help her tackle bulimia. But it’s not worth developing a 
drug for bulimia, there are too few cases, so it would be down to the clinician 
to decide whether to use it or not.
The rest is routine development for any drug, but since we had already conducted 
clinical trials with a selective 5-HT
3
 antagonist in phase 1 and 2, we could 
go straight into simple phase 2 studies in cancer patients. We had one false 
start with a compound that, as well as being a potent 5-HT
3
 antagonist, also 
186 Butler et al. (1988); Tyers, Bunce and Humphrey (1989). Dr Mike Tyers and Professor Gareth 
Sanger were jointly awarded the 1998 Pharmaceutical Research and Manufacturers of America (PhRMA) 
Discoverers Award for the 5-HT
3
 receptor/antiemesis research. Further recollections by Dr Mike Tyers on 
the development of ondansetron are archived with the records of this meeting. See also note 190.
187 Costall et al. (1986, 1987); see also, Florczyk et al. (1981); Florczyk, Schurig and Bradner (1982).
188 Professor Paul Andrews wrote: ‘The first paper I can find on PubMed by J F Smyth on ondansetron 
and cisplatin is Smyth et al. (1991). This is not the first clinical paper on ondansetron in chemotherapy (I 
think that this is Cunningham et al. (1987)), nor is it the first on cisplatin and ondansetron in either the US 
(Kris et al. (1988)) or the EU (Marty et al. 1989)). He may have done studies that were unpublished or that 
were presented at a conference – there was a big ondansetron meeting, I think, in 1987...There are basic 
and clinical papers in the same time window on other 5-HT
3
 antagonists and, in particular, granisetron the 
Beecham/SmithKline compound. The first granisetron paper with cisplatin that I know of is Carmichael et 
al. (1988).’ Email to Ms Caroline Overy, 26 June 2013. 
189 Stables et al. (1987).
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inhibited cytochrome P450, indicating a number of potential drug interactions 
would be possible. Ondansetron was the next compound to come off the line 
and was quickly substituted for the ‘toxic’ compound.190
flower:  Would anybody else like to say anything about 5-HT
3
 since Mike has 
started the thread? 
Blackburn:  In support of Mike, and 5-HT
3
’s role, particularly in the CNS as being 
a lost cause, it was following the work from Mike’s group at Glaxo and others, 
that at Beecham we were working on a compound BRL 46470, which we took 
190 Professor Gareth Sanger wrote: ‘[at Beechams] we were working on a series of compounds that blocked 
cisplatin-induced vomiting in ferrets, but we weren’t sure exactly how – the mechanism was either because 
the compound regulated gastric motility (by 5-HT
4
 receptor agonism) or because it antagonized at 
5-HT
3
 receptors. We suspected the latter because (a) John Fozard had demonstrated that relatively high 
concentrations of a related compound (metoclopramide) antagonized at the 5-HT
3
 receptor and because 
Dr Gralla had previously published a paper that showed that cisplatin-induced vomiting in cancer patients 
was blocked by high doses of metoclopramide (then assumed to be a better way of accessing dopamine 
receptors in the brain). The result was that I asked John Fozard for a sample of MDL 72,222, his selective 
5-HT
3
 receptor antagonist. We found that this compound blocked the vomiting caused by cisplatin and 
published our data (as the first full paper on the subject, previously abstracted elsewhere, by us). Clearly, our 
previous abstracts had also alerted the competition! In pouring rain in Melbourne, Brian Richardson (then 
from Sandoz, later Novartis) apologized to me for reacting to our abstracts as fast as he could, contacting the 
Bradford group of researchers (Bob Naylor and Brenda Costall) to quickly test their compound (tropisetron) 
and publish as soon as possible (it came out shortly after ours)! We then had several beers together! At 
around this time, Glaxo had taken the brave (and wise) decision to develop a 5-HT
3
 receptor antagonist 
and then see what it did, originally focused on several CNS disorders. This approach was clearly evident in 
the patent on ondansetron. Tough to know what happened next – anecdotal reports that migraine patients 
were vomiting less + reading our abstracts? Whatever the story, the very efficient Glaxo clinical development 
and marketing team then took over, accelerated the development of ondansetron and dropped the previous 
CNS indications (the subsequent PharMA award recognized the discovery of a new drug, which had then 
been successfully marketed; perhaps we in Beechams could claim more on the discovery side and Glaxo on 
the development side? It will now always be a moot point). Ondansetron and granisetron then competed, 
but when SmithKline Beecham and GlaxoWellcome merged to form GSK, ondansetron was retained and 
granisetron sold off, to mitigate competition laws. A great story! With hindsight, perhaps we shouldn’t have 
alerted the world with our abstracts, so we could have kept the credit for the discovery. However, for cancer 
patients, maybe it’s a good thing that we did! 
In addition, however, it is important to note that we in Beecham Pharmaceuticals (soon to be 
SmithKlineBeecham and then GSK) took a use patent out on the Glaxo compound (ondansetron) after 
reading their own patent, which did not mention the control of nausea and vomiting. As a result, Glaxo 
had to pay royalties for many years!’ Email to Ms Caroline Overy, 16 July 2013. See also Appendix 1. 
For further discussion on the development of ondansetron at Glaxo and granisetron at Beechams, see the 
Witness Seminar on platinum salts as chemotherapy agents for cancer (Christie and Tansey (eds) (2007)), 
especially pages 51-4.
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into a number of clinical studies. Unfortunately, the mindset within the industry 
and management was that some of these models didn’t travel or translate from 
the Bradford/Glaxo groups’ initial findings. That was not the case at Beecham, 
we actually repeated a lot of the work both in vitro and in vivo. However, what 
we found, like many drugs in pharmacology with agonists and antagonists that 
produce ‘bell-shaped’ dose response curves, a fact the clinicians couldn’t get their 
head around, these compounds were very potent. So the question was how to 
make a tablet when you’re talking about sub-microgram levels of compound, 
although clinicians were well aware of the action of, for example, LSD in humans 
at low concentrations equal to those determined for 5-HT
3
 antagonists. This was 
perceived as a challenge for 5-HT
3
/CNS compounds in the clinic when they 
were active at such low concentrations. It was the initial work of Gareth Sanger 
on BRL 46470, from which we knew that there was something different about 
this compound, because you didn’t see the same GI effects as with other 5-HT
3 
receptor antagonists.191 Despite much effort, sadly we failed to show efficacy 
in the clinic with this compound. There were, however, some pluses with this 
compound in funding a number of PhD students with Jerry Lambert in Dundee 
and Nick Barnes in Birmingham, looking for subtypes of the 5-HT
3
 receptor, 
with some success. It was following Beecham’s merger with SmithKlineFrench 
in 1989, that the emphasis on this particular therapeutic target soon lost its way. 
But, in support of Mike, we reproduced a lot of his early data.
mr Wesley miner:  I’d just like to step back a little bit and return to what Tom 
was saying, to put things in perspective in 1984, particularly at Beecham. The 
actual driver of the 5-HT
3
 / 5-HT
4
 programme was Gareth. He was working 
hard on the whole thing at the time and knew the pharmacology, that is the 
classic pharmacology, of 5-HT. He knew 5-HT backwards and forwards, and 
he was the first one to actually make this quantum leap from 5-HT
3
 to the 
anti-emetic activity on that. But, as Tom was saying, we ran into some very stiff 
opposition from management. On one occasion, we had a project meeting where 
our second in command of research sat there and told us that Beecham would 
never go into anti-emetics again, because they had been burnt in that area before. 
Gareth and I sat there and we had all this data produced at the time. We 
knew exactly what was happening, we had the data right down the line. The 
compounds, 5-HT
3
 antagonists, were so effective against anti-cancer therapy-
induced emesis that we both just got up there and, even though the chairman 
was telling us ‘No we’re not going to do it’, we kept on at it. After we came out 
191 See, for example, Bermudez and Sanger (1994).
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of the meeting, one of our colleagues, Christine McClelland, turned to us and 
said: ‘I thought you were both going to get fired on the spot’ [laughter], because 
we just would not give up on it; we knew we had something.192 It was because 
of Gareth’s drive in the 5-HT
3
 area and on into the 5-HT
4
 area, that Beecham 
research really was very focused; and that was where a lot of the drive (5-HT
3 
and 5-HT
4
) came from on the Beecham side of it. However, for a long time 
Gareth did not get much support, but ultimately things moved forward.193
192 Mr Wesley Miner wrote: ‘While Gareth (Sanger) and I did have to overcome some pretty high hurdles 
before senior management bought into our 5-HT
3
 anti-emetic work, at one point we were summoned by 
the chairman of research at Beecham, Dr Keith Mansford, for a private viewing of a video that we produced, 
which showed the very dramatic effects of a 5-HT
3
 antagonist completely inhibiting cisplatin-induced 
vomiting in a ferret almost instantly after I had dosed the animal intravenously with the anti-emetic.  Once 
Keith (Mansford) saw this amazing anti-emetic activity of the 5-HT
3
 antagonist, the company position on 
anti-emetic research became extremely positive.’ Email to Ms Caroline Overy, 17 July 2013.
193 Miner and Sanger (1986). Mr Wesley Miner wrote: ‘At about the same time (around 1983 to 1984) that 
Gareth Sanger and I were doing early work in the 5-HT
3
 (labelled “M” at the time) receptor antiemesis area, 
Gareth was also working extensively with “in vitro” preparations while he elucidated the multiple activities 
of the drug metoclopramide. It was at this time that he actually identified a “metoclopramide antagonist”; 
now known to be a 5-HT
4
 antagonist. No one at Beecham was exactly sure where this discovery might lead, 
but along with Gareth, the Head of the Beecham, Harlow, research site, Dr Bob Poyser, was absolutely 
insistent that this discovery should be followed up and investigated further.’ Note on draft transcript, 
17 December 2012. 
figure 15: mr Wesley miner. 
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Wallis:  The 5-HT
3
 effects observed in the intact animal date back to the 
work of Paintal that I mentioned earlier which was in 1954;194 he was actually 
recording responses from nerve cells responding through, what we now know 
to be, 5-HT
3 
receptors. Rod, you just asked who proved it all, who established 
it was a ligand-gated-ion channel, and I’m not exactly sure who I would credit, 
but I would suggest it was probably Higashi and Nishi who did intracellular 
recordings from nodose ganglion cells.195 A lot of the work on 5-HT
3
 receptors is 
in the periphery because it produces fairly profound and easily recordable large-
scale depolarizations – to that extent its effect is dramatic. It was questioned 
earlier why progress in the CNS physiology and pharmacology of 5-HT 
apparently went through a period of hiatus. I think it’s partly because, when 
you look for the electrophysiological signal for 5-HT
1
 and 5-HT
2
 receptors, it 
is actually difficult to discern, difficult to measure and it tended to be ignored 
by mainstream physiologists, who wanted to concentrate on the main signalling 
molecules causing excitation and inhibition, like glutamate, GABA (gamma-
aminobutyric acid) and glycine. 
To come back to 5-HT
3
, we did a lot of work in the 1970s in establishing a 
technique for recording sizable depolarizations extracellularly and being able to 
produce dose response curves. The method used was based on one developed 
by Hans Kosterlitz, Gordon Lees and myself in Aberdeen called the sucrose 
gap technique.196 This is essentially a method of extracellular recording, where 
you diminish the shunt between two recording points on a tissue by using a 
high resistance solution, such as one that contains sucrose and deionized 
water. This was work that led to collaboration with Merrell Dow and John 
Fozard to investigate MDL 72,222; and with Sandoz and some of their 5-HT
3
 
antagonists.197 So extracellular methods of recording, like the sucrose gap 
technique, were important staging posts in investigating the pharmacology 
of 5-HT
3
 receptors. It didn’t prove that they were not acting via a second 
messenger but I think the Higashi and Nishi paper demonstrated the receptor 
was behaving exactly like a ligand-gated channel.198 
194 See pages 10–11. Paintal (1954, 1955); see also Wallis and Elliott (1991).
195 Higashi and Nishi (1982); see also Wallis and North (1978).
196 See, for example, Kosterlitz, Lees and Wallis (1968). 
197 See page 56. 
198 See note 195.
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Professor Paul Andrews:  I want to come back to a point about the site of 
action, the 5-HT
3
 receptor antagonists in emesis. I have to disagree slightly 
with Mike, as we’ve often disagreed; it’s embarrassing because he funded quite 
a bit of my work over the years, for which I’m very grateful. Yes, there are a 
lot of binding sites within the brain stem, but in the acute phase of cisplatin-
induced emesis in the ferret model, the primary action is in the periphery 
on the activation of the abdominal vagal afferents. This actually was a very 
important point to demonstrate, because it clearly showed that the peripheral 
axons of the vagus conveying information from the gut to the brain could be 
a valid drug target.199 Of course, if one now thinks of anti-obesity drugs or 
perhaps drugs for reflux, peripheral terminals, not the central terminals, are 
seen to be one of the potential targets. So, it was a very important point but 
clearly at the time, a lot of people thought that because it was an anti-emetic, 
the site of action must be in the brain stem, but actually I think it caused the 
paradigm shift in the way that people thought about targeting anti-emetic 
drugs and that’s still true.
flower:  I’d like to move on to my next topic: how did molecular biology 
impact on the area? Danny, I wanted to ask you whether you felt overwhelmed 
when molecular biologists started to clone receptor proteins or receptor-like 
genes? 
199 Andrews, Rapeport and Sanger (1988).
figure 16: Professor Paul Andrews.
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Hoyer:  Not at all, because it was all predicted. The first 5-HT receptor to be 
cloned was actually 5-HT
1A
 and it was by accident. Lefkowitz and Kobilka and 
the people at Merck had cloned the beta 2 receptor and by homology cloning 
they were looking for the beta 1 receptor.200 In between, they got something that 
was called G21 and had no clue what it was. Bob Lefkowitz is not interested 
in anything that is not a catecholamine: ‘5-HT? Never heard of it’. Although, 
shortly afterwards, we supported Annick Fargin, a post doc in the Lefkowitz 
lab, who was working specifically on 5-HT
1A
 receptor.201 And my good friend 
Chema Palacios spent a sabbatical at Duke with Bob and Marc (Caron). The 
interesting thing was that they noticed that the G21 receptor was not beta 1 
or beta 2 because the pharmacology did not fit any catecholamine receptor. 
But they didn’t look at anything else, except that pindolol was still binding. 
If we go back, pindolol is an indole and we had described that pindolol and a 
lot of beta blockers were actually decent 5-HT
1
 receptor ligands.202 When the 
paper was coming out and they had no clue what it was, we said: ‘Well, that’s 
probably a 5-HT
1
 receptor.’ The point I want to make is that pharmacology, 
namely the fingerprinting we were doing at that time, predicted much of what 
was going to happen in molecular biology.203 So, for instance, at some point we 
shifted the appellation from 5-HT
1C
 to 5-HT
2C
 because the pharmacology was 
more 5-HT
2
-like. One of the predictions from this was that the 5-HT
2A
 and the 
5-HT
2C
 receptor must be very similar. This is precisely what happened: around 
1990 we had a meeting in Lucerne and I walked back with Peter Seeburg to the 
train station, 5-HT
2C
 was halfway cloned and I said: ‘My bet is that 5-HT
2A 
is going to be very, very similar.’ He asked why I said this. I said: ‘Well, this is 
what pharmacology tells us.’ Seeburg went back to the lab, pulled stuff out of 
the fridge, he had it already but he didn’t recognize it, and indeed got 5-HT
2A
, 
which was published within just a few months.204 I understand what Charles 
is saying about the negative impact that molecular biology had at the time 
on some of the more functional researchers, because the funding authorities 
wanted to have molecular biology and if you were not doing this you were 
not sexy enough. It’s like these days, you have to use optogenetics and such 
200 Dixon et al. (1986). Robert Lefkowitz and Brian Kobilka were jointly awarded the Nobel Prize in 
Chemistry in 2012 ‘for studies of G-protein-coupled receptors’. 
201 Fargin et al. (1988).
202 Hoyer, Engel and Kalkman (1985 a and b); Engel et al. (1986).
203 See page 46 and note 146.
204 See, for example, Pritchett et al. (1988); Schofield, Shivers and Seeburg (1990).
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things; it comes and goes in waves. But, if you read the 1994 paper, the good 
thing is that many of the things we had put together at the time were later 
confirmed precisely by molecular biology.205 This was at the time when, in 
industry in particular, lots of senior management had just joined. They didn’t 
know much about chemistry and had no clue what functional pharmacology 
was all about, but molecular biology was there, so you had to have a molecular 
biology twist. It went on much further, because now you have to show that 
there’s a link between your target and the disease and the link must be genetic, 
which is a big joke. There are not many diseases where you can establish a 
clear link, certainly not many monogenetic diseases. There are indeed genetic 
disease links, as there are epigenetic links, with lots of diseases, but it’s not 
simple. So this was a hindrance. But the good thing was that, whenever we were 
working on the target, which was poorly defined according to the new wave of 
senior executives, if you could show that this target was indeed cloned and the 
result of a gene product that you could then put in a cell system and do high 
throughput screening (HTS). This was extremely important to get the project 
off the ground and approved. I’m still waiting for compounds actually coming 
from HTS to go into the clinic, in most cases medicinal chemistry is still doing 
the job. [Laughter] It was important to make the point, that what we were 
talking about was real. You could point a finger at a gene. For instance, when 
we had this long debate about 5-HT
1B
 and 5-HT
1D
, the whole situation became 
messy for about six months because two receptors, 5-HT
1Dα
 and 5-HT
1Dβ, were 
cloned pretty much at the same time.206 As we had predicted from the animal 
work, there is the species difference between rodents and other species, between 
what was called 1B and 1D; this was perfectly verified using molecular biology. 
That was making the point again, helping people to work on ‘real’ targets/gene 
products. Molecular biology messed up the whole system again, then we found 
out that the 5-HT
2C
 receptor was undergoing editing and so potentially there 
are about 25 different forms (more or less edited) that differ between species. 
Depending on the form, which is edited or non-edited, you will have more 
or less constitutive activity; this means that the compound you are working 
on (acting on the same 5-HT
2C
 receptor) may be acting as an agonist, as an 
inverse agonist, or neutral antagonist at times, depending on the edited form. 
This becomes important since, in the clinical situation, these edited forms are 
changing with disease state. The worst of all cases is actually the 5-HT
4 
receptor, 
205 Hoyer et al. (1994).
206 See, for example, Harwood et al. (1995).
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which has so many splice variants that we (still) have no clue what’s going on. 
There’s the difference between species in splicing and there are also differences 
in the splice variants when you move along the gastrointestinal tract, from the 
oesophagus to the colon, for example. I’m not sure that we know that this 
explains the differences that we see, but it’s one possibility. We don’t yet have 
compounds that are working specifically on different splice variants. Maybe 
they will come, maybe they will never come, I don’t know. But clearly it helped 
us to make sure that what we had said was real and so it’s the final proof. When 
we said 16, or 15 or 14 5-HT receptors, people were jumping up and down 
saying it wasn’t possible. Well, molecular biology nailed it.
Coming back to what we said before about the influence of industry. At some 
point Janssen Pharmaceuticals were only working on the 5-HT
2
 receptor and 
everything else was not relevant. Dr Pierre Laduron, who was very influential 
at the time, would tell us the 5-HT
3
 receptor was of no importance because 
no-one cared about the electrophysiology of these receptors. A fast ligand-
gated channel was of no relevance. Everyone knew that glutamate, glycine or 
GABA for that matter, were unimportant! It was the same thing for 5-HT. I’m 
sorry, they seem to be important targets in the clinic. For 5-HT
1
 it was the 
same. 5-HT
1
 just did not exist. It was only at a meeting we had in Houston 
in 1991 that Dr Paul Janssen stood up and told us the wonderful stories about 
the cloning of these receptors. The point I wanted to make is about Fillion, 
who was working at the Institut Pasteur, specifically on 5-HT
1B
 and 5-HT
1D
 
receptors, was undergoing some scrutiny by his research management, as is 
normal. Pasteur called in external reviewers, I will not name names, but some 
of these people claimed to be experts. They came round and said that this 
5-HT
1
 receptor did not exist. The net result was that, based on these experts, 
his INSERM lab was closed.207 Pasteur was more liberal, they kept it going and 
then two people, Rene Hen and myself, got called upon. Rene, who is really 
a cloner, came in to tell them that actually these receptors existed and for all 
we know, from Pat’s work and everyone else, 5-HT
1
, what we called 1B and 
1D receptors, were clinically of high importance. But the people at Pasteur 
and INSERM hadn’t a clue about this, because some of the self-proclaimed 
leaders in the field were ignoring everything. Just another point: I happen to 
be French; no one is perfect. [sanger: ‘True’]. [Laughter] Only once in my life 
did I go to any French meeting and it was in 1986 when I presented 5-HT
1A
, 
5-HT
1B 
and 5-HT
1C
 receptors. Laduron stated: ‘There’s only one receptor; this 
207 See also comments on page 31.
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is the 5-HT
2
 receptor, just like the D2 receptor.’ I can remember all these old 
professors, excuse me to the professors, standing up, applauding saying: ‘This 
is real; we don’t need these complexities.’ So this is why the molecular biology 
is important, because if anything it confirmed these complexities. Of course, 
it added more complexities, but we can deal with that. We’ve been around for 
some time; it’s part of the job.
flower:  Mike, did you want to respond to Paul’s earlier remark? 
tyers:  I always respond to Paul, my friend. [Laughter] I think that the site of 
action of 5-HT
3
 anti-emetics is not critical, clearly it still works by blocking 
5-HT
3
 receptors, which are all over the body on nerves where emesis can arise. 
Wherever it blocks them it is effective. The vomiting caused by cisplatin and 
other cancer chemotherapeutic drugs is probably caused by release of 5-HT 
from enterochromafin cells in the gut wall, which activates 5-HT
3
 receptors 
located locally on the vagus nerve, which projects to the chemoreceptor trigger 
zone that we showed to have the densest population of 5-HT
3
 receptors in the 
brain – the emetic centre.208
Nausea and emesis from any cause, even including pregnancy, are mediated via 
that centre. So perhaps because the vagus nerve arises as the Xth cranial nerve in 
208 See Ireland and Tyers (1987).
figure 17: Professor Paul Andrews and Dr mike tyers. 
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the area postrema this is probably the source of 5-HT
3
 receptors, which migrate 
down the vagus nerve into its vast field of innervations in the gut.209 
Blackburn:  To follow on from what Danny and Charles were saying earlier about 
disabling and enabling technologies: molecular biology is extremely important. 
However, in the 1990s, Dr Peter Goodfellow210 joined SmithKline Beecham 
and I think he/we were all seduced by Bill Haseltine and others who had started 
Human Genome Sciences (HGS),211 and to quote Haseltine: ‘Genomics will 
change drug discovery overnight and we’ll all have new medicines by tomorrow.’ 
Well, not quite in those words. [Laughter]
flower:  Almost.
Blackburn:  SmithKline Beecham were very much leaders in genomics research 
in the 1990s and were de-orphanizing G protein-coupled receptors (GPCR) 
hand-over-fist, trying to keep up with HGS and the Human Genome 
Project.212 However, to my knowledge, only one compound has come out of 
that particular genomic collaboration with HGS and they have only one in-
licensed compound in their development portfolio to date!213 As a disabling/
enabling technology, molecular biology resulted in scientists shooting off one 
orphan receptor after another, which basically caused a major distraction of 
focus in various therapeutic areas, one of which was the 5-HT area. My lasting 
memory of Peter was when I left for America in 1999. It was my last winter 
BPS meeting as President and I was sitting on the dinner table platform, next 
209 See note 181.
210 Professor Peter Goodfellow (b. 1951) was Balfour Professor of Genetics at Cambridge University 
from 1992 to 1996. He was Senior Vice President at SmithKline Beecham (1996–2001) and Senior Vice 
President, Discovery Research, at GlaxoSmithKline from 2001 until his retirement in 2006.
211 William Haseltine (b. 1944), was Professor at Harvard Medical School from 1976 to 1993 and Chief of 
Human Retrovirology at the Dana Farber Cancer Institute (1988–1993); he founded the biopharmaceutical 
organization Human Genome Sciences (HGS) in 1992, of which he was chairman and CEO from 1993 
until his retirement in 2004. HGS was acquired by GlaxoSmithKline in 2012.
212 For an introduction to the Human Genome Project, see Fletcher and Porter (1997) and the main 
Human Genome Project information website at www.ornl.gov/sci/techresources/Human_Genome/home.
shtml (visited 16 April 2013). 
213 Dr Tom Blackburn wrote: ‘Benlysta (belimumab) is the company’s lead drug, and it is an antibody 
created for the treatment of lupus (systemic lupus erythematosus), and when it was approved in 2011, it 
became the first new lupus treatment approved by the FDA in 50 years. Human Genome Sciences also 
sells raxibacumab, an inhalation anthrax treatment, to the American government for use in the Strategic 
National Stockpile.’ Email to Ms Caroline Overy, 7 June 2013.
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to Jimmy Black and John Fozard, who was sitting next to my wife Jacqui. Peter 
Goodfellow was presenting a prize to the late Dr Rob Kerwin for his excellent 
clinical pharmacology studies.214
This was one of the most embarrassing times of my BPS career, as I had to 
introduce Dr Goodfellow to present the clinical prize. Before presenting the 
prize, he went on to ask why the BPS wasn’t embracing molecular biology. To 
cut a long story short, a young PhD student came up to me after the dinner and 
said: ‘Dr Blackburn, was Dr Goodfellow trying to influence us with regard to 
the importance of molecular biology? because he failed miserably.’ [Laughter] 
All he had to do was to look at the BPS abstract book where 70 per cent of 
the abstracts in that book were all related to molecular biology, in some form 
or other. So, yes, molecular biology has been, and is, extremely important, 
not only in 5-HT research. But in certain places at certain times with certain 
people, it can be very disabling. 215
flower:  I think we can all agree with that! 
Humphrey:  I want to stick with 5-HT
3
, as we seem to have gone on to molecular 
biology.
green:  I’d like to link the molecular and Tom back to Charles because in the 
1970s, Grahame-Smith came up to me and said that there had been a paper in 
the BMJ saying that propranolol was good in schizophrenia.216 It turned out to 
be wrong, but he said: ‘Well, wouldn’t it be interesting to try it in our 5-HT 
model?’ We gave propranolol and it blocked the behavioural syndrome and we 
published it in Nature.217 Then I was invited up to ICI, as they were at that 
time, and they said: ‘Oh, well, we knew it is a 5-HT blocker, but we’ve never 
published it because the company might want to do something with producing 
214 Dr Robert Kerwin (1955–2007) was a psychiatrist and neuropharmacologist who pioneered treatments 
for schizophrenia.
215 Dr Tom Blackburn wrote: ‘Without doubt the “Genomics Revolution” and the fast pace of molecular 
biology in the 1990s was transformational and had both positive and negative effects on 5-HT research 
at SmithKline Beecham and the industry in general. The focus then was on deorphanizing novel (GPCR) 
receptors and trying to relate these genes to a pathophysiology at the demise of several 5-HT neuroscience 
projects, where we knew much more about the physiology and pharmacology.’ Email to Ms Caroline Overy, 
7 June 2013.
216 Yorkston et al. (1974). 
217 Green and Grahame-Smith (1976).
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derivatives. So, yes, they might be interested now that you’ve actually published 
this.’ But we then went on to show that pretty well all the non-selective beta 
adrenergic blockers were actually 5-HT antagonists.218 This then went on, 
and so was all functional, and went on, of course, to pindolol being used. You 
[Hoyer] mentioned it being used in molecular biology219 and, of course, for a 
while, it was also tried clinically to block the 5-HT
1A
 pre-synaptic receptor to 
increase 5-HT function. So, in fact, the molecular biology and the function can 
work well together, but without function you’re not anywhere, and that just 
happened to be one area where the function appeared well before the molecular 
biology. It’s never worked clinically, has it? But we can’t have it all.
Professor Alberto kaumann:  I’d like to tell you how the work with vagal 
5-HT
3
 receptors in the heart inspired me to discover the 5-HT
4
 receptor of 
human heart. Basically, in the 1980s, we did some experiments on cat heart 
and we were interested in the Bezold-Jarisch reflex elicited by 5-HT. We 
measured bradycardia and also sympathetic nerve activity at the level of the 
renal nerves. During the reflex, induced by 5-HT injected into the pericardial 
sac, we observed not only bradycardia, but also that the renal nerve firing was 
abolished. Vagotomy prevented the 5-HT-evoked bradycardia and suppression 
218 See Costain and Green (1978). 
219 See page 63. 
figure 18: Professor David clarke and Professor Alberto kaumann.
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of renal nerve activity, but now 5-HT produced tachycardia.220 The reflex was 
also prevented by Fozard’s compound MDL 72,222, which was consistent 
with mediation through 5-HT
3
 receptors. The cardiostimulation observed in 
vagotomized cats with 5-HT prompted the thought that 5-HT could cause 
cardiostimulation in human heart, which was indeed detected in the human 
atrium and later ventricle.221 At that time I had been working for ten years with 
the pharmacology and biochemistry of β1- and β2-adrenoreceptors in human 
atrium and ventricle. We found that 5-HT also increased cyclic AMP (cAMP) 
and the activity of cAMP-dependent protein kinase in human atrium. My second 
point is that MDL 72,222 and granisetron did not antagonize the inotropic and 
biochemical effects of 5-HT in human atrium, ruling out mediation through 
5-HT
3
 receptors. I also obtained a potent 5-HT
3
 receptor antagonist (pKB ~ 9) 
from Sandoz called ICS 205,930, nowadays tropisetron, which at micromolar 
concentrations caused competitive antagonism of the cardiostimulant effects of 
5-HT with a moderate affinity around 200 nM (i.e. a pKB ~ 6.7) on human 
atrium. At that, it had become apparent that ICS 205,930 antagonized both 
intestinal contractions induced by 5-HT through acetylcholine release222 and 
the 5-HT-evoked increase in neuronal cAMP through 5-HT
4
 receptors.223 This 
is how working with 5-HT
3 
receptors and 5-HT
3
 antagonists triggered the 
discovery of the human cardiac 5-HT
4
 receptor.
Humphrey:  I want to come back to 5-HT
3
 because I think it’s very interesting. 
I remember talking to John Fozard years ago, in 1980 or so, and he told me 
his idea about getting a 5-HT
3
 antagonist to work in migraine and he was 
very enthusiastic about it. I think John did some terrific pioneering work to 
find compounds and get out there,224 and obviously tropisetron was finally the 
deluxe 5-HT
3
 antagonist that didn’t work in migraine. I must admit I didn’t 
believe in it simply because it was a brilliant idea that John had of 5-HT
3 
receptors on afferent nerves as well as on motor nerves, you can imagine if 
5-HT
3
 was released on afferent nerve terminals those receptive terminals could 
be on cranial nociceptive neurones. But I always felt, ‘where’s the 5-HT coming 
from?’ What we did do at Glaxo, following on from having a whole cupboard 
220 Mohr et al. (1987).
221 See, for example, Kaumann et al. (1990, 1991).
222 See, for example, Craig and Clarke (1991). 
223 Dumuis et al. (1988).
224 See Fozard and Kalkman (1992, 1994).
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full of 5-HT
3
 antagonists, was to think about irritable bowel syndrome (IBS) 
because I’ve often thought of this as migraine of the gut. You can think there 
about proprioceptor and nociceptor afferents, and wow, where’s all the 5-HT? 
There’s tons of it – 95 per cent of 5-HT is in the gut. You’ve got all these 
enterochromaffin cells, you can imagine some kind of damage, inflammation 
and you could have a very important role for 5-HT
3
 receptors. We had actually 
developed one of Mike’s compounds that came out the CNS cupboard, which 
was alosetron.225 We already knew that 5-HT
3
 antagonists are constipating and 
that’s probably through blocking cholinergic motor nerves, so we thought we 
should study IBS patients who had a predominant bowel habit of diarrhoea. 
These were people who were really in a terrible way; they couldn’t get to work. 
There were stories of people in the US buying a second house that was halfway 
to work so that they could stop off – it’s a very debilitating condition and very 
painful as well. With alosetron, which became Lotronex, we got good efficacy. 
Not only did it block the diarrhoea, but people said they’d never felt so well. 
This looked like a very exciting, potentially important drug. Unfortunately very 
soon into the drug’s life on the market, less than a year, I think, there were 
several patients who had ischemic colitis, a very serious side effect, and the drug 
was stopped by the FDA, or GSK probably withdrew it before the FDA stopped 
it. Interestingly though, this drug is very effective and to this day we don’t know 
what causes the ischemic colitis, but we do know that a lot of people said that 
this drug was so important that now it’s been brought back, but it’s under very, 
very tight specialist control.226 So this is an interesting example of where a drug 
has worked and is very effective, but we’ve suddenly come up with a side effect 
that we think is related to a 5-HT
3
 mechanism, as opposed to the drug itself, 
but nobody knows what the mechanism is. I think somebody should get in the 
lab and find out, because if you could circumvent that, or understand it, maybe 
there’s another important clinical indication for 5-HT
3
 antagonists.
flower:  Gareth’s got his hand up, he knows the answer. [Laughter]
sanger:  It’s an interesting point, because I teach a little bit of drug discovery, 
believe it or not, to students now. I can cite the 5-HT
3
 receptor antagonist story 
as saving so much human misery if you get the patient population right, in this 
case, cancer patients needing anti-emetic treatment. However, if you get the 
patient population wrong, as in the case of patients suffering from IBS, drugs 
225 Humphrey et al. (1999).
226 For a discussion on the withdrawal and subsequent reintroduction of alosetron, see Lievre (2002). See 
also note 229.
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acting at the same receptor are thought to be associated with deaths. What I 
really want to draw attention to is that it is this withdrawal of alosetron, perhaps 
coupled with cisapride’s withdrawal, because of its ability to block the HERG 
channel (potassium ion channel) on the heart, perhaps also coupled with 
the withdrawal of tegaserod (a 5-HT
4
 agonist), because of poor efficacy and some 
apparent cardiovascular effects,227 that has combined to make the regulatory 
authorities and drug companies as a whole, scared of the word 5-HT. Everybody 
I know who plays in that area cannot get management support, because they 
are aware that the regulatory authorities will make life so difficult. Last week 
we saw the Shire close down the former Movetis company (now owned by 
Shire) with the loss of 60 jobs in Belgium, because prucalopride, the world’s first 
selective 5-HT
4
 receptor agonist – demonstrated to have good intrinsic activity 
using native tissues, not molecular, because that’s the only way you can do it – 
failed to live up to expectations.228 They can’t get it in the US; the regulatory 
authorities still want trial after trial to demonstrate that there is no cardiac side 
effect. So there’s been a sort of legacy now from those three compounds, in 
particular, that the industry, and 5-HT as a whole, is still suffering from. We 
cannot seem to move forward.
Hoyer:  I was going to say something similar to what Gareth has already said. 
The problem was that once the FDA had understood that there was a problem 
with 5-HT
3
 and alosetron, everything else that came after that and should work 
through a 5-HT mechanism in IBS, was bound for failure, because they just 
remember 5-HT. So this is the bad thing for 5-HT
3
 and 5-HT
4
 and I think 
we should revisit these compounds. In fact alosetron is still on the market, 
but not with Glaxo.229 5-HT
4
 seems to be forgotten and yet I think it’s an 
important mechanism. Basically what you need is to identify the right patient 
and give the right compound. When we started looking at 5-HT
3
 in the brain, 
we did autoradiography, since we had found that ICS 205,930 was working on 
neuroblastoma/glioma cells. When we did the first autoradiography experiment, 
we exposed for one month, no result; two months, no result; three months, 
no results. After five-and-a-half months of exposure we saw the receptor to 
227 For cisapride, see, for example, Mohammad et al. (1997) and for notice of its withdrawal, Anon (2000); 
for a discussion of tegaserod and alosetron, see Fayyaz and Lackner (2008). See also, Sanger (2009).
228 See comments on page 109. 
229 Prometheus Laboratories in San Diego, CA, acquired Lotronex from GlaxoSmithKline in 2007. Due to 
the risks of developing ischemic colitis the drug can only be prescribed by those who have enrolled in the 
Prometheus Prescribing Program. See page 71 and note 226.
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be indeed present in the vagus complex and area postrema and another bit 
of binding in the hippocampus. The interesting thing was that when the first 
papers were published, we were told that this is almost impossible, because 
everyone knows that the 5-HT
3
 receptor is a peripheral receptor, it has nothing 
to do with the brain. This is what the dogma told us.230 But anyway, the good 
point was that in those days we could play and perform the kind of experiment, 
which today is almost impossible, at least in the non-academic set up. This is 
why and how industry is suffering from short-term vision. 
flower:  We’ve been joined by Jackie Hunter and Gerald Curzon and I’m going 
to ask them in a minute if there’s anything they want to say about what we’ve 
already discussed. David, did you want to make a remark about what we were 
talking about earlier? 
clarke:  I wanted to go back and say that it’s important to recognize the 
work of Joel Bockaert in the discovery of the 5-HT
4
. He did it by measuring 
adenylate cyclase in colliculi neurones from mouse brain, and we did it quite 
independently in the gut. Our work was really based on Gareth’s years of trying 
to find out how prokinetic agents worked in the gut. He never quite got there, 
but it was his pioneering efforts that led me to move into the gut and have a 
look to see what the receptor really was. Plus, I was always fascinated by some of 
the 5-HT dose effect curves I used to see coming out of John Fozard’s and other 
people’s labs. They were biphasic curves and the first phase of the dose response 
curve was very small, very variable, but nobody took the slightest bit of notice of 
it. John started his curves halfway up the dose response curve and so I thought: 
‘Well what is this receptor?’ That question, plus Gareth’s work, led to looking at 
5-HT receptors in gut and led to finding the 5-HT
4
.
Dr colin Dourish:  I have a couple of comments. First of all responding to 
Gareth’s pessimism about the 5-HT area and the attitude of regulators. I shared 
his pessimism until relatively recently, because one of the most difficult areas 
to convince regulators is in obesity and for many years a number of companies 
have struggled because of all the side effects with obesity compounds, the recent 
example being the withdrawal of the cannabinoid antagonist rimonabant. 
The gratifying thing was just three months ago the FDA approved the first 
230 See, for example, Bradley (1987). Professor Paul Andrews wrote: ‘There was lot of confusion at the 
time about central 5-HT
3
 receptors, at least in the brainstem, and this resulted in a publication in Trends in 
Pharmacological Sciences on a consensus view (Pratt et al. (1990)).’ Note on draft transcript, 7 January 2013. 
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compound for many years, lorcaserin, which is a selective 5-HT
2C
 agonist.231 
That finally suggests that the regulators are starting to look at risk–benefit again, 
which is a big boon to all of us if they start to do that. Clearly what happens to 
that compound in the market is going to be very important over the next few 
years, but at least that’s one slight glimmer of hope. Coming back to something 
we were discussing earlier, we talked a lot about the prototype selective 5-HT
1A
 
receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) and 
I’d just like to give credit to the Swedish group that developed that compound. 
It was originally synthesized by Lars Erik Arvidsson at Uppsala in Sweden.232 
That group provided the compound initially to a number of other groups, and 
it was also synthesized by a number of other labs, like Merrell in Strasbourg, 
and I believe that’s where we got it from. I was working with Gerald Curzon at 
the time in 1984 and I think we got it from Merrell. What was really interesting 
about that compound, and we’ve heard this from a number of people already, 
is that it helped us to really understand function for the first time with receptor 
subtypes. We were interested in Gerald’s lab in both neurochemistry and 
behaviour and trying to tie the two together, so we were getting into, like 
Charles was at the time, in vivo microdialysis using HPLC detection. But also 
we wanted to try to link function with that neurochemical change and when we 
got hold of the compound we didn’t really know what it was going to do, so we 
gave it to some rats and observed their behaviour. What we knew about 5-HT 
effects on behaviour from previous studies was that 5-HT generally had an 
inhibitory effect on feeding, so we were rather shocked to find that these animals 
seemed to be looking for something to eat.233 We started giving them some 
food and all of a sudden what we found was that 8-OH-DPAT, a compound 
that apparently was a 5-HT
1A
 agonist, was having the opposite effect to any 
other serotonergic agonist we knew about that generally decreased food intake. 
That led to an understanding, or towards an understanding, of pre- versus post-
synaptic 5-HT
1A
 receptor localization. It turned out that the reason the animals 
were increasing their eating, rather than decreasing, was that this compound at 
a low dose was selectively activating the 5-HT
1A
 receptors on the cell bodies of 
5-HT neurones in the raphe nuclei and this was later borne out in studies we 
did using microdialysis and studies by other people, such as Trevor Sharp, who 
231 For a discussion of the FDA’s approval of lorcaserin, see Colman et al. (2012).
232 Arvidsson et al. (1981).
233 See, for example, Dourish et al. (1986). 
Drugs Affecting 5-HT Systems
75
unfortunately couldn’t be here today. Again, the Swedish group led by Stephan 
Hjorth showed that 8-OH-DPAT and other 5-HT
1A
 agonists at low selective 
doses would decrease raphe firing and thereby decrease 5-HT release.234
flower:  So, Jackie and Gerald, we had a good session this morning when we 
tried to collect, amongst other things, some reminiscences of the very early days 
of 5-HT research and went over this era in a bit of detail. But I’d like to give 
you two the opportunity to contribute to the discussion. Is there anything you’d 
like to add?
Dr Jackie Hunter:  I think this gathering here is for people far closer to a lot 
of the early discoveries than I was. In fact the earliest work was carried out 
when I was working with Cathy Wilson in the Department of Obstetrics and 
Gynaecology at St George’s Hospital and that was on the effects of selective 
receptor subtype agonists and antagonists on the reproductive system. Perhaps 
one of the most interesting times was working at, what was then, Glaxo with 
Mike Tyers, and Pat Humphrey was there, looking at the whole story of 5-HT
3 
antagonists in cognition and actually showing that there were, in the pre-
clinical species, effects of the 5-HT
3
 compounds on memory and learning. 
That interest in cognition is something that has stayed with me throughout my 
234 Hjorth and Sharp (1991).
figure 19: Dr colin Dourish.
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career within the industry and we can come back and talk about some of the 
later developments afterwards. That’s all I wanted to say in terms of the early 
study.
Professor gerald curzon:  Who funded my group’s 5-HT research? That was 
one of the main questions of this session. Initially, I was interviewed at Queen 
Square by Dick Pratt for a research fellowship.235 He showed me the structure 
and formula of something I’d never heard of, LSD (lysergic acid diethylamide). 
That was about 1953. He said: ‘How do you think this acts on the brain?’ I 
said: ‘Well it looks like something called serotonin that’s recently been found in 
blood serum.’ He asked if there was any in the brain. I answered, not as far as I 
know. In fact Marthe Vogt had just detected it in brain but it had not yet been 
published.236 
On another point, the job that I was applying for had already been offered to 
two people. Both turned it down. Dick Pratt was then a mere senior registrar 
and those who turned it down decided instead, not unreasonably, to take jobs 
235 Dr Richard Pratt (1917–1983) was senior registrar in the Department of Psychiatry at Queen Square 
from 1952 to 1954 when he was appointed consultant in psychological medicine to the National Hospitals 
for Nervous Diseases, London.
236 Dr Marthe Vogt (1903–2003) was a pharmacologist whose research focused on neurotransmitters. See 
Cuthbert (2005).
figure 20: Dr Jackie Hunter.
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with Fellows of the Royal Society. They both eventually became FRSs themselves 
and one of them got a Nobel Prize.237 As for me, I took the fellowship at Queen 
Square, which later became a lectureship. My lab was mainly supported in 
those years by the MRC with three research grants followed in succession by 
three five-year programme grants, all centred on 5-HT. There were also smaller 
grants from the Migraine Trust and the Brain Research Trust. Looking back, 
the research of my group was mainly driven by the emerging availability of 
new laboratory techniques. At first there was something that seems very ancient 
now, paper chromatography, but it seemed revolutionary in the early 1950s. 
As Wordsworth said: ‘Bliss was it in that dawn to be alive.’238 Sir Charles Dent, 
who worked down the road from Queen Square at University College London, 
encouraged my work. He said: ‘With paper chromatography the world will be 
at your feet.’ Well, not entirely. [Laughter] After paper chromatography there 
was colorimetry, fluorimetry, HPLC and in vivo dialysis. We put a lot of effort 
into in vivo voltammetry, which turned out to be a lot more difficult than 
I first imagined. Something perhaps of historical interest was the small grant 
given by Pfizers in 1986 for me to prepare a lecture and a poster demonstration 
on Frederick Gowland Hopkins, discoverer of tryptophan.239 This was using 
information from Hopkins’ daughter, Jacquetta Hawkes. The posters on this 
are now in the Science Museum. If I can go back just for a moment to what 
Colin [Dourish] was talking about: he really had get up and go – doing an 
experiment with his right hand and writing it up for a journal with his left 
hand. He worked with Peter Hutson, who was an absolutely superb observer, 
but wasn’t at all keen to write things up. So between them it was really a good 
combination. The other things I want to talk about are on the question of 
industry and academia: tensions and collaborations. 
237 Professor Ivan Roitt and Professor Sir John Vane.  The latter was awarded a Nobel Prize (with Sune. 
Bergström and Bengt I. Samuelsson) ‘for their discoveries concerning prostaglandins and related biologically 
active substances’.
238 William Wordsworth wrote the line in his poem, ‘French Revolution, As it Appeared to Enthusiasts at 
its Commencement in 1805’, first published in The Friend in 1809. It is part of his autobiographical poem, 
The Prelude, book XI. ‘France (concluded)’, line 108.
239 Frederick Gowland Hopkins (1861–1947), Professor of Biochemistry at the University of Cambridge 
(1914–1943), isolated tryptophan in 1901. He was awarded the Nobel Prize in Physiology or Medicine 
(shared with Christiaan Eijkman) in 1929 ‘for his discovery of the growth-stimulating vitamins’; see Dale 
(1948). Professor Gerald Curzon wrote: ‘Hopkins isolated tryptophan but got the structure wrong, see 
Curzon (1987).’ Email to Professor Tilli Tansey, 16 August 2013.
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flower:  We’ll come back to that in a minute if we might, Gerald, because there 
is something I just want to raise. A couple of other people have touched on this 
topic, so can we discuss to what extent invertebrate models contributed towards 
progress in the 5-HT area. There was quite a lot of activity: Charles already 
mentioned the snail, but there was a lot of work done on C. elegans, looking 
at feeding and appetite suppression and that sort of thing. So I want to ask 
whether that was something that had an impact or not. 
Wallis:  Well, two important and long papers from 1974, were by Gerschenfeld 
and Paupardin-Tritsch,240 who analyzed synaptic responses in snail neurons 
and did quite a lot of work in analyzing what might be the receptor, or more 
than one receptor, involved, but I’m not sure who followed up on that work. 
I guess now those receptors are recognized as being part of the panoply of 
G-protein linked receptors. They were important and provocative papers at 
the time. 
marsden:  To reiterate what I said before: there was an advantage of using neurons 
in species like the snail in the early days because you could very clearly identify 
large nerve cells that contained 5-HT. That had an impact at that stage. What 
impact it had in the 1980s and 1990s, which is the time we’ve been talking 
240 Gerschenfeld and Paupardin-Tritsch (1974 a and b). 
figure 21: Professor gerald curzon.
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about more recently, I don’t think it was that important because molecular 
biology essentially took over at that stage, in terms of the identification of 
individual receptors. 
sanger:  I’d agree. I used to collect all these papers and read them and I honestly 
don’t think they had any value whatsoever in interpreting mammalian physiology. 
Even now, I’d question the translational value of some of these models that are 
held up as something that will solve all our problems. 
Wallis:  A point I should perhaps have added: as far as I can see the invertebrates 
retained the amines like 5-HT as major transmitters in their signalling pathways 
throughout evolution, whereas mammals and vertebrates seem to have not so 
much abandoned them, but used them as modulators. Amino acids became the 
rapid, direct signalling molecules.
Humphrey:  Following on from that, I think molluscan hearts and things like that 
were incredibly sensitive to 5-HT, so were very good as bioassay preparations.241 
I could never make head or tail of all the work that was done with drugs on 
invertebrate receptors. I remember Michael Berridge had a very erudite paper 
in, I think it was the Journal of Physiology, on 5-HT receptors in blowfly salivary 
glands and he used all sorts of drugs and it just didn’t equate with anything we 
knew in terms of mammalian pharmacology.242 In the end, out of intellectual 
curiosity, I actually had a PhD student working on the snail receptors and it just 
did not make much sense. The only thing that seemed to work was the ergots, 
they seemed to have some potency but it just didn’t relate to our mammalian 
work. I know nothing about the molecular biology, but I suspect they’re very 
different receptors.
flower:  I thought it would be useful to talk about the question of who funded 
research in the field. Gerald mentioned the importance of discreet funds; did you 
mention the Brain Research Trust? And what about industry? You mentioned 
Pfizer?
curzon:  The Brain Research Trust funded research over quite a wide area but 
I think the only person, as far as I can remember, who was supported by them 
for 5-HT research was myself. Most of my funding at that time came from the 
241 See page 13. 
242 Berridge, Lindley and Prince (1975). 
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MRC. It was then so much easier getting money out of them than now. One 
sat down, wrote an application in an afternoon and quite often they granted it. 
Not like it was even 20 years ago.
green:  Unless I’m wrong on this, the Brain Research Trust will only support 
research conducted at Queen Square.243
flower:  Oh, is that right? Okay. So, other academics, where did you get your 
funding from? 
Andrews:  From my perspective, with the 5-HT
3
 work that we did on emesis, 
there’s no doubt that it was funded mainly by industry. Quite a variety of 
companies supported it over the years, I think that was true for a number of 
us. Glaxo and, as it was originally, Beecham and then as it became SmithKline 
Beecham, probably were the two major funders, but then others came later. 
That made a very important contribution because, as far as I can recall looking 
back at the papers that were published in this area, there were almost never 
acknowledgements to the Wellcome Trust or the MRC for funding. I think I’m 
only aware of one grant, maybe two that they funded in that whole period that 
involved emesis in any of this pharmacological work. So it was really industry 
that drove it.
sanger:  Is it worth commenting on the opinions that fellow academic colleagues 
had about the receipt of so much industry money?
Andrews:  Yes. I think the attitude clearly has changed and now it’s seen as 
quite favourable to have links with industry and be seen to be collaborative and 
having work that’s translational, but it was certainly not viewed quite so well 
in those days, let’s put it that way. Even though, of course, it led to peer review 
publications and other things. Attitudes have changed.
flower:  The problem these days is there’s no industry left to collaborate with. 
[Laughter]
Andrews:  Well, that’s the problem and, of course, the other problem is that, 
in a way, the golden goose has been killed because a lot of people perceive that 
the problem of emesis is solved because we’ve got 5-HT
3
 and NK1 antagonists. 
243 The Brain Research Trust is a charity established in 1971 to fund research at the Institute of Neurology, 
University of London, ‘to promote and support research into the causes, treatment, prevention and cure of 
neurological diseases’, see www.brt.org.uk (visited 17 April 2013).
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So for people who don’t look clearly at the small print it’s an area that’s shut off 
and, I think, there’s a perception in other areas that is rather similar. 
Hunter:  When I first started working with Cathy [Wilson], Wyeth funded 
some research and also gave a lot of compounds that were really important in 
terms of dissecting out the pharmacology. There was also a charity, I might be 
wrong, the Neuroscience and Mental Health Foundation that actually went 
because of Baring’s bank; it had all its funds in Baring’s bank and they used to 
fund quite a lot on the charitable side.244 It’s unfortunate that Robert Naylor 
isn’t here because obviously, Costall and Naylor were important in defining 
certain 5-HT
3
 pharmacology and Glaxo funded them to quite an extent. 
Subsequently over the years, when I was working with SmithKline, we had very 
good links with Nottingham and some of the work around the 5-HT
6
 receptor 
and defining its role in cognition was done in collaboration.245 There was a lot 
of industry funding and also a lot of provision in kind, in terms of tools as well 
as for imaging. A lot of important work was done in, for example, positron 
emission tomography (PET) to be able to look at occupancy; you’ve probably 
touched on that this morning so I won’t harp on it. In terms of advancing our 
knowledge of 5-HT pharmacology, industry funding played a big role and it 
would be interesting to actually think what proportion that represented over 
the years. 
marsden:  I was also going to mention the Mental Health Foundation and I 
think both Richard and I served on their committee as well, at some stage, 
being recipients of grants from the Foundation.
green:  They were called the Mental Health Research Fund and I had a year of 
my PhD with Gerald on that. Then they became, I think, the Mental Health 
Foundation and I was on their research committee for a while with Trevor 
Robbins. They did fund both pre-clinical and clinical research but the amount 
of money they had wasn’t great, and they switched to supporting only clinical 
type of work from psychology through to psychiatry; they stopped supporting 
any pre-clinical work at all.246 
244 In 1972 the Mental Health Research Fund merged with the Mental Health Trust and in 1973 changed 
its name to the Mental Health Foundation.
245 See, for example, King et al. (2009). 
246 The charity moved away from laboratory research to work directly with people with mental health 
problems. See Mental Health Foundation (2009); see also note 244.
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marsden:  As regards my other sources, as an academic there was the MRC, of 
course, but also the Wellcome Trust, which had a very significant interest in 
mental health and had earmarked funds for mental health and as that was the 
area that I was in, the Trust was another one of our major funders.247 One of the 
most helpful sources of funding were the Biotechnology and Biological Sciences 
Research Council Case Awards in terms of training PhD students. That was a 
marvellous scheme and I had a lot of links with companies both in the UK and 
in Europe. It was a very effective means of educating PhD students because they 
got a feel for both sides of the business, both the academic and the industrial. 
clarke:  I must be unique here because I was funded by the NIH. I was at the 
University of Houston and put in a grant to characterize 5-HT receptors plus 
some other receptor targets and they were delighted. There was no biochemistry 
in it; no hint of molecular biology; they said: ‘Give him the money.’ I got that 
grant and thought: ‘This is so damned easy’, so I thought I’d write another 
one and I more or less got the same response. But at that time I moved from 
academia into what was Syntex, later Roche, in California, and the NIH 
were terrific. They allowed me to take my grant with me and I had a lab with 
two PhD students in it and a post doc and I could run that NIH grant in 
industry. Of course, they wouldn’t renew it after that, but they were very good 
to me; they weren’t big grants but I don’t think they got that sort of functional 
pharmacological approach in other grant applications. The molecular biology 
aspects of 5-HT came from America, functional pharmacology from Europe 
and the binding is sort of mixed. Thus my grants were unusual grants and they 
were the easiest grants I ever got. [Laughter]
flower:  I guess, of course, it wasn’t only funding from industry that helped 
the field along, but also the provision by them of highly selective agonists and 
antagonists. One question I have for you all is whether there were any really 
important pharmacological tools that came from industrial labs that enabled 
you to do all these sophisticated studies with receptor subtypes that were so 
crucial in the development of the area?
247 Professor David Wallis wrote: ‘I should like to record my thanks to the Wellcome Trust, who funded 
my research into 5-HT
3
 receptors on peripheral neurons and subsequently on 5-HT receptors present on 
spinal motoneurones and reflex spinal cord pathways in the years 1983, 1985–6, 1988, 1990, 1991, 1992 
and 1993. The Welsh Scheme for Development of Health and Social Research also provided support. Brian 
Richardson and Gunther Engel from Sandoz sponsored work at my laboratory in Cardiff (1985–86) on the 
blockade by ICS 205,930 of the depolarizing actions through 5-HT
3
 receptor on sympathetic and vagal 
afferent neurons; and Beechams funded research in my laboratory to quantify the antagonism of BRL 43694 
at 5-HT
3
 receptors in rabbit vagal afferent neurons (1987–88).’ Note on draft transcript, 14 December 2012.
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Dourish:  We’ve already talked in the 5-HT
1A
 field about 8-OH-DPAT. The 
other important compound in the 5-HT
1A
 field was the Wyeth compound, 
WAY 100,635, which not only was used in binding studies pre-clinically, 
but also was used in a lot of pharmacology and in vivo behavioural studies. 
Crucially, it was also then developed as a PET radio ligand and was used in 
studies at Hammersmith and other centres to visualize and map the 5-HT
1A 
receptors in the human brain for the first time.248 I think Phil [Cowen], you 
and Paul Grasby were then involved in some of the subsequent studies with 
WAY 100,635 looking at 5-HT
1A
 receptors in depression.249
Andrews:  Just a comment: my perception was that it was much easier to get 
compounds in those days. The amount of bureaucracy to get a compound to 
try something in your model to see if it worked was a lot simpler. The speed 
with which compounds circulated was probably a lot faster then than it would 
be now if a similar situation arose. 
tyers:  Supplying compounds wasn’t only between industry and academia, it was 
also between industry and industry, because most of us had exciting compounds 
to work on that were in the public domain.250
Blackburn:  I think the relationship between industry and academia has always 
been very strong. There seems to be this notion that perhaps things weren’t right 
in the early days or perhaps are not much better now, but certainly as far as the 
companies I’ve worked for, they’ve always been strong, culminating in excellent 
PhD students from Nottingham, Birmingham, Dundee and other universities. 
Dr Guy Kennett came out of Gerald’s laboratory, and in my lab at Beecham 
and SmithKline Beecham he helped to develop several 5-HT
2C
 selective 
compounds.251 Dr Gordon Baxter in my lab was another classical pharmacologist 
trained by the likes of Dave Clarke. Gordon developed a number of 5-HT
2B 
248 Fletcher et al. (1995); Pike et al. (1995).
249 See for example, Sargent et al. (2000).
250 Dr Mike Tyers added: ‘Our Intellectual Property Department always made us get a Confidential 
Disclosure Agreement signed, which we always thought was a little excessive amongst such nice people! But, 
20 years later, the importance of this became apparent in the law courts of the USA! It is also surprising that 
any of us were able to publish anything. Where would we be if we had published nothing?’ Note on draft 
transcript, 20 December 2012.
251 See, for example, Kennett et al. (1994).
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selective compounds, so there were some very good selective 5-HT compounds 
and pharmacological tools that were developed at SmithKline Beecham at that 
time.252
sanger:  A small point about the generosity of people working in this area, which 
you’ve touched on before, but the first 5-HT
3
 receptor antagonist I had was 
from John Fozard. I was in industry, he was in industry; he sent me a sample 
so we could actually explore our ideas in the laboratory before we’d made our 
own. So there was industry-to-industry contact. You’ve talked a lot so far about 
academics finding funding; industry people have to find funding too. They 
have to get acceptance from whatever the organization is, in order to get the 
ideas progressed; some found it difficult; we found it difficult, I think, to get 
things going.253 I don’t know about the then Glaxo group, Pat and Mike, but 
I have always been impressed by the fact that it seemed to me that you’d taken 
all the receptors and you were just going to go for them all and figure out what 
they did later. And, if that was correct, I think that was a wonderfully brave 
thing to have done. 
marsden:  I was just going to give an example of an academic/industry 
collaboration, which I think worked very well and that was in more recent 
years with the 5-HT
6
 receptor. We had a long-term link with Hofmann and 
so got very immediate approach to the new compounds they developed. This 
collaboration was a sort of wheels within wheels situation because the person 
responsible for the link on the industrial side was an ex-PhD CASE award 
student of mine, Andrew Sleight, and I think that’s the way a lot of these links 
worked.
Humphrey:  Yes, it may seem like that from the outside [laughter] but I don’t 
think it was ‘tons of money, do what you like.’ David Jack was very determined 
that we should be very applied and I think we got things right, therefore we 
were successful and therefore the money came in. It’s as simple as that. I was 
waiting for an opportunity to give you a bit of an anecdote, and I think it fits 
in here. David Jack said: ‘You know, we should be like chess analysts, watching 
all the world’s chess games and we’re looking for a game that’s in the end game, 
we think we can take on and win.’ I said to David: ‘Well, that’s great, but if you 
want good chess analysts you’ve got to let them play chess.’ He went pale at 
that point [laughter] because he didn’t like people messing around on the side. 
252 See, for example, Forbes et al. (1995).
253 See also comments by Mr Wesley Miner on pages 59–60. 
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In general we were allowed to do about ten per cent basic research at least, and 
we probably did a lot more, because it was always focused on trying to make 
sure that our project delivered somehow. It wasn’t a question of having tons of 
money; it was a question about focusing the money we had in the right places.
Hoyer:  Across the board it’s the same thing that industry was doing in those days, 
looking for new targets, meaning indications. If you were to have indications 
first and you knew what the target was, it was simple, but sometimes the target 
was ill defined, then you had to make sure that you defined the target. That’s 
precisely what happened for 5-HT
3
, 5-HT
1A
 or 5-HT
1B/D
 and 5-HT
2C 
eventually. 
The bottom line was that you can play with these targets but make sure that 
you get a compound, a tool, first, followed by a development candidate. The 
best way to finish a programme early is to get a compound that doesn’t work in 
any kind of a clinical setting, because suddenly the trust in the whole approach 
is gone. Unfortunately it takes about ten to twelve years to go into the clinic 
and eventually into market, or at least that’s what it used to be. More recently 
you would do early proof of concept and if for whatever reason your compound 
doesn’t have the right pharmacokinetics (PK), you are in trouble. PK is very 
difficult to predict, as you know, from mouse to man you can do allometric 
scaling, but that doesn’t add much, because of species variation etc. From the 
outside it looked like we could play, and indeed we did play in the very early 
days, there was much more freedom in those days than is currently available. 
Another good thing was that, and again this is where the BPS is very important, 
on the continent we had students from England. They were from Manchester, 
Cambridge and other places and would come for a year and do these placement 
studies before their Masters and PhD. They didn’t cost much, they were pretty 
bright because they were coming out of the right universities, they would speak 
English and write it occasionally, which is important because you have to write, 
and they would go back and then attract the next generation that we met at the 
BPS meeting. We kept doing this on a regular basis. Of course, having lots of 
Brits on the Continent helped to have students from the UK. So again, it’s an 
indirect but major contribution of the BPS – we went to the BPS meetings, met 
these people in the meeting itself or at the bar, which was at least as important, 
and then you have already selected the next brilliant student to come over. 
Quite often these students came back to England to finish their year and then 
realized that the Continent wasn’t bad at all, so they would come to Switzerland, 
and finish their PhD. This has happened repeatedly. And so it was feed forward 
and that was great. This has changed, PhD students are now less considered 
than post docs, probably a big mistake. 
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With respect to compounds, yes, some were made available to select groups and 
not to others and so you had to figure out how to get the compound. Fortunately 
in those days we had chemists who were prepared to synthesize compounds as 
tools and not just as a final end product that you would make a patent and then 
enter the clinic with. We would quite often replicate chemistry made at Glaxo 
or ICI or SmithKline, etc. Occasionally we would get the compound from the 
real source and I know that John Fozard had been distributing MDL 72,222 
and others; we used to give ICS 205,930 to many investigators, but eventually 
it stopped. I had been distributing 5- carboxamidotryptamine (5-CT), which 
was a Glaxo compound and I think that legally this was just about at the limit 
of what we could do. I remember a Brighton Christmas BPS meeting where 
Pramod [Saxena] was presenting some data with the 5-HT
1B
 triptan from Merck 
at the time and, of course, it was not Merck who supplied the compound. We 
know who it was but it was never revealed. Eventually, we had to save Pramod 
from being kicked off the stage because Merck didn’t want an abstract to be 
published as long as he wouldn’t reveal the source of the compound. Pat played 
a major role in saying that Pramod actually could be trusted [laughter] and the 
abstract was accepted. 254 We all agree that the industry has played a major role 
in providing the tools and this is what we should have done anyway because 
this is how we made progress. Occasionally, industrial groups were biasing 
the research, probably to an extent that I think is at the limit of ethics. I will 
stop here [laughter] but I would think that one should go back to the basics 
and make sure that even if the money is being provided by whoever it is, that 
these people have no influence on what you publish or what you don’t publish, 
because quite often the important thing is what you don’t publish. Just to 
remind you about the ketanserin antihypertensive story. Hans Kalkman’s thesis 
was showing that ketanserin was not working via 5-HT
2
, because although it’s a 
good 5-HT
2
 antagonist, it is also an alpha 1 adrenergic antagonist.255 This was 
largely neglected by people for the next eight years until Janssen realized that 
actually most of the 5-HT
2
 agonists they were developing had no cardiovascular 
effects in the first place. A surprise! 
curzon:  The economics of clinical trials has changed tremendously over the 
years. I remember Merton once remarking about some compound of which 
there was a lot lying around that looked as if it might be a monoamine oxidase 
inhibitor. It was given to one or two patients without any kind of ethical trial 
254 VanDenBrink et al. (1997). 
255 See Kalkman, Timmermans and Van Zwieten (1982). 
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and it worked.256 That was how the monoamine oxidase inhibitor field started. 
There was another crucial stage, I don’t know whether there’s been a proper 
study done on it, that was the influence of the thalidomide disaster.257 After that 
happened, it became much more laborious and expensive to do clinical trials of 
any kind. 
Hunter:  I wanted to come back to industry funding, which you may have 
discussed this morning, the role of the commercial organization in defining how 
you position a programme of research and what you can and can’t do. I think 
sometimes that really constrains what you do. So, for example, Carol Routledge 
was leading the programme on 5-HT
6
 compounds at SmithKline Beecham. 
A compound was being developed as an antipsychotic agent, that indication 
was very much on commercial grounds, the first molecule was SB 271046.258 
Luckily, because of Kevin Fone’s work, it shifted to Alzheimer’s.259 There are 
other potential indications that are less well characterized and, because of the 
costs of clinical trials, could not be pursued even though they might be more 
likely to succeed or to work in subsets of patients and populations. That has the 
potential to hinder research within industry and that’s why it’s so important to 
try to get compounds out and people using them outside of industry, either in 
clinical or pre-clinical settings. But you’re right, there are a lot of barriers now to 
sharing compounds and there are barriers to doing the clinical studies, with both 
the sponsorship and ethical issues, that have to be overcome. So in some ways 
we are a lot less free, even when we’ve got very selective and potent compounds, 
to be able to pursue them in perhaps what might be the most logical indications. 
I think it is good when people make compounds independently and go off as 
they did with SB 271046 because that validates your view. If you can get more 
laboratories independently to confirm what you see, then you feel much more 
comfortable about moving forward.
256 For monoamine oxidase inhibitors, see, for example, Pare (1985).
257 Thalidomide was introduced in 1958 in the UK as a sedative and anti-emetic in pregnancy. It was 
withdrawn in 1961 following widespread malformations in children of mothers who had taken the drug. 
This tragedy accelerated the establishment in 1963 of the Committee on the Safety of Drugs, chaired by Sir 
Derrick Dunlop, which resulted in the Medicines Act of 1968. See the Witness Seminar on the Committee 
of the Safety of Drugs, Tansey et al. (eds) (1997), passim.
258 Routledge et al. (2000).
259 Professor Kevin Fone has been Professor of Neuroscience in the School of Biomedical Sciences, 
University of Nottingham, since 2006. See his review of 5-HT
6
 receptors (Fone (2008)). 
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Bakhle:  All this discussion has created in my brain the impression that 
certainly the whole area has moved forward because of, and due to, industrial 
pharmaceutical companies’ research rather than the academic research. Most 
of the academics perhaps felt a little bit vox clamantis in deserto, left on the 
fringes of everything. It wasn’t until the companies became interested in and 
started to make compounds and drive research and give out grants, that the 
field really moved forward. Now is this a usual pattern? Are there other areas 
of pharmacology in which this has happened? As an academic all my time, I’ve 
always had this romantic notion that the real advances, the new discoveries 
that you didn’t quite know what to do with, all came out of academic labs, and 
what happened was that the companies saw a new idea and said that they could 
do something with it, and did it. Whereas it seems to be quite different in this 
particular case. If you look in this area of pharmacological research again, is it 
the companies who actually are leading, and are driving the field or is it in fact 
my romantic idea which is correct? I just wondered about that because it’s a 
general fundamental question and I’d be very interested to hear from people 
how they feel on that general topic.260 
The other practical question that I have is: in the early days, say for instance 
when Pat (Humphrey) started trying to convince David Jack, and everybody in 
their own industrial company tried to persuade their directors to take up 5-HT, 
the forgotten compound as it was, what point of 5-HT action did they use in 
order to convince them? Was it always a CNS aspect for which there was, I don’t 
know, good or bad evidence? Or was it a peripheral aspect? What was the initial 
driver to convince the companies to get into this area?
flower:  Two tough questions.
miner:  I think actually the way I look at it, in the past, particularly coming 
from the 5-HT
3
 side of it, the industry/academia interaction has always been 
a real two-way street. I know in the first instance that we in industry got the 
selective 5-HT
3
 antagonists, but without Paul (Andrews) pushing us on a little 
bit and doing some really interesting work on the physiology side of it, which 
was purely academic, I don’t think the story would have come out quite as 
nicely as it really did in the end. So I feel that there is not just one side to this 
story, it really is a partnership between academia and industry.
260 For recollections on the relationship between academia and pharmaceutical companies, see the Witness 
Seminar on clinical pharmacology (Reynolds and Tansey (eds) (2008b)).
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Blackburn:  In my experience data trumps everything, whether that data 
comes internally or externally. I spent my research life in Pharma doing 
a lot of work externally because it was sometimes difficult to get a slot for a 
particular experiment within the Pharma matrix management system. So you 
went outside and you knew where to focus your research. Like Pat said, you 
know the areas you want to go, you work with the academic departments, you 
build up a trust within the academic department where both groups work well 
together, whether it’s on 5-HT
6
, 5-HT
2C
 receptors, whatever. That is the way it 
happens, you bring back the carrot into the organization to get the funding for 
you to move on. As in academia, I was growing projects each day, month, year, 
basically trying to move each project forward internally. In my time, before I 
left SmithKline Beecham, we had several projects running at the same time to 
deliver two development compounds into the clinic per year, which was a major 
task. So you were looking at all ways and means to try to fund and manage that 
research, whether it be from your own project internally or externally.
curzon:  On the question of industry and academic funding, when I used to 
have visitors from the old Soviet Union in my lab, I’d say to them: ‘The best 
thing that I can do for you is let you look along the shelves and if there are any 
compounds of interest to you there, take a little of them.’ The fine chemicals 
industry was much, much more advanced in the West than in the East – an 
advantage of capitalism with the competition between drug companies leading 
to all these nice, new compounds. On the other hand, they put a tremendous 
amount of effort into persuading themselves – and the rest of us – that their 
compound is a lot better than anybody else’s compound. When it comes 
down to it, it can be very, very difficult to demonstrate whether any particular 
monoamine oxidase inhibitor is better than any other monoamine oxidase 
inhibitor. It often comes down to the question of side effects and compliance. 
The MAOI antidepressants first came onto the market 50 years ago or more, 
but is there any great difference between the newer drugs and the older drugs in 
their effects on depression? 
tyers:  I want to come back to a comment about research of subtypes, whether 
it’s the research that comes first or the application. At Glaxo, we were very much 
of the mind that we needed to look for a receptor antagonist first and then find 
a disease for it afterwards. We knew that 5-HT
3
 receptors were present in the 
brain and so there must be a clinical target there somewhere. That’s why we 
collaborated with Brenda Costall and Robert Naylor at Bradford University 
because they had a lot of animal models that predicted activity in the brain, 
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and several other neuroscientists around the world were working on models of 
diseases of the brain. So we sent them all a number of highly selective 5-HT
3 
antagonists and said: ‘Go and test these compounds in your CNS models and 
see what emerges.’ 
flower:  That makes sense. 
green:  Having been on both sides, I found industry was very generous when 
I was with the MRC Clinical Pharmacology Unit, including the fact that we 
managed to publish on one of the 5-HT
2
 antagonists from Janssen before their 
own internal people published it, which caused a bit of aggression for a while.261 
I think the situation changed because, like Tom, I got involved in doing quite 
a lot of work for AstraZeneca by trying to get a drug we had got, not a 5-HT 
drug but I’m sure it’s a generality, worked on in specific models in universities. 
By the very late 1990s, early 2000s, the university had really got serious about 
making money in every direction. You would ask them to do something fairly 
straightforward, you know: ‘Will you do this and we’ll pay you for it?’, and then 
you would get tied up for months because the university’s department officers 
would be saying: ‘But if we find anything unexpected, we expect to take the 
patent; we expect to take 25 per cent of any money you make if you get it onto 
the market.’ Suddenly it was almost on the other foot. It wasn’t that academia 
was grateful for getting these things and would be paid, but the university was 
trying to actually take intellectual rights and all sorts of things off you at an early 
stage. On one or two occasions we gave up because we could never actually get 
agreement: even the things we knew about they were trying to get a hook into 
you, that if they got a positive result with this they would expect to get royalties 
from it and things like that. I think academia for a while made it very difficult; 
it wasn’t industry being difficult, it was academia.
flower:  Still is, I’m afraid. 
Hoyer:  Richard raised the point I wanted to make as well. It has become 
increasingly difficult to get academics to understand that if we have a compound 
or product that is made available and they play with it, if it’s contract research, 
what’s the point? Getting a patent out is ludicrous: who is going to write the 
patent and who will accept it? So, it’s become more and more difficult. But to 
answer Mick’s point, 25 years ago the people in 5-HT were just nice people. 
It sounds a bit over the top but that’s what it was. I think most of us here are 
friends and yet we’ve been in different companies, we’ve been in competition 
261 Green et al. (1983).
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and you don’t see this very often. Now, of course, things have changed. For one 
thing, from the 1990s, chemists were less and less prepared to synthesize tools; 
they prefer compounds that go into the clinic, therefore it’s very difficult to get 
just tool compounds, and then to give them away for free. This attitude has 
changed. Management doesn’t like that concept anyway, because if a compound 
is going to make it to the clinic, and an academic reports something that could 
be negative for the compound, then that’s bad news. The other thing is that 
compounds in those days were distributed just out of the synthesis lab; there 
were no good laboratory controls or good laboratory protocols. They may be 
99 per cent pure but not 99.99 per cent, so there could be some impurity 
that is detrimental. And if you have a toxic finding it has to be reported. In 
essence, life has not become easier. My final point is that the field has changed 
with molecular biology; biologics have made their way. No one cares about 
just another small molecular weight (SMW) compound; they want to have a 
specific short interfering RNA or an antisense or a transgenic mouse and the 
like; if you don’t have a transgenic, people are not going to buy what you have 
shown using a SMW drug. This is where attitude and emphasis have changed. 
But coming back to Mick’s point: the 5-HT field is an exception just because 
these people were nice. 
Dr Jeffrey Aronson:  I think that 5-HT probably is an exception, but there are 
formal studies of this question. The classic text on this is a book called The 
Sources of Invention, which is now something like 50 years old, by Jewkes and 
others.262 There have been other studies since then and covering a wide range of 
technologies, not just drugs. On balance, my reading of that literature is that it 
is about 50/50 industry and academe. A lot of this information comes indirectly 
from the balance (a false dichotomy in my view) between basic and applied 
science. But there is quite a lot of actual information on this that you can read 
– my impression is it’s about 50/50. As Richard has said, however, there are 
tensions and I don’t think they are all in the one direction necessarily, they have, 
at different times, been in both directions. 
Humphrey:  Following on from Daniel’s point, yes, I think everybody in the 
5-HT area did happen to be nice and was that a coincidence? I don’t know. 
Part of me thinks it was something to do with the era in which we were. I was 
in academia before I went into industry but I wanted to discover a drug and I 
262 Jewkes, Sawers and Stillerman (1969).
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think most people in the industry in those days were very altruistic about their 
mission in life. They weren’t there to make money, they wanted a job obviously, 
but their main mission was to find a medicine that would benefit patients. 
That’s why working with David Jack was so inspirational because he told us 
that’s what our job was – to find new drugs, better drugs that would benefit 
patients. Today, I think of the pharmaceutical industry just like the bankers 
– put the wrong people in charge and the motivation is entirely wrong. The 
motivation today seems to be to make money for yourself and that’s not just the 
guy at the top but all the way down. That’s all that counts. So all the good things 
that come from altruism are being lost.
sanger:  At least for some of the larger companies the influence of molecular 
biology and the human genome changed things dramatically. We would be told 
to take advantage of this wealth of molecular targets and try to make a new drug 
every two years! But what happened in the end was that a process developed 
and people began to ask where the creativity was within that process. We lost 
creativity. All we did was take a target and process it; we put it up for high-
throughput screening, developed a molecule for it, and put it into, perhaps, 
a standard animal model, before taking it to the clinic to find out if it would 
work or not. Suddenly invention and creativity were lost. I remember at some 
figure 22: Dr Jeffrey Aronson
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stage being interviewed about what I thought had improved since we were able 
to mine the human genome for new targets and I said: ‘Well the process is bad. 
It’s good, obviously, because you get new targets to work on but the process 
kills creativity.’ The message I got back from the guy interviewing me was: ‘Yes, 
that’s what I hear consistently.’263 You can see that in other parts of the industry, 
the process kills biological creativity. And maybe that’s been a big problem with 
some of the big pharmaceutical industries, they’ve had tools but no invention.
flower:  Are you saying they are being de-skilled, in a sense?
sanger:  In a sense – although I’m being a bit ‘over the top’ to make a point.
Hunter:  I think it’s really apposite that Gareth who is the least process person 
I know would make that comment. Partly it isn’t always down to individuals 
because, as a personal reflection on Gareth, Gareth has the little drug discovery 
genie that sits on his shoulder and tells him what’s the right question to ask and 
the right hypothesis. That was coming back to the original question: I would 
say that there is a role, it is 50/50, but perhaps you can say predominantly 
in academia it’s knowing what question to ask and industry is providing the 
resources, for example, the tools and technologies, to be able to answer that 
question. Now is 5-HT different? I would actually argue that it isn’t. If you 
look at the era of the NMDA receptor and neuroprotection, the work that 
was done by companies to provide selective compounds really drove a huge 
amount of research in that area. When those compounds failed, I would argue 
potentially because the trials were not appropriate in the clinic, neuroprotection 
in terms of funded research crashed.264 If you look at the number of sessions at 
the Society for Neuroscience, for example, versus ten years ago, you can see it’s 
hugely reduced from what it was. So I don’t think it’s unique. Deeply wonderful 
though you all are, I’m not sure it’s just because people who work in 5-HT 
are nice people. I do wonder whether it’s something like the Serotonin Club, 
which brought people together around a particular topic, in this case 5-HT 
that actually fostered that cross-creativity between companies and people and 
industry and academia. That could be, perhaps, something to think about. I also 
see a move in the industry now, not so much away from the industrialization 
263 Professor Gareth Sanger wrote: ‘He [the interviewer] was a senior American academic, employed for a 
while by GSK (Dr Allen Roses). Among others, I was interviewed as part of an internal review of activities 
conducted on behalf of senior management. Difficult to remember, but this took place maybe 10–15 years 
ago?’ Email to Ms Caroline Overy, 16 July 2013.
264 See, for example, Palmer (2001).
Drugs Affecting 5-HT Systems
94
but a realization that, until we find a way of improving our chance of success, 
we’re going to have to cut the cost of failure. Therefore you do see many more 
precompetitive activities. But when you get the medicinal chemistry or the 
actual biologics, I think that’s probably a step too far. So, a slightly different 
perspective.
Andrews:  I want to come back to what Richard said. I agree very much from an 
academic perspective that the difficulties of getting compounds have increased 
immensely on both sides and also what you said about universities, that’s been 
precisely my experience. We’ve got IP officers and business officers and I think 
what we have to try to do on both sides, if you call it that, is to learn the lessons 
from this. Because I think this is a fairly unique set of circumstances that have 
happened around 5-HT and really the question would be: could we do this now? 
Certainly in my own small area the answer would be ‘no’, because it would just 
be too difficult for multiple reasons. I think there was a particular time when it 
all just seemed to work in a lot of people’s favours for reasons on both sides of 
the fence. I do wonder whether we’re losing something, so I think somehow we 
need to try to distill a few of the positive lessons for both industry and academe, 
as we’re supposed to work more closely together now officially and with more 
blessing than before, and try to work out what it was that was really good about 
this period that made it work. Clearly there are going to be other circumstances 
where we need this and I’m worried that something has been lost. Maybe it’s 
just getting older, you begin to feel that. There may be some parallels here with 
NK1 receptor antagonists as well, where there was a lot of background data on 
substance P, but really I think that it was the availability of small molecules that 
again advanced this further. So there may be some other parallels.
Blackburn:  Apart from this sort of parochial view with regard to 5-HT and it all 
being very nice, Gareth’s comment about process, and Jackie saying it’s much 
wider: well, it is much wider in the sense that the late 1980s and the 1990s were 
a very important era with regards to Pharma and the way the whole industry 
was thinking. It’s a fact that McKinsey, like many consulting companies, came 
out and promoted: ‘This is the way to follow.’265 And we all did! We followed 
with ‘me-too ism’, so you had many companies all jumping on the same 
265 McKinsey and Company is a global management consulting firm. See Booth et al. (2002), which states: 
‘Our research indicates that first-in-class drugs don’t always deliver the highest returns…For the long-
term sustainability of the business, it is crucial to improve the pipelines’ productivity. To that end, most 
drugmakers will have to orient more of their drug development efforts toward best-in-class rather than 
first-in-class approaches.’ 
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bandwagon. What we’ve seen from that is a destruction of creativity. I asked 
a question at a New York meeting a few years back because everyone showed 
these wonderful graphs of New Chemical Entities (NCE) disappearing over 
decades. I asked: ‘Is there a correlation, a graph, showing the amount of money 
we’ve spent on consultancy companies over these years with regard the number 
of NCEs?’ And one of the luminaries of the pharmaceutical industry said: ‘Oh 
yes, but they’ve taught us how to write reports well.’ Well, if you haven’t got a 
compound to write a report on, you don’t have an industry. The dependence 
on management processes, whether it was matrix management, proved to be a 
failure in many industries and was one of the undermining problems that I saw 
within the pharmaceutical industry in the 1990s, in destroying that creativity of 
individuals or scientists like Gareth and others around me. 
marsden:  My interest was in mental disorders and there was a difference in 
approach between the academic and the industrial side during the 1980s and the 
1990s in particular. With all these 5-HT receptors being identified, the industry 
thought very much of a single target approach but it always seemed hard for 
me, and many others in the academic field, to think that you could explain a 
mental illness by attacking a single, very specific receptor. It is interesting when 
you think of Bill Deakin’s work on anxiety, which implicated at least two 5-HT 
receptors in this disorder, that a single target approach could ring true when 
trying to treat mental disease.266 Understanding has moved on now and people 
are beginning to think of these disorders as being more complex. Maybe the 
‘magic bullet’ approach did hold research up in the 1980s and the 1990s, as 
we had a too simplistic approach about how you might treat a mental disorder. 
clarke:  When we’re talking about academia and the pharmaceutical business, 
we’ve got to consider three things and I think there’s always an uneasy 
relationship between these. One is the businessman: I admire businessmen but 
I don’t understand them. They’re willing to put everything on the line for an 
idea and sometimes I don’t get the reasoning behind it. Then there’s the applied 
scientist: now he’s a man who wants to discover a drug, discover and develop 
a molecule for a defined medical application, if he’s in the pharmaceutical 
industry. His brain works differently; it’s always thinking about trying to get 
a molecule for the target, going down the road to try to get to that point 
where he wants to be and that is make a compound that hits the target, that 
is clean, and that one can get into the clinic. Then you’ve got the academic: 
266 Bill Deakin is Professor of Psychiatry and Head of the Neuroscience and Psychiatry Unit at the University 
of Manchester. For his work on receptors, see, for example, Mekli et al. (2011).
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now the academic is often a blue-sky researcher; he’s not interested in an end 
effect. He’s a reductionist researcher, he’s goes into it and into it and into it 
because it’s interesting, not because he’s going to hit a target that is valuable 
and therapeutic. He’s just interested in science and discovery and what nature 
is all about. So you’ve got the academic, you’ve got the applied scientist and 
you’ve got the businessman, all in an uneasy relationship with one another. 
The businessman wants something now; the applied scientist says: ‘You can’t 
have it now; we haven’t got the molecule’; the academic doesn’t really want 
anything now, he just wants to do some research that’s paid for and to find 
out how things work. This has always been the case: their brains are different. 
The academic brain is different from the applied scientist’s brain in industry 
and it’s different from the businessman’s brain. What happened years ago in 
my opinion, and it’s only my opinion, that despite these brain differences 
there was trust. I think we’ve lost that very important element: a trust that 
the businessman would trust the applied scientist. The applied scientist who 
needed help at Bradford would send out his compounds; he’d trust Bob Naylor 
and Brenda Costall. That is gone. As Dan says, now the academic is more like 
the businessman. He is there, he wants money for what he’s doing, he wants 
rights for what he’s doing, and all this undermines trust between these three 
elements. And that removes freedom. If you’re going to get creativity, you’ve 
got to have freedom; you’ve got to be able to say to somebody: ‘We trust you, 
we think you’re good, your idea is good. Here’s some money, go in the lab, get 
stuck in and do the work and don’t even bother to give me a report for two 
years. I trust you. Come out with an answer.’ That’s gone. Now you can get 
into a lab for two weeks and if you haven’t got an answer, they stop the project 
in industry these days. I think these are very important elements that pervade 
current drug discovery, universities and applied science. And that’s why we 
haven’t got new chemical entities coming out.
flower:  I’d just like to make one comment and that is it’s not actually the 
academics it’s the university administrators who are responsible for all these 
rules and regulations. It will kill everything. 
curzon:  Again and again, people here have said 5-HT workers are so nice. 
There are few of us in this room who are under 60 and there are quite a few who 
are over 80. We come from a different world. When I graduated, less than about 
one per cent of British graduates got PhDs. Only a tiny fraction of society was 
involved in research. Because far more people are now doing research, they are 
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recruited from a more ordinary pool. I’m not saying we’re better people than the 
newer generation but we’re different to them.267 
It was easier in our day to help other scientists but things nowadays are more 
grim and competitive. Scientists are under greater pressure to get the next grant 
and are much less relaxed. Tony Blair wanted 50 per cent of the population to 
have degrees, which is fine, but this is altering what it means to be a scientist.
flower:  I certainly agree with that. 
Professor Helen cox:  Two points: one is to echo what you’ve just said Rod, 
in terms of the tensions that exist in academia, they are between academics and 
the enterprise arm. I would like to emphasize the fact that there is trust, a lot 
of trust, between scientists on both the academic and the pharmaceutical side. 
Although I’m not a 5-HT expert, certainly in my area of neuropeptides I know 
that I can communicate with my compatriots in Pharma companies and, with 
material transfer agreements in place, still get compounds readily, but I’m sworn 
to secrecy on that. So there is a degree of trust but it is challenged by internal 
‘hurdles’ along the way. I’ll leave it at that.
Bakhle:  In your particular area, Helen, where are the advances coming from? 
Are they coming from industry that you can identify in this crude way, or are 
they coming from the academic sphere? That’s what I really want to find out: 
is 5-HT different from other research areas? We’ve heard from Jackie about the 
NMDA area; is that common?
cox:  I’d say that in the neuropeptide Y (NPY) receptor field, we’re also very 
communicative and supportive people, but largely this is driven by the fact that 
we’ve had meetings, a bit like the BPS, once every two years for pretty much the 
last twenty years.268 The same Primary Investigators turn up to these meetings 
with a core group of us in academe and Pharma who end up writing IUPHAR 
recommendations in Pharmacological Reviews.269 When a group of people do 
267 Professor Gerald Curzon wrote: ‘Research is becoming just another profession like accountancy or law. 
But some of us saw ourselves as almost a kind of scholarly knighthood. A band of brothers (and sisters). We 
were proud to be research scientists.’ Note on draft transcript, 22 January 2013. 
268 Professor Helen Cox wrote: ‘To clarify, the neuropeptide Y meetings I referred to have been organized in 
an ad hoc way, and have occurred on average every two to three years since 1989, largely due to the common 
interests of a proactive group of scientists working in different countries in this area (of which I am one). 
There’s no organizational entity as such.’ Email to Ms Caroline Overy, 12 June 2013.
269 See Michel et al. (1998).
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meet on a regular basis, those links are maintained and I’d like to think that 
that’s true in the Y receptor field just as much as I’ve heard today that it obviously 
exists in the 5-HT field. So, in answer to your question, Mick [Bakhle]: what 
is driving it? In the 1990s when NPY receptors were being cloned and when 
Pharma was really interested in anti-hypertensives and anti-obesities, there was 
a preponderance of work going on in Pharma. But then as a consequence of 
the compound attrition, those compounds came into academic circles and this 
helped significantly in the classification of the receptors. So, research in this area 
is cyclical as I see it and now with the anti-obesity drug targets in the limelight 
again Pharma is contributing significantly again, ten to fifteen years later. 
Andrews:  A final point about funding, we’ve talked about funding research 
directly, but I think we shouldn’t forget that the industry has also funded a 
large number of meetings in this area in general, and particularly in 5-HT
3
 at 
the time. Those regular meetings of pretty much the same people but sharing 
data almost in real time, played a very important role in keeping the area going, 
giving a momentum to the area and in some ways keeping some aspects of the 
science alive. We shouldn’t forget those meetings because they’re the ways, in a 
sense, in which we can plot the course of the development of the area. Many 
of those were funded by industry, and I think that is not likely to be the case 
figure 23: Professor Helen cox
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now where funding for a meeting from industry is very difficult to get hold of; 
small sponsorship but not exclusively funding from two or three companies and 
making it a very open, international meeting. So that’s another aspect of this.
flower:  We ought to move on a bit and discuss the advent of specific drugs in 
the 5-HT field. It was Tom who mentioned four or five of the top twenty drugs 
acted on the 5-HT system. Is that right, Tom? 
Blackburn:  In a recent article from the American Chemical Society it was 
interesting to note that neuroscience attrition rate was less than that for anti-
cancer and anti-infective drugs, yet neuroscience is seen as a high risk therapeutic 
area!270 I mentioned Seroquel earlier, which is coming off patent and was a $4–5 
billion drug in 2010. Duloxetine, a 5-HT uptake plus noradrenaline uptake 
was a $4 billion drug in 2010 and there are one or two others that are still highly 
efficacious and highly profitable drugs. 
flower:  I’d like to come onto that a bit later because I think that’s a very important 
question. What I’d like to do now is to record and capture personal anecdotes 
or reminiscences about the introduction of particular groups of specific 5-HT 
drugs. Pat, I wonder whether you could say a few words about the triptans for 
us. Maybe some personal reminiscences about their introduction and so on and 
then we’ll go on to talk about others.
Humphrey:  Well, that could be a long one or a short one, I don’t know how 
to deal with this. From the reminiscence side, as I told you, I was a lecturer 
at St Mary’s Medical School in the Physiology Department and I didn’t really 
want to just teach medical students and end up with a line in a textbook, so I 
thought I wanted to discover a drug, and I was very fortunate and was asked 
to go down to Ware and find an anti-migraine drug. When I got there I found 
an empty lab and a girl sitting on a stool saying: ‘What are we going to do?’ I 
said: ‘Well, I don’t know; we’ll have to think about this’ because there were no 
preconceived ideas about how we should proceed. That would never happen 
today, to be given that freedom. I don’t think I would have discovered anything 
if I’d gone to Glaxo 20 years later. So the empty room is the first thing you 
need if you want innovation and what did I do? I went and spent three months 
talking to clinicians while I was waiting for equipment to arrive, finding out 
about migraine. I don’t think I want to bore everybody with the details, but 
there were two or three clinical people to this day who I think are brilliant 
because they understood their patients, they knew which drugs worked. But 
270 Lindsley (2012). See also Table 3 on page 126.
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as I said, the key for me, the seminal observation, was James Lance who said 
that there was a prophylactic drug, methysergide, which was a 5-HT
2
 blocker 
or a D receptor blocker, whichever terminology you want to use. It was given 
prophylactically; it was taken every day for months and months and didn’t do 
very much. However he noticed that some of his patients took a tablet and while 
they were in his clinic, his office, with a migraine, suddenly it went away.271 In 
other words, it had another action that the other 5-HT
2
 antagonists didn’t. 
So I was studying what it was that methysergide did. What we discovered was 
that there was another receptor at which methysergide was a potent agonist, 
and so that turned out to be the 5-HT
1B
 receptor.272 So clinical observation is 
absolutely critical. Another part of the mix is really intimate discussion, trust 
and interaction with the clinical field, really find out about the disease first. 
Then all bets are open. It could be that you want to look at it in a complex way. 
When I first started, I used to work on prostaglandins and 5-HT because there 
was a story that if you infused prostaglandins into people, I think it was PGE1, 
it caused migraine-like headaches. So we were going to measure prostaglandins 
in jugular venous blood during an attack. Unfortunately we couldn’t find a 
medic who was prepared to do it, so we never did that experiment. We had 
all sorts of bioassays worked out and everything. I quickly moved onto 5-HT 
in preference over prostaglandins because of this clinical observation that I’ve 
just described, and then it was just about looking at blood vessels and we were 
actually lucky enough to be able to have identified a receptor through using 
different tryptamine analogues prior to the molecular revolution.273 What we 
discovered turned out to be correct. It’s interesting that we knew this receptor 
was also on nerve terminals and would inhibit nerve terminals and it looked 
like the identical receptor: everything we did, hundreds of compounds, couldn’t 
differentiate them. I’m pretty confident now that that was probably the 5-HT
1D
 
receptor and so we discovered two receptor types in reality but they were so 
similar pharmacologically and, as it happens, molecularly. Of course, the proof 
of the pudding then was in the eating and that was ‘get hold of a migraineur and 
find out whether it works.’ And to be fair, it’s analogous to getting an asthmatic 
who’s wheezing and giving them something to inhale, ‘Does it work?’ You know 
when your bronchodilator works.274 In the same way with a migraine attack: 
271 Curran and Lance (1964). See note 52.
272 Apperley, Humphrey and Levy (1976).
273 See, for example, Apperley et al. (1980).
274 For discussions on bronchodilators, see Reynolds and Tansey (eds) (2001), passim.
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with a severe migraine I think it’s pretty obvious if your drug has worked or not. 
That was the exciting thing about it, that there were patients who were really ill 
and they were just getting off the bed and going home happy.
flower:  Bearing in mind some of the comments other people have raised, what 
battles did you have to fight internally in order to keep this project going – or 
was it plain sailing?
Humphrey:  Well, it was a bit of an open door because at Glaxo at the time, it 
was led by David Jack, who was not a micromanager, but you were pretty clear 
what he wanted of you and that was to do what you were supposed to do. All 
he asked of you was that for every experiment you did you had to have a reason, 
and knowing if it worked out, where it would take you. That would take you to 
the next step, on to the next step, to the final end, which was always the drug: 
the medicine that would benefit patients. I think that was absolutely critical. 
What was also lucky was that I had an academic interest in 5-HT receptors as a 
consequence of getting in through that door and you could see that 5-HT was 
everywhere, and in the brain and in the gut and one just felt that this had to be 
an opportunity to find other drugs. Now that wasn’t something that convinced 
David at the time particularly, he didn’t like that blunderbuss approach but it 
didn’t matter. The thing was, if you were always doing the right things, that was 
fine. But I just can’t imagine how such a drug would be discovered today. First 
of all if someone said: ‘Well, there are 14 different 5-HT receptor types and we 
know that 5-HT aborts a migraine attack, you go and find the right one.’ You 
know with just the molecular biology and paucity of whole tissue and in vivo 
pharmacology, it just wouldn’t work. Then if you have the Clipboard Charlies 
going around telling you how to run your project and how you should be doing 
it, that would kill it as well. So I think I was very, very fortunate in being at the 
right time in the right place with the right organization.
flower:  And the right person, too.
Humphrey:  That’s what I mean about the right organization, it was the leader 
at the top.275
flower:  I mean you actually.
Humphrey:  Oh right, well, that’s very nice of you. Thank you.
275 i.e. Sir David Jack. For biographical details see page 151.
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Hunter:  I talked to the guy who ran the clinical study276 and in the first 12 patients, 
you know, it was almost like you said, it was almost like a Lazarus moment, so that 
must have helped as well that you were able to show that so quickly.
Humphrey:  There was one person in which it didn’t work but they later found 
that he had a broken jaw. 
flower:  You mean it doesn’t fix broken jaws as well? [Laughter] 
green:  I think Pat has brought up a vital point, which is that he went and talked 
to clinicians. One of the great things of working in the Clinical Pharmacology 
Unit in Oxford, and if you go back and look at the NIH in the 1960s and 
people like Sjoerdsma, is that they worked together closely. I found it invaluable 
being with Phil Cowen and Dave Nutt and others because I was working mainly 
on depression and I would say something like: ‘Oh, you know, I believe most 
depressives have this and that’, and I’d get people like Phil saying: ‘Well, yes, 
the books often say that but I almost never see it’ – actually picking up what the 
vital components are and this goes exactly with what Charles has said as well, 
one size fits all, one receptor will do everything. If we actually knew much more 
about the problems of things like depression and schizophrenia and could break 
them down because we were working and talking with clinicians, we would then 
be producing much better animal models. To give you an example, for years I 
worked on neuroprotection and stroke. When I look back now, why were we 
using young, healthy male animals for almost everything when, in fact, the 
stroke patient, and if we’d had a stroke clinician on the pre-clinical group this 
would have been pointed out, is mainly an elderly hypertensive diabetic. We 
should have been using hypertensive animals, diabetic animals, elderly animals. 
I think this is something that we have lost, that happened much more in the 
early 5-HT research, meeting people like Merton Sandler, Mike Pare and Alec 
Coppen.277 Every time we met these people and talked with them, they told us 
what the clinical problems were and what they wanted. I think we were much 
276 Referring to Dr Malcolm Thomas. See the interview ‘Sir David Jack CBE FRS FRSE in interview with 
Dr Max Blythe (Interview III) and in conversation with Professor Patrick Humphrey, Oxford, 6 August 
1997’, which can be accessed at the Medical Sciences Video Archive at Oxford Brookes University, ref 
MSVA 173/174, and at the Wellcome Library, Moving image and Sound Collections 1843V.
277 Michael Pare (1925–2002) was a Consultant Psychiatrist at St Bartholomew’s Hospital, London, from 
1959 until his retirement in 1984. His work centred on the treatment of depression. See Professor Merton 
Sandler’s comments on pages 8 and 20. Alec Coppen (b. 1923) is a British psychopharmacologist who 
worked at the MRC’s Neuropsychiatric Research Unit in Epsom, Surrey. See pages 29, 40 and note 133.
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more aware than a lot of the young scientists are now, particularly in industry, 
trying to develop a specific antidepressant drug or something like that, because 
they don’t get the clinical input. I really would love to see, and Jeff Aronson and 
I have talked about this, clinical pharmacologists and the basic pharmacologists 
interacting much more closely again.278
Hoyer:  When I started, and my background is in beta receptors and alpha 
receptors, I had no clue what 5-HT was all about. However on the day I 
presented my PhD in Strasbourg, in the afternoon I went to Merrell Dow and 
made a presentation to Dr Fozard and we have kept in touch ever since. This was 
1981. In 1983, I was asked to join Sandoz, at the time I was at Penn University 
of Pennsylvania, to work on 5-HT. I said that I still didn’t know anything about 
5-HT, and one person said that this was important because I was unbiased. The 
way 5-HT research started at Sandoz was in 1978, when Brian Richardson was 
asked to lead a 5-HT task force. We knew that the receptors were complicated, 
the goal then was to characterize receptors, compounds, tools first and then go 
into the clinic with the best ones. This is how the 5-HT programme started, 
pretty much at the same time as John [Fozard at Merrell Dow] was doing it 
and presumably Mike [Tyers at Glaxo]. The good thing then is that once they 
realized that there was mileage, and there was quite some mileage, they said: 
‘Go and look for more, and go into other indications.’ Initially we were talking 
about pain, migraine, of course in both cases it failed but actually we were the 
first ones to ever try a 5-HT
3
 antagonist in a clinical set-up with cancer patients: 
chemotherapy induced vomiting, all these things were happening at the same 
time in different places.279 The problem is that, quite often, by the time you 
have the clinical data the company will not follow because in the meantime the 
management or strategy has changed. This is one of the major disappointments 
that you experience. But at least at that time the freedom was given: for 
example, we had one of these 5-HT
1
-like receptors to play with because we had 
a compound that was reducing blood pressure to the extent that we couldn’t 
really believe it.280 Nothing else would match the profile: it was working in rats, 
in dogs and in other species and so we went on a fishing expedition to find out 
what this compound was doing on which receptor. Note that this would not 
be feasible today. Eventually we found out it was actually 5-HT
7
-mediated, it 
278 Green and Aronson (2012). 
279 See Christie and Tansey (eds) (2007).
280 See comments by Dr Patrick Humphrey on pages 42–3. 
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was not a 5-HT
1
 effect. The so-called 5-HT
1
-like receptor was actually a 5-HT
7 
receptor.281 It took quite some efforts chemically to sort this thing out, until the 
receptor eventually was cloned, but this was many, many years later. It turned out 
that this compound never made it, for again PK issues etc – PK is one of many 
critical issues in drug development. In one of my latest teams, the first thing I 
did was to hire a clinician because he knew what he was talking about, actually 
he had already developed a compound in the indication we were pursuing, but 
on another mechanism. This was an eye-opener, we knew precisely what we 
were looking for and, importantly, we also knew what we were not looking for. 
The side effects, depending on the indication, are going to kill your compound 
so you’d better know early what you don’t want. One of the major issues that we 
have experienced more recently is that clinical research and pre-clinical research 
have been totally separated, I don’t know if it was a McKinsey or whoever’s 
effect, but there was a wall.282 In the old days we had clinical pharmacology, 
these clinicians would take compounds and put them into probands/volunteers. 
Actually I’ve been testing beta blockers on the bike and I can tell you that some 
of them don’t help you to go up the hill [laughter], others are a bit better. This 
sort of expertise had totally left the company because they thought they could 
subcontract all these studies and then the link between pre-clinic and clinic 
was totally lost. So one of my first things in another team, around the end of 
2002, was to create a translational biology group in neuropsychiatry; I made 
sure that clinicians would be at the meetings, as quite often the doctors are busy, 
because without clinicians, pre-clinical people are lost. This is important, it has 
to be fixed, so in my new job, I will have to convince my friends in the clinic 
that what people do in research departments is important too.283 I remember 
at the BPS meetings in the old days, clinicians and pre-clinical people would 
be together and talk happily. Toxicology was a bit different, it has always been 
a bit different, but at least clinical and pre-clinical were very much linked and 
we would go all to the bars and restaurants together, because clinicians know 
the good places! Now we have more and more molecular biologists who don’t 
care about the other end of the spectrum. One of the hurdles that we have with 
respect to academic–industry collaborations is that, in America, every scientist, 
281 Villalón et al. (1997, 2000).
282 See page 94. 
283 Professor Daniel Hoyer became Chair and Head of the Department of Pharmacology in the School of 
Medicine at the University of Melbourne in December 2012.
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at some point or another, thinks that he’s going to be able to create a biotech 
company and become a millionaire. This leads to information retention because 
he always thinks about his future, when actually the future is rather grim for 
most biotechs. This has become a major issue as well. 
sanger:  In some ways my experience is rather similar to yours, Pat, in that, 
when I started in industry, I was given an empty room and I was told to help 
the programme develop new dopamine receptor antagonists. At that time they 
were working on metoclopramide, which was deemed to be the lead dopamine 
receptor antagonist. It quickly became apparent that it wasn’t just a dopamine 
receptor antagonist, it had something to do with 5-HT as well. I had to go 
through the process of defining its ability to stimulate a 5-HT receptor in the 
gut – ultimately named externally as 5-HT
4
284 – and also identifying, for the 
first time, the clinical significance of its ability to antagonize at the 5-HT
3 
receptor and from here developing anti-emetic drugs. Part of that process 
was reading the literature and there were clinical observations that said: 
‘There’s something peculiar going on here.’ Gralla’s work on the anti-emetic 
activity of high doses of metoclopramide was particularly important in our 
discovery of the anti-emetic role of the 5-HT
3
 receptor.285 Another part was 
reading competitor activity, in particular by John Fozard, who identified the 
receptor pharmacologically and showed that metoclopramide antagonized at 
this receptor.286 So it was then possible to read these two areas of literature 
and test the hypothesis that metoclopramide exerted anti-emetic activity by 
antagonizing at the 5-HT
3
 receptor – in terms of new anti-emetic drugs, the 
rest is history! New pharmacology and drugs came out of that kind of research, 
but today we don’t have extensive literature on any of the new drug targets that 
we work on, the ones that create the high impact papers. It’s very difficult to go 
out and find the clues. You’ve got to do it yourself or you do it in a very limited 
way. You may choose a knock-out mouse, which may or may not be relevant. 
So Danny’s point about trying to pull the clinicians in is a good one, I can see 
284 Professor Gareth Sanger wrote: ‘After publishing papers which suggested the existence of a 5-HT 
receptor mediating the abilities of drugs such as metoclopramide to stimulate gastrointestinal motility (for 
example, Sanger G J (1987)), I received a phone call in the lab from Joël Bockaert who announced, in his 
rich French accent, that he had found my receptor in the brain!  This was amazing!  Joël then went on to 
publish his findings and named the receptor as 5-HT
4 
(Dumuis et al. (1988)).’ Email to Ms Caroline Overy, 
9 October 2013.
285 For Gralla’s work see note 185.
286 Fozard and Mobarok Ali (1978).
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it helps, I don’t know how much, because even they don’t know what this new 
molecular target might be because they haven’t got ten years of literature behind 
them on that target, which I certainly did and others did at the time. You had 
that literature behind you; you don’t have it so much now, so it’s more difficult.
tyers:  I’ll tell you a couple of anecdotes. Before ondansetron was approved in the 
States by the FDA it was possible to use it off-label with the Surgeon General’s 
permission. There was a report through from our clinical trial researchers, who 
said that this woman was suffering from severe nausea and vomiting and could 
she take ondansetron as a means of overcoming it and the Surgeon General said, 
‘Yes she could.’ Well, she took it and it worked very, very effectively. She said: ‘If 
I ever meet the guy who discovered this drug I want to give him a big kiss.’ And 
the researcher told her, ‘Don’t look forward to it.’ [Laughter] Another one is after 
ondansetron (Zofran) had been on the market in the UK for only a couple of 
months. I have a cousin who is an oncologist in Gloucester Hospital and she said 
one day she visited the oncology ward after their daily doses of chemotherapy 
and everyone was vomiting indiscriminately, the nurses were running around 
with mops and buckets and things. That night they were all given ondansetron 
and the next day when she went in for her ward round at the same time of day all 
the patients were sitting up in bed having their breakfast and the nurses were just 
standing around wondering what to do. So, one of the rewards of discovering a 
useful drug is that it that does what it is supposed to do.287
Blackburn:  To address Danny’s question: in my days at ICI, I was thankfully 
working alongside clinicians like Steve Howard and David Milson and we 
were developing a trust in the project with regard to their clinical buy-in and 
enthusiasm for the science. In those days, we were looking at biomarkers, 
looking at pupillary constriction, platelet aggregation and EEG changes and 
several other models, which were hoping to determine the dose to take us into 
the clinic. We were interested in migraine prophylaxis, whereas our competitors 
in Glaxo were really going full-steam for the intervention therapy,288 so the 
marketing people at ICI were basically saying ‘no to prophylaxis treatment and 
that intervention therapy is going to sweep the board and you guys have got it 
wrong.’ Okay, fair enough at the time, but migraine prophylaxic treatment is a 
287 Dr Mike Tyers wrote: ‘Now just about every cancer patient in the world given chemotherapy or 
radiotherapy receives ondansetron or a 5-HT
3
 antagonist to treat the sickness.’ Note on draft transcript, 7 
January 2013. For a discussion of a paediatric study of ondansetron, see Christie and Tansey (eds) (2007), 
pages 59–60.
288 Intervention therapy using the Glaxo drug sumatriptan.
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big market and still is, if you have the right compound. An anecdote, and Pat 
might remember this; it was at the Migraine Trust Symposium in 1992, where 
Glaxo made a major sumatriptan marketing presentation with all their excellent 
science and marketing guys culminating in a top-class PR presentation. Then 
there were these poor guys from ICI pharmaceuticals, Barry Cox and myself, 
with Clifford Rose in the chair, giving their presentation. After my presentation 
using one of those huge lantern projectors, Dr Wasyl Feniuk from Glaxo, a 
good friend of us all, came to me and said: ‘How did you do that, Tom?, I said, 
‘What?’ ‘You presented a slide talking about spreading depression in migraine 
and all of a sudden on the picture of the brain you could see this shadow moving 
across the slide’289 [Laughter] It’s just what we do best at ICI. 
flower:  You were ahead of the curve as always, Tom. 
curzon:  Those who are 25 years or more younger than I am have no idea of 
the enormous gulf of mutual ignorance between the laboratory workers and 
the clinicians, due to the overlaps between their trainings being so slight. There 
was also the tremendous prestige and self-confidence of the top clinicians, while 
good research scientists are cautious and self-doubting. I remember an eminent 
neurologist, now dead, saying quite dogmatically that pharmacology had very 
little to teach the neurologist. Then levodopa appeared and I stood up at a 
meeting at Queen Square saying very diffidently: ‘There’s this new thing called 
levodopa and it helps people with Parkinson’s disease.’ A comparably eminent 
neurologist, now dead, said through clenched teeth: ‘If Dr Curzon had been a 
clinician he’d know that biochemistry or pharmacology have nothing to do with 
Parkinson’s disease.’290 [Laughter]
kaumann:  I’d just like to comment how surgeons and clinicians influenced 
the design of my experiments. I often fetched human coronary arteries, atrial 
and ventricular tissues from explanted hearts at Papworth Hospital and also 
human atria from patients undergoing coronary bypass surgery. I used to get 
notice about three hours before the next operation. Before receiving cardiac 
tissues I used to have time for chats with the clinicians and surgeons and I’d 
like to give you two examples how this influenced the experimental design and 
hence results with adrenaline and 5-HT. For example, I was told by a surgeon 
289 Heat from the beam of the projector sometimes caused condensation in glass-mounted 35mm slides or 
burnt those mounted in cardboard.
290 Professor Gerald Curzon wrote: ‘The “eminent neurologist” was Roger Gilliatt.  The “comparably 
eminent neurologist” was John St Clair Elkington.’ Email to Ms Caroline Overy, 3 July 2013.
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that, on occasion, some patients undergoing coronary bypass surgery and 
treated with atenolol, a selective β1-blocker, developed transient post-surgical 
atrial fibrillation. This was surprising because it was known that propranolol 
reduced the incidence of these arrhythmias. That prompted me to compare 
carefully results from patients treated with β-blockers, usually β1-selective, 
such as atenolol or metoprolol, with non-β-blocker-treated. Paradoxically, 
we discovered on isolated atria from β1-blocker-treated patients that the β2-
adrenoreceptor function was enhanced and that the latter receptors mediate as 
many experimental arrhythmias as β1-adrenoreceptors. During my experiments 
with human atrial tissues, I had also noticed that 5-HT, on occasion, elicited 
arrhythmias. Louise Sanders, Sian Harding and I discovered that the 5-HT
4 
receptor function of human atrium was increased in β1-selective-treated patients 
and that these receptors mediated more arrhythmias in β-blocker-treated than in 
non-β-blocker-treated patients.291 The other example is coronary arteries. With 
one particular case, I was shown the contrast radiography of the coronary tree 
and I could clearly see atheroma in certain sections with stenosis of the patient 
that was going to be transplanted that night and going to receive a new heart. I 
was fortunate to experiment with those bits of coronary artery and discovered 
that the prestenotic and atheromatous section of the artery responded to 5-HT 
with a contraction through 5-HT
1B
 receptors, whilst on the non-atheromatous 
poststenotic segment a 5-HT-evoked contraction occurred through 5-HT
2A 
receptors. These findings were prompted by conversations experienced at 
cardiac surgery in Papworth. I learnt enormously from these contacts.
Aronson:  I don’t have a drug discovery story, but I’d like to comment on the 
clinical scientist interface from the clinician’s point of view. Notwithstanding 
Gerald’s story, I was very impressed by Pat’s story that he took three months 
out to talk to clinicians and discovered a drug that I keep permanently in my 
pocket. The story that we’ve just heard about the coronary arteries, I think it’s 
hugely important that basic and clinical pharmacologists – or let’s avoid words 
like that – pharmacologists and clinicians should speak together, but then as 
Danny says, the clinicians are not always available. We can’t always find them. 
They’re not always interested, perhaps. That, I think, is a real problem that 
we do need to tackle. These days clinicians are expected to be innovative, I’m 
talking about academic clinicians, we’re expected to be innovative researchers, 
effective clinicians, and inspiring teachers in addition to all the other things that 
291 Sanders et al. (1995). Professor Alberto Kaumann wrote: ‘It is still an open question whether transient 
post-surgical atrial fibrillation can be initiated by 5-HT.’ Note on draft transcript, 9 December 2012.
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one does: policies, committees, all kinds of things. I’m not sure that it was ever 
possible for a clinician to do all of those three things. I think some clinicians 
whom I’ve admired were good at pretending they were doing all three things, 
but the pressures are greater nowadays. Clinical medicine is much more difficult 
to practise than it was, people are living longer and have more complicated 
illnesses, there’s specialization, and so on. I think it’s now not possible, even if it 
ever was, for a clinician to do all three things to a high standard. I do think we 
need to tackle this, and my suggestion has been to take any two activities out of 
three and develop people who are good clinical researchers, or people who are 
good research teachers, or people who are good clinical teachers, mix and match 
those disciplines and get them all talking to each other and with the scientists.292 
We really do have to do something about encouraging clinicians to take part in 
the process that you’ve all been discussing.
clarke:  To take the opposing view about clinicians, a little warning: management 
takes a lot of notice of clinicians. The more eminent they are the more notice 
they take. Syntex/Roche was developing prokinetic drugs based on 5-HT
4
 
agonists and they’d gone down the road quite a long way, although I was not 
in charge of this programme, I never was; I handed 5-HT over to other people 
immediately I got into industry. But the company moved that programme 
forward and then they brought in some very eminent gastroenterologists after 
an awful lot of pre-clinical work and one of them asked in front of management: 
‘Does this compound prevent pain? Gastrointestinal pain,’ and the answer was: 
‘No, it doesn’t.’ The clinicians said: ‘Well, that’s it, it’s useless. We must have a 
drug that is analgesic for these IBS patients.’ The company called him in and 
no matter what we said to management it was of no avail – the programme 
was stopped. As we know, although it’s got a chequered history, Resolor is on 
the market as a prokinetic agent for IBS despite a big question mark as to why 
some of these prokinetic agents cause cardiovascular adverse effects, it’s not at 
all clear.293 So there is room there for further work. It can be very damning how 
very quickly a whole programme can come to an end. 
Hoyer:  My point was to speak to clinicians early and not in the presence of 
management! 
clarke:  I think the point is that I should have been more like Pat.
292 Aronson (2011a).
293 Resolor (prucalopride) is manufactured by Shire Pharmaceuticals. See comments by Professor Gareth 
Sanger on page 72. 
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flower:  And gone to the bar? 
clarke:  And more like Dan, and more like everyone else in this room, but as it 
is, it’s usual for me to be about 50 years behind everybody else. 
sanger:  Very quick empathy with both points and the difficulty of getting good 
clinical advice into development. I was at the World Health Organization a 
month ago where we were discussing prokinetic compounds and laxatives. 
The prokinetic drug prucalopride, for example, is not registered for the 
treatment of IBS and the proposal was to reclassify it as a laxative. However, 
a separate group of prokinetics – which also included alosetron, a drug which 
inhibits colonic motility – would have been separately classified as drugs for 
treatment of IBS, even though the pharmacological mechanisms were similar. 
We had the 5-HT
4 
agonist tegaserod in the IBS box; the 5-HT
4
 agonist 
prucalopride in the laxative box and the 5-HT
4
 agonist metoclopramide in 
the gastric prokinetic box. To me it was utter chaos, and so we had half a 
day’s discussion on this. I talked to the woman running the session afterwards 
and she admitted that it was imperfect, but the problem was that she found 
it difficult to get good, clinical gastroenterologists who understood both the 
science and the pharmacology. And this is the World Health Organization. So 
I’m empathizing with both of you.
Hunter:  One comment on the clinical side. A lot of companies are trying to 
fix this by bringing clinical people in to run things, but I actually think that 
there are different phenotypes: you need good clinical researchers in your 
company, but you don’t want to take the clinician out of the environment in 
which it’s most valuable for you to interact with them, i.e. the clinic. Just a 
couple of personal reminiscences about the 5-HT
6
 programme: SB 271046 
was about to go into Phase II trials when the six-months toxicology came in 
and it said there was a retinal problem in the dog and so there was a huge 
thing about killing the project. Luckily we had the transgenic mouse and 
were able to show that this wasn’t a 5-HT
6
 specific effect, that it actually was 
a compound specific effect and that allowed us to go on and carry out further 
work.294 The other thing I want to mention, vis à vis clinical understanding, 
is that I was lucky within the set structure we had at Glaxo, I could be fairly 
autonomous in my decision-making process. I actually wanted to do a dose 
294 Dr Jackie Hunter wrote: ‘The retinal stuff was never formally published, although it has been mentioned 
in talks – the compound that was a 5-HT
6
 antagonist that made it into Phase II clinical trials was published 
in Maher-Edwards et al. (2010, 2011); Upton et al. (2008).’ Email to Ms Caroline Overy, 18 June 2013.
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ranging study, a Phase IIB study with that molecule, thinking it might fail 
because we had seen no signal in the Phase I studies that there was a positive 
effect on cognition. It’s very hard in Phase I to see an effect on cognition, 
but we hadn’t seen any signal at all. I wanted to have a clear-cut result, and 
there were a lot of people within GlaxoSmithKline at the time who were 
saying that I should do a small, IIA study, and what you would have got was 
‘Junk In and Junk Out’. Because of the variability with Alzheimer’s in a mild 
to moderate population, you needed to do a big enough study. Amazingly 
enough it worked. I think that points to the fact that you’ve got to really 
understand your patient population to be able to test the hypothesis, and 
sometimes it does mean doing a larger study. I’ve seen studies done by industry 
where they’ve done a one month, one dose, 40 patient group study in mild to 
moderate dementia. You will never, ever see a positive effect, even if you’ve got 
a compound that works. The clinical knowledge is very important but also 
it’s having some of the other tools that you can use to really test whether your 
molecule has the right legs to make it. 
flower:  Tom, you mentioned earlier that such a high proportion of the top 20 
drugs came from the 5-HT programme and you said that it would be interesting 
to know what other 5-HT drugs there are in people’s pipelines.
Phase i Initial studies to determine the tolerability, metabolism and pharmacological 
actions of a drug in humans; the adverse effects associated with increasing 
doses; and to gain early evidence of effectiveness. May include healthy 
participants and/or patients (c. 20–80 people).
Phase ii Controlled clinical studies conducted to evaluate the effectiveness of a 
drug for a particular indication or indications in patients with the disease or 
condition under study and to determine the common short-term adverse 
effects and risks (c. 100–300 people).
Phase iii Expanded controlled and uncontrolled trials to evaluate the overall benefit/
harm balance of the drug and provide a basis for labelling (c. 1000–3000 
people).
Phase iV Post-marketing studies to delineate additional information, including the 
drug’s long-term adverse effects, benefits and optimal use.
table 2: A summary of the organization of clinical trials. Adapted from:  
www.clinicaltrials.gov/ct2/info/glossary (visited 5 June 2013), and reprinted from  
reynolds and tansey (eds) (2008), page 10. 
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Blackburn:  How many of us are still actively involved in 5-HT research would 
be interesting to hear. Jackie, with the 5-HT
6
 or other people who know about 
compounds moving forward, because if you look at that Scrip Report for 1988, 
there’s a vast array of different 5-HT compounds, but very few, if any, actually 
made it to market.295 Certainly the 5-HT
3
 antagonists have been a spectacular 
success in their own right, as has sumatriptan. But the 5-HT
2A
/dopamine D
2 
pharmacology has obviously been a very important area too in schizophrenia 
and it would be just interesting to hear more about the successes, did anything 
even come out of 5-HT
1A
 area? These are the sort of questions we should address.
flower:  Let’s talk a bit about the legacy of the area and what’s coming. 
Dourish:  To address the 5-HT
1A
 receptor, Tom, as far as I’m aware buspirone, 
which is used to treat anxiety, was obviously not discovered as a 5-HT
1A
 compound 
but subsequently, when we started characterizing 5-HT
1A
 receptors, it looked 
like that was one of its main effects. Then Bayer went on to develop ipsapirone 
as an anti-anxiety drug and Bristol-Myers’ buspirone follow-up was gepirone. 
But none of these compounds were really any more effective than buspirone. 
So, a lot of companies – Wyeth were the leaders at one point, obviously now it’s 
Pfizer – tried to develop 5-HT
1A
 antagonists with the idea that they’d either be 
effective as anxiolytics or antidepressants or potentially cognitive enhancers, or 
have other beneficial effects in the CNS. Again none of those compounds has 
ever got beyond late Phase II and so this area has not been terribly successful. 
Whether any drug that acts at the 5-HT
1A
 receptor (with the exception of 
buspirone) is likely to be marketed to treat CNS disorders, I think the evidence 
that I’ve seen would suggest not at the moment.296 In terms of other compounds 
that are in development, I think we mentioned the 5-HT
2C
 approach; clearly 
that’s being looked at in a lot of different areas including psychiatric disorders, 
such as anxiety and depression.297 But for now where those 5-HT
2C
 agonists 
seem to have found a place is in the treatment of obesity, where the first agonist 
lorcaserin has got on the market.298 In terms of the other things we haven’t 
discussed very much, for depression there are the SSRIs and then the SNRIs and 
the add-ons, and that’s certainly still a fruitful area for a number of companies. 
295 Scrip (1988).
296 Dourish (1987); Fletcher, Cliffe and Dourish (1993).
297 See, for example, Stahl et al. (2013).
298 Dourish (1995). Belviq (lorcaserin), manufactured by Arena Pharmaceuticals, was approved in the US 
in June 2012 to treat overweight or obese adults. 
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A number of companies have got compounds that are add-ons to the SSRIs in 
development with interesting components that the SSRIs may not have. So in 
fact Phil [Cowen] and I were just discussing a compound that Lundbeck have 
developed called vortioxetine, which looks interesting, and they’ve submitted 
for regulatory approval so it may be approved next year. We were discussing 
how this compound has been described and there’s a new term apparently called 
a multimodal antidepressant. We used to call it a dirty drug. Hopefully it’s 
without some of the unwanted effects of SSRIs and SNRIs. Vortioxetine has got 
a whole range of receptor affinities and the interesting thing is that it may have 
some cognitive-enhancing properties that, if you can add that into treatment of 
depression, clearly is going to be very interesting. 
Blackburn:  I know this compound very well because when my first biotech 
company, Synaptic Pharmaceuticals, was bought out by Lundbeck in 2004, 
the compound which I was developing at the time lost out because it was too 
innovative. It was a galanin R3 receptor antagonist that has a very similar profile 
to an SSRI, with hopefully fewer side effects associated with SSRIs. Because this 
compound was too innovative, the multimodal LU AA21,004 (vortioxetine), 
which was a mixed SSRI, 5-HT
3
, went ahead.299 However, thankfully the 
galanin R3 compound is still alive today with another company and in a Phase 
II study for depression, so I still know of a compound which modulates 5-HT, 
somewhere in development.
sanger:  One of the ways forward is, perhaps, to avoid concentrating just on 
5-HT but to look at the whole tryptophan pathway, and in the GI area there 
are tryptophan hydroxylase inhibitors that have gone into Phase 2, although I’m 
not sure where they are now. People are getting more interested in melatonin 
and its receptors and the kynurenine metabolism pathway.300 It’s a way of 
broadening out from just 5-HT and avoiding the regulators and finding other 
ways of making drugs.
miner:  I would like to make a comment. I worked on the periphery of a 5-HT
1A 
project in industry and we were looking at 5-HT
1A
 antagonists for visceral pain. 
It was a terrific concept, but about a year down the line we found several of our 
compounds were agonists. 
299 See, for example, Baldwin, Hansen and Florea (2012). 
300 For melatonin in the GI tract see, for example, Zagajewski et al. (2012); for depression and kynurenine 
pathways, see, for example, Oxenkrug (2013).
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green:  We’ve currently got quite a lot of interest for one reason or other with 
MDMA and Dave Nutt’s trial.301 We’ve got a terrific 5-HT releasing drug there 
that he’s now looking for post-traumatic stress. He was asking what else we 
can release 5-HT with, and I said that he has fenfluramine, but he said that it 
doesn’t work in the same way clinically. So again there’s something special about 
MDMA, but that may be because it also releases dopamine. We’re getting to a 
generality of hitting the brain with everything and 5-HT has to be playing a role 
there somewhere. If David [Nutt] and the other people in the States can show 
that MDMA really does have clinical efficacy, it’s important.
Hoyer:  5-HT
1A
 may not be completely dead, since Adrian Newman-Tancredi still 
thinks that 1A compounds have a great prospect in pain and other indications.302 
We will see, he has just created a company to elaborate on this.303 The 5-HT
2
 
story, actually 5-HT
2A
 story continues, iloperidone was recently registered as a 
dopamine D2, 5-HT
2A
 antagonist (with many other activities like a number 
of atypical antipsychotics). Whether it’s going to be the best antipsychotic on 
earth, I have serious doubts, but at least they managed to register it; I don’t 
know how they did it. Furthermore, Servier registered a drug with melatonin 
1 and 2 agonist combined with 5-HT
2C
 antagonism, agomelatin.304 Their 
argument is that 5-HT
2C
 antagonists will increase dopamine in the right place 
and have antidepressant effects, which is a very twisted way of achieving it. The 
melatonin component should, of course, be beneficial for sleep. If you can treat 
sleep in depressed patients you may have some mileage as well, because most 
depressed people don’t sleep very well, or sleep too much, or at the wrong time 
of the day. The problem with a melatonin agonist is that you have to administer 
it at the right time. If you give it in the morning then it may not work, you have 
to give it in the evening. 5-HT
4
 is still ongoing. Pat can tell us more, one of his 
compounds from Theravance is undergoing development.
301 Professor David Nutt and Professor Val Curran carried out a trial to look at the effects of MDMA 
(ecstasy) on 25 healthy volunteers under laboratory conditions. Drugs Live: The Ecstasy Trial was televised 
on Channel 4 in September 2012. For a discussion of the potential medical uses of MDMA, see Sessa and 
Nutt (2007) and the subsequent discussion (Green, Marsden and Fone (2008); Sessa and Nutt (2008)).
302 Newman-Tancredi (2010).
303 Dr Adrian Newman-Tancredi is co-founder and Chief Scientific Officer of the biopharmaceutical 
company, Neurolixis Inc, which was founded in 2011 to carry out research ‘focused on the discovery, 
development and commercialization of novel drugs for the treatment of human central nervous system 
diseases including depression, schizophrenia, Parkinson’s disease, ADHD and autism.’ See www.neurolixis.
com visited (24 April 2013).
304 Carney and Shelton (2011). 
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Humphrey:  Theravance has a very good compound, velusetrag; clean as a whistle, 
does what it’s supposed to do and it’s a full agonist rather than a partial agonist 
like the prototypes, metoclopramide and cisapride, but the problem is that big 
Pharma is reluctant to develop such a compound because of the perception 
that there’s likely to be an issue with the FDA, stemming from cardiovascular 
concerns with tegaserod.305 Nevertheless it’s been in a lot of patients and careful 
cardiovascular studies have been done and they are continuing their efforts to 
attract a partner. I do believe that they may have done a deal, but I can’t talk 
about it and I don’t know anything about it anyway.306 
flower:  Colin mentioned the SSRIs and we haven’t really paid any attention 
to those and we should. So far we’ve concentrated on receptor agonists and 
antagonists, but would anyone like to say something about the uptake inhibitors?
Professor Phillip cowen:  I’m the tame psychiatrist here and I think that SSRIs 
have transformed the treatment of major depression, in the sense that they’re 
now a first-line pharmacological treatment in any depression guideline.307 I 
suppose it wasn’t too surprising that SSRIs worked in depression because we 
had the example of the tricyclic antidepressants, we knew that they blocked the 
uptake of 5-HT and I think clinicians seemed to prefer using the tricyclics, like 
amitriptyline that had a rather more prominent effect on 5-HT, than they did 
on noradrenaline. 
SSRIs are not just antidepressants – they’ve become a cultural issue that you 
could have a whole meeting about anyway, you know, Listening to Prozac and all 
that.308 I guess SSRIs are rather better tolerated than the older antidepressants 
and I would say that they’re perhaps a little less effective. On the other hand 
they’re safe in overdose and they work very well in anxiety. Also I was just 
thinking about Charles’ comment that: ‘How can a simple pharmacological 
action translate into efficacy in such a complex condition’ in terms of something 
like major depression, because if you think about it, there are abnormalities in 
so many neuropsychological and biological domains. Really an SSRI isn’t doing 
305 Manabe, Wong and Camilleri (2010). See also page 72 and note 227.
306 Theravance, Inc. and Alfa Wassermann announced in October 2012 that they had entered into 
an agreement to develop velusetrag, Theravance’s investigational 5-HT
4
 agonist for the treatment of 
gastroparesis. The phase 2 proof-of-concept study was announced in January 2013. 
307 Harmer and Cowen (2013).
308 Kramer (1993); Wurtzel (1994); Metzl (2003).
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very much, it’s just boosting the action of 5-HT a bit in a rather general way, 
and somehow, surprisingly, this simple effect can sometimes be enough to make 
all of those really nasty psychological and biological symptoms go away.
We don’t know much about the neuropsychological effects of SSRIs at the 
moment. However, there are some quite interesting effects on other psychological 
processes that we don’t normally think about, such as emotional processing and 
pro-social behaviour. We’ve talked about how people researching in 5-HT tend 
to be rather kind and community-minded and, of course, in animals and in 
some human trials, if you boost 5-HT, animals and people behave rather more 
nicely. It does tie in with my own experience in that I once took Seroxat for 
three or four weeks for a study and at the end of it I didn’t notice any difference 
in how I felt, but my wife asked if I could stay on it. [Laughter] 
Blackburn:  I spent about ten years as a sort of ‘front person’ for paroxetine 
(Seroxat/Paxil) at SmithKline. Visiting psychiatrists, from Europe and America, 
were presented with pre-clinical and clinical data. Sometimes it was very difficult 
to find a clinician who would actually step up to the mark, which often left 
me presenting the pre-clinical and the clinical pharmacology. However, it was 
fascinating to get the feedback from the neurologists and psychiatrists on their 
clinical observations, like the effects on sexual dysfunction, seen more in the 
garlic-eating southern European countries rather than north European countries. 
figure 24: Professor Phillip cowen.
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With such observations, how do you design a test, to look at sexual dysfunction 
in garlic-fed rats? But, apart from that, it was all good clinical feedback.
flower:  I can see that would be a challenge. 
Blackburn:  There were lots of other observations coming out of the clinic. I 
remember one Dutch neurology group who were very interested in whiplash 
syndrome in their specialist centre in Holland, and they swore by SSRIs for the 
treatment of whiplash injury. Now whether the drug was relieving depression 
associated with severe whiplash syndrome or increasing the pain threshold 
which 5-HT is well known to do within the spinal cord, is something that is 
still unclear. So there were lots of observations coming out of the clinic with 
these compounds, which were helping us basically to design the next generation 
of 5-HT compounds.
clarke:  There may be room for dual uptake inhibitors, even triple uptake 
inhibitors. Duloxetine, which Tom mentioned, is earning a lot of money,309 it’s 
a terrible drug to take for many people and nausea is a big problem with it, 16 
to 19 per cent of patients are nauseous. The other thing is sweating, you get a 
lot of sweating when on the drug. But the interesting thing is that, although 
it is an antidepressant, it’s also one of the very few drugs that will work in 
neuropathic pain and it’s on the market for neuropathic pain in the United 
States, and in addition it is a drug that works in the lower urinary tract for stress 
urinary incontinence. That area, for instance, hasn’t had a really effective new 
drug mechanism in years, except mirabegron, so there may well be room for a 
new compound. But the key would be: how do you stop nausea, or how is it 
mediated, and when you block noradrenaline uptake one gets noradrenergic 
cholinergic sweating and what are you going to do about that? So those are two 
questions but I wouldn’t necessarily write off new dual uptake inhibitors.
Wallis:  Of course, what an SSRI does depends on the activity of the neurons it 
targets. I just wondered, and this is a question really for the psychiatrists, what 
use they have been able to make of the studies done by Barry Jacobs where 
he records from single serotonergic neurons in conscious cats under various 
behavioural situations and charts the change in activity and relates them to 
behaviour.310 Has this been of any help in deciding what SSRIs are doing to a 
human?
309 See page 99. 
310 Professor Barry Jacobs is Professor of Psychology at Princeton University; see, for example, Horvitz, 
Stewart and Jacobs (1997).
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cowen:  There’s a short answer, which is unfortunately ‘no’. I think what 
Barry pioneered was the goal of conceptualizing the action of 5-HT in a single 
neuropsychological formulation. This is hard to do because, as we’ve said, 5-HT 
has got so many actions in the brain and affects so many processes. I think Barry 
also said that 5-HT is involved in everything but responsible for nothing.311 
People have tried to capture that complexity in a single overarching function, 
as Barry did himself. However, because Barry’s concept focuses on motor 
behaviour, it doesn’t fit in very easily with the kind of emotional disorders that 
SSRIs are used to treat. The formulations you see done by people working in 
computational neuroscience now would be more like the notion that 5-HT has 
the role of signalling aversive experience and for dealing with it. That’s another 
overall way of conceptualizing its function. 
Wallis:  Barry Jacobs’ emphasis on exercise and the effect on motor neurons 
being facilitated has prompted him to promote exercise as a way of increasing 
your 5-HT levels and treating depression.312
Aronson:  I’m interested in adverse reactions to the SSRIs. If a drug turns up 
an adverse effect that translates into an adverse reaction, everybody throws 
up their hands in horror and the drug is withdrawn or it’s contraindicated or 
restricted. Sometimes you can learn something from the adverse reaction, and 
I’m particularly interested in the suicidal ideation that young people get from 
this. Older people don’t seem to, if the evidence is the way it is. I wonder if 
we can learn something from that observation. Phil’s reply to the last question 
makes me not too sanguine about that, but nonetheless I think we should turn 
adverse reactions to our advantage by thinking about what causes them and 
whether we might learn something from them.
Blackburn:  That was my question. I really want to understand from our clinical 
colleagues why suicidality was perceived as such an issue for 5-HT CNS 
compounds. It appears that the regulatory authorities are now seeing this with 
many classes of CNS compounds, including anticonvulsants, so it may not be 
specifically related to 5-HT compounds?
cowen:  As always with SSRIs you can take a number of different positions. 
At a population level increased SSRI prescribing seems to be associated with 
lower suicide rates, if anything. On the other hand, you see individual case 
311 ‘Serotonin is an enigma. It is at once implicated in virtually everything, but responsible for nothing’, 
Jacobs and Fornal (1995), page 461. 
312 Jacobs (1994). 
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reports where people seem to become agitated and distressed and do something 
dreadful when they first go on treatment.
I think Jeff ’s point is a good one, that if you look at older depressed people 
SSRIs are protective against suicide, but in people under 25 there’s an increase 
of suicidal behaviour on SSRIs.313 At the moment the controlled trials don’t 
show an increase in what’s mistakenly called ‘successful suicide’, what you see 
is an increase in suicidal acts and it’s hard to know what to make of that. Is it 
that the 5-HT system is differentially developed in young people, so the drugs 
have a different effect; or, is it that if young people get a bit revved up by any 
kind of antidepressant drug they’re more likely to harm themselves impulsively? 
So I don’t think people understand the mechanism, but there certainly is a 
phenomenon to explain. 
Hunter:  Jeff ’s point is a good one and it would be interesting to explore that 
more. In an age where reimbursement is king, I’d like to challenge how much 
mileage there actually is in serotonin reuptake inhibitors and whether or not 
the comments made earlier about more selectively targeting release through 
intermediate mechanisms is something to focus on. There are obviously issues 
in depression trials anyway, where you have to do three trials to get one or two 
working. That’s something that, if it’s not sorted out, will not really encourage 
Pharma companies to invest, considering large-scale Phase III failures like the 
Targacept AstraZeneca nicotinic agonist, and it is a real issue.314 Maybe we are 
deluding ourselves that somehow there is more mileage in the serotonin uptake 
inhibitor area?
Andrews:  To pick up on the point about looking at the side effects, particularly 
in relationship to nausea, because this is something I’ve been working on, 
looking at why certain drugs have a particular nausea or vomiting liability and 
trying to find ways of identifying this much earlier in the pre-clinical studies,315 
bearing in mind, of course, rats and mice don’t vomit.316 Also to say that there 
are studies on-going at Queen Mary, University of London that Gareth and I 
are both involved in, brain imaging in human subjects, looking at the central 
313 Barbui, Esposito and Cipriani (2009).
314 AstraZeneca and Targacept announced in 2012 the failure of the drug TC-5214 in the randomized, 
double blind, placebo controlled Phase III studies.
315 Percie du Sert et al. (2012).
316 Horn et al. (2013); Sanger, Holbrook and Andrews (2011).
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pathways involved in nausea, so if it works we can identify particular areas 
that, in theory, one could then go on and look at whether these areas are or 
aren’t activated in certain pharmacological treatments.317 So I agree with you, 
looking at side effects of well-characterized drugs gives us a map if you look at 
it systematically.
reynolds:  Implicit in all this discussion about side effects and responses is the 
concept of individual variability, which brings us to personalized medicine, 
which of course some drug companies are beginning to embrace, though 
somewhat reluctantly. It’s interesting that it’s the 5-HT transporter that has 
really been central to individualized medicine in psychiatry. It was Lesch’s work 
on the short/long variants polymorphism in that area that’s really sparked a 
huge development of pharmacogenetics.318 And we see that 5-HT
1A
 has a very 
important polymorphism too that may well explain quite a lot of the differences 
between individuals in responses to drugs. So I think this is where the field is 
developing and we would hope that the pharmaceutical industry might embrace 
personalized medicine rather more strongly than they have done in the past.
flower:  With 14 receptors to pick from there’s a lot of work on polymorphisms 
to be done. 
reynolds:  There is, and there are a lot of people doing it, of course.
marsden:  I was just going to say that most of the pre-clinical work on SSRIs in 
rats is done on sexually mature rats. There’s very little work that has compared 
the treatment in young, non-sexually mature with the sexually mature rat. If 
you look through the limited data available, there is evidence for differences in 
behavioural response to certain SSRIs between the young and mature rat that 
might have clinical relevance. We did do some of this type of work that was 
funded by a drug company and unfortunately we were unable to publish the 
results. We found, and there’s now stuff which has appeared, that says the same 
thing, that you get a greater aversive affect in a young rat treated with an SSRI 
in the acute phase than you do in a mature rat.319 So maybe there should be 
more work along that line?
317 See Ng et al. (2012). 
318 Lesch et al. (1993, 1996); Costafreda et al. (2013).
319 See, for example, Fernández-Guasti, Ulloa and Nicolini (2003); Herrera-Pérez, Martínez-Mota and 
Fernández-Guasti (2010); Iñiguez, Warren and Bolaños-Guzmán (2010). 
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green:  The other problem, it seems to me, and we’ve known this since about 
1970 at least, is that if you take a normal rat and you give it an SSRI, the first 
thing that happens is 5-HT synthesis shuts down. We still have even Phil saying: 
‘Well, we give SSRI and we increase 5-HT function.’ I don’t think we really know 
what is going on. Certainly that happens acutely but I’ve never heard anyone 
explain it. We give the drug, something acute happens, and then there’s this sort 
of black box for about two weeks, which is what the psychiatrists say is about 
the time these drugs take to work, and then we get an effect. What’s happening 
during that period? Is it just that the brain takes a long time to adapt and for us 
to see an overt antidepressant effect? Or is the brain altering very fundamentally 
as the result of this insult and something else much more important is going on? 
I’ve never heard anyone explain why there is this long interval between starting 
to give the drugs, measuring various biological markers like inhibition of uptake 
in platelets and things like that, and then the clear antidepressant effect. We 
know that some patients will change almost overnight, it’s rare, but it happens. 
We know you can get a mood change happening quickly but these drugs don’t 
do it, do they?
cowen:  No. I think if someone switches mood very quickly after starting 
SSRIs, it normally means that you’ve made them manic. Obviously some kind 
of manipulations can produce very rapid changes: sleep deprivation and more 
recently IV ketamine. In David Grahame-Smith’s lab we spent many years trying 
to identify what neuroadaptive changes might underpin antidepressant action, 
we went through beta receptors and alpha 2 receptors, then the desensitization 
of the 5-HT
1A
 receptor.320 Current activity focuses on changes in brain-derived 
neurotrophic factor (BDNF) and synaptic plasticity.321 We’re always searching 
for the molecular secret that underpins the antidepressant action. More recent 
work looking at the neuropsychology of antidepressant action suggests that 
emotional processing changes very rapidly after treatment initiation so, at an 
implicit level, one is rather emotionally different but you don’t feel better. One 
reason for the delay in feeling subjectively better is that you have to, in a sense, 
learn where you are again in an emotionally transformed world. So that’s a 
psychological explanation of why it takes a long time for SSRIs to work.
320 Cowen et al. (1982); Metz et al. (1983).
321 See, for example, Dwivedi (2013). 
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sanger:  This is a naive observation, but since the SSRIs hit the market, has 
CNS research really moved on very much in terms of 5-HT research? What’s 
actually come out of it and why do I keep hearing of receptor studies that have 
not worked or not gone beyond a rat. Is it time to move on? 
Blackburn:  Gareth used to ask this question of me in the 1990s, so nothing’s 
changed! We’re talking about understanding multiple receptor subtypes and 
the pharmacology associated with them, whether it’s in the periphery or the 
CNS. One of the articles I read some years ago and I always try to relate 
to regarding neurohormonal changes, is the work of Bruce McEwen from 
Rockefeller, New York, where he talks about non genomic and genomic 
activity where there’s a receptor event, however transient or prolonged, and 
then there’s a more prolonged effect through transcription factors.322 We’re 
only just starting to get to grips with a lot of these mechanisms of action. To 
answer your question, Gareth, there are a number of compounds, one of which 
was mentioned earlier, lorcaserin (Belviq), a 5-HT
2C
 agonist for obesity, that 
has cost Arena Pharmaceuticals over $1 billion to develop to overcome the safety 
problems related to the 5-HT
2B
 affinity of the compound that’s been associated 
with cardiac hypertrophy.323 So like Lorcaserin, there are other compounds 
coming through as we’ve heard today, for 5-HT
6
 and 5-HT
7
 and others we’re 
still waiting on.
clarke:  This is just for my own interest: do you know whether ondansetron 
blocks nausea with duloxetine? Does anyone know?
cowen:  There’s been some work showing that if you give ondansetron you 
can block nausea induced by fluvoxamine.324 On the other hand, the drug we 
just mentioned, vortioxetine,325 is an SSRI, it also blocks 5-HT
3
 receptors and 
causes as much nausea as a standard SSRI. As Colin said, vortioxetine has other 
actions too that complicate interpretation. What we need is a proper study with 
more selective compounds.
clarke:  It seems pretty basic.
322 McEwen (1991). Professor Bruce McEwen has been Head of the Harold and Margaret Milliken Hatch 
Laboratory of Neuroendocrinology at Rockefeller University since 1981 and Alfred E. Mirsky Professor 
since 1999. His research focuses on how stress and sex hormones react on the brain.
323 See pages 74 and 112 and notes 231 and 298.
324 Bailey et al. (1995).
325 See page 113. 
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Dourish:  I was just going to address Gareth’s question about SSRIs. Most 
companies in the area have moved on from SSRIs, with the exception perhaps 
of vortioxetine, and what’s really driving the depression field now is the 
observation that Phil mentioned, which is the rapid onset antidepressant effects 
of IV ketamine. Many companies are very interested in that and clearly the issue 
with ketamine is that it has other effects apart from an antidepressant effect, 
but there are NMDA compounds such as AZD 6765 now that are in late phase 
trials that appear to have the antidepressant effects without having these sort of 
dysphoric or euphoric effects.326 In response to the original question, no, these 
compounds don’t act on 5-HT receptors. I think the common view is that that 
the SSRI path is exhausted and that’s why they’re now looking at excitatory 
amino acids.327 
flower:  5-HT has obviously been a very highly successful area. Is it a general 
model for drug discovery, do you think? It does seem to have been characterized 
by an unusually good rapport between the academics, the clinicians, the 
industrial scientists, the Pharma companies and everybody else. Is this a sort of 
exemplar of how drugs should be discovered, given the fact that we have such 
a fantastic output from the area in terms of blockbuster drugs? What do you 
think? 
Bakhle:  We now have 14 receptors and perhaps an unknown number of uptake 
mechanisms – and how many drugs do we have out of it? I mean usable 
medicines – really rather few. We think that one of the successes, practically 
speaking, is an SSRI which, by definition, doesn’t affect any particular receptor. 
Is pharmacology becoming too obsessed with ‘the receptor’ and the unique 
single action drug? Have we done all we can with that one specific drug idea? 
Do we now have to change and say that we have to go for what we used to 
call, and still do call, ‘dirty drugs’ with all the things that we feel as wrong?’ 
Polypharmacy – Joe Collier used to spit upon its grave.328 Okay, he was a pretty 
aggressive guy but there are lots of clinical pharmacologists who think that 
polypharmacy is trash; should not be allowed, etc. However we have also been 
told about the polypill, me included, I’m a ‘mild hypertensive’ but I’ve got 
326 Zarate et al. (2013).
327 Hashimoto et al. (2013).
328 Professor Joe Collier (b. 1942) was Professor of Medicines Policy and Clinical Pharmacology at St 
George’s Hospital and Medical School, London, until his retirement in 2007. He was a participant at the 
Witness Seminar on clinical pharmacology (Reynolds and Tansey (eds) (2008)).
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four drugs to take, including a statin. Now are we too obsessed? Should we 
now think of pharmacology no longer in terms of single receptors, but accept 
the fact that we should go functionally for an effect, a physiological and/or 
pharmacological effect? In a sense, damn the torpedoes, let’s go for the effect. 
Because if you were to look at this area of pharmacology, you would say: ‘I’ve 
got 14 receptors beautifully categorized, but what good are they doing me in 
terms of medicine?’
flower:  Okay, that’s a very provocative thought.
Humphrey:  You’ve just woken me up, Mick. Seriously, that’s a real challenge, and 
I’m horrified by what you say. Combination therapies are very, very important. 
Look at asthma – you inhale a steroid and you inhale a bronchodilator and 
you transform the treatment. Hypertension – most people have more than one 
form of hypertensive drug and it transforms the tolerability and the efficacy and 
everything. So combination therapy is a good idea, but the minute you move 
away from Ehrlich’s magic bullet, i.e. not using specific and selective drugs in 
any combination, it is at your own peril because you don’t know what you’re 
doing.329 You don’t know what you’re dosing, you don’t know what you’re giving 
anybody. The challenge is that we’ve got to work out what these receptors do 
and how we can harness them, but just because they’re there doesn’t mean 
God put them there so we can make a drug. They’re there for other reasons, 
maybe, and they may not be functional. So don’t get too hung up on: ‘We’ve 
got to find a drug for every receptor.’ We’ve got to work out the physiology and 
pharmacology in vivo and then harness what we can.
Hunter:  I think we’re entering an era where I personally believe that with human 
genomics, transcription genomics, the data coming out of human biology will 
be much more powerful than doing a lot of transgenic models, etc. The question 
for us is how to get that information into making a compound that affects that 
pathway and then iteratively going back into the clinic to test whether that has 
a significant action. That’s going to be a challenge because it’s a very different 
way of thinking about things. We may find from the computing power of the 
big data sets that the potential for optimal combinations, rather than random 
screening, is going to be very interesting. That’s one area where we may see 
progress in terms of thinking about different combinations. Like all paradigms, 
329 Paul Ehrlich (1854–1915) was a German immunologist whose concept of drugs designed to attack 
specific targets, or ‘magic bullets’, revolutionized the treatment of disease. He shared the Nobel Prize in 
Physiology or Medicine in 1908 with Ilya Ilyich Mechnikov ‘in recognition of their work on immunity’.
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there are aspects that are good but it will also need champions as all successful 
molecules do. For example, paroxetine was an in-licensed molecule and as such 
had champions within the organization which promoted it at times when it 
would have been usual to stop development or ‘kill off ’ the molecule. It was 
only the fact that it was an in-licensed molecule that meant that people had to 
do something with it, that really pushed it ahead to be the success that it was.330 
There are champions and circumstances that can change things. So there are 
aspects that are good, but there are a lot of receptors and a lot of money is being 
spent on trying to find those particular tools and the actual disease they may 
be useful for. Maybe there are some lessons to be learnt and actually are there 
some areas where one is better doing things precompetitively rather than alone?
Blackburn:  I mentioned earlier the American Chemical Society article that looked 
at the top psychiatric medicines prescribed in 2011 to address Mick’s question: 
‘How good have these been?’ (see Table 3)331 Number one is alprazolam, Xanax, 
and that drug achieved 47 million prescriptions in 2011. Celexa and Zoloft 
are numbers two and three and between them they’ve achieved 70 million 
prescriptions in 2011. Then we get another benzodiazepine, number four, and 
then Prozac, which is still selling 24 million prescriptions a year. After Prozac 
comes Lexapro and then trazadone (Desyrel), a trazidole that is a 5-HT
2
 blocker 
plus SSRI which is used mainly for its antidepressant–sedative properties and a 
number of other properties, achieving 22 million prescriptions in 2011. Then 
there is duloxetine (Cymbalta) at 17 million and then Seroquel at number ten, 
with 14 million prescriptions. Thus, of the top ten drugs prescribed in 2011 
the majority of them have a 5-HT-related mechanism of action. So I think 
it is obvious that 5-HT-like drugs have had a major impact, particularly in 
psychiatric medicine.
Bakhle:  Because there are a zillion prescriptions doesn’t mean anything in my 
context. The question I’m really asking is: are we treating the diseases for which 
we use these 5-HT drugs as well, in terms of patient outcome, as we treat 
hypertension? You may prescribe as much duloxetine as you like, but if half of 
the people who take it are puking and the other half are committing suicide 
or whatever, I’m saying the actual prescription rate, the fact that you use these 
compounds, doesn’t answer the question: is the disease actually being treated 
330 Dr Jackie Hunter wrote: ‘The fact that it was an in-licensed compound meant it was visible and much 
harder not to commit to solving development issues – in turn this focus, and the fact it was effective, made 
it into the successful drug it was.’ Email to Ms Caroline Overy, 18 June 2013.
331 Lindsley (2012). See also page 99. 
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adequately or better than we could, say, ten years ago? Maybe there is a real 
advantage; if there is, fine. I’m putting a question to you and I’d like to see it in 
terms of patient outcome rather in terms of prescription.
Hoyer:  Mick has a point, actually he has several points. But the proof of the 
pudding is in the clinic. We can do as much as we want with normal animals 
in pre-clinical studies, but it is the clinic that will give you the answer. The 
problem is that not so long ago most of these diseases, at least the brain diseases, 
had very poor clinical or biological definitions in the first place. The DSM-V 
Brand name drug  
(generic name)
Prescribed / indicated for 2011 prescriptions 
(in millions) 
Xanax (alprazolam) Short-term use in anxiety 47.7
Celexa (citalopram) Depressive illness; panic disorder 37.8
Zoloft (sertraline) Depressive illness; OCD; panic disorder; PTSD; 
social anxiety disorder
37.2
Ativan (lorazepam) Short-term use in anxiety or insomnia; status 
epilepticus; peri-operative use
27.1
Prozac (fluoxetine HCl) Major depression; bulimia nervosa; OCD 24.5
Lexapro (escitalopram) Depressive illness; generalized anxiety disorder; 
OCD; panic disorder; social anxiety disorder
23.7
Desyrel (trazodone HCl) Depressive illness especially where sedation 
required; anxiety 
22.6
Cymbalta (duloxetine) Major depressive disorder; generalized anxiety 
disorder; diabetic neuropathy; stress urinary 
incontinence
17.7
Valium (diazepam) Short-term use in anxiety or insomnia; acute 
alcohol withdrawal; status epilepticus; febrile 
convulsions; muscle spasm; peri-operative use
14.6
Seroquel (quetiapine) Schizophrenia; mania; depression in bipolar disorder 14.2
table 3: the top psychiatric medicines prescribed in 2011 using information adapted from the 
British National Formulary and 2011 prescription data from Lindsley (2012), page 631.
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will come out some time next year with a more, bigger emphasis on biology.332 
So far most of that stuff was purely descriptive, so we talk about depression; it 
doesn’t mean anything to me. ‘Hypertension’ doesn’t mean anything to me: some 
guy will react to a calcium antagonist, another guy will react to beta blockers 
and another guy will need diuretics, an angiotensin antagonist, or a renin 
antagonist. When I started, I was told repeatedly by marketing that what we 
need is monotherapy because that’s the only way you can sell compounds. And 
guess what? We’ve gone full circle. Now we’re prescribing fixed combinations 
of angiotensin antagonists, calcium antagonists and maybe renin antagonists 
to patients, only to find out that occasionally we do too much, so you should 
perhaps take one away. The fixed combination is not going to be the answer. 
We do have compounds that are, what are called, ‘dirty’, but even these dirty 
compounds will work on some part of the population; how well or not well 
described is the population. Personalized medicine will work once we know 
the biological basis for the disease and then we will know what we will need 
to get to patients. Asthma is the perfect example, where a long-acting beta 2 
agonist is great, yet will not work in isolation. I’m not sure I would take one, 
given what I know. But you take these steroids and you take this and you take 
that, so we go to chronic obstructive pulmonary disease (COPD) and we add 
a long-acting muscarinic compound and then it will work. We know that in 
these indications monotherapy does not work. Hypertension is pretty much 
the same, monotherapy is useless. I don’t know of any patient that suffers from 
hypertension that has a monotherapy that works effectively, so they take more 
and more. In depression we know by tradition that people are just mixed bags, 
it’s the cocktail. Again, the question that we are trying to answer is: what is the 
disease you want to treat and what is the biological basis for this disease? In 
many cases we don’t know yet what it is. We do guesswork and by the end of 
the day the smart clinician will try compounds, sometimes even off label, in 
combinations and find out what works best for the patient. Epilepsy is another: 
there’s no single treatment for epilepsy, although I can mention two or three 
that would work perfectly well, except that the compounds are probably in the 
clinic. So what we do is combination. Every patient has combination treatment 
and yet 40 per cent of these guys eventually will undergo surgery to get a piece 
of the frontal lobe or hippocampus taken out and this is the thing that works 
best. In Parkinson’s disease you also have combination treatments because 
monotherapy doesn’t work; l-DOPA alone doesn’t do anything, you have to 
332 The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM) was published in 
May 2013 by the American Psychiatric Association. It is the standard classification for mental disorders.
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help with a DOPA decarboxylase inhibitor, and then you put the D2 agonist 
and you keep going. After about ten years of treatment these people are in a 
bad shape and there’s nothing you can do, and for some people what we do 
then is deep brain stimulation. So personalized medicine is coming but we need 
to know what the disease is all about, so we’re still searching and there’s hope. 
Coming back to the question asked by Mick: single treatment will work in some 
cases and we know perfectly well that some people with migraine react extremely 
well to sumatriptan or to zolmitriptan, but I do know some people don’t react 
to zolmitriptan, when sumatriptan works. How is that feasible? In principle, it’s 
the same mechanism but it’s not the same drug. Probably the receptor repertoire 
from one guy to the other is a bit different. We haven’t talked about epigenetics 
and we know very well from Bruce McEwen and a number of other people that 
there are modifications depending on your experience.333 Post-traumatic stress 
disorder (PTSD), where you have been undergoing mistreatment and all kinds 
of traumas in your youth, will change your way of reacting to compounds and 
some depressed people will react to SSRIs, while others will not. We haven’t 
talked about neurogenesis. Half of the population will believe in neurogenesis; 
the other half will say that it is bad science and it is never going to happen, 
because 20 years ago we said there was no neurogenesis in the brain. Now we 
know that there is neurogenesis and we know that 5-HT and some treatment in 
the hippocampus will induce neurogenesis and it has to do with BDNF etc.334 
But we don’t have the right tools to work on BDNF for the time being so this 
is all up in the air. The Human Genome Project that was supposed to solve 
everything when it was published in 2001 has actually created an awful mess 
and I’m not talking about the epigenome. Was 5-HT the right example to be 
followed by people in the industry and academe for the next targets to come? 
I think it was the right example at the right time, but things have changed. 
Now everyone needs biologics and things like this, and you cannot get excited 
by the next small molecule, although I still believe that there’s mileage in these 
as well. But with biologics you can ask $400 000 a year to extend your life for 
about six months or something like that, which you cannot do with a simple 
low molecular weight anti-hypertensive. So this is one of the major issues we 
are facing; Wall Street is still trying to dictate what people are doing and what 
big Pharma is doing. This is wrong, and one has to react at some point, because 
333 McEwen and Getz (2013).
334 Quesseveur et al. (2013).
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the whole mess that has been created in the last five or ten years is because of 
analysts, Wall Street and the bankers. The bankers have shown us that they are 
totally incompetent to start with, so what are we talking about? 
flower:  Thought for the day. 
sanger:  Gerald will probably be more sensible than I am. I can’t add to what 
Danny said because he went through a tour de force beautifully. I was simply 
going to react to my own area, where I look at IBS, and one of the biggest drugs 
that’s prescribed there is a proton pump inhibitor (PPI) that inhibits gastric 
acid.335 I have a relative with slow transit constipation, who was prescribed a 
PPI. It’s crazy, absolutely irrational, but that’s the logic of prescription because 
there is nothing else and poor understanding of that syndrome. I think you 
just have to be so careful with these patients. But I agree with everything else 
everybody said.
Blackburn:  These 5-HT drugs are out there in the clinic, whether their efficacy 
is 30 per cent of the population or 50 per cent of the population. But these 
drugs do show efficacy in patient populations. 
sanger:  Perhaps marketing would say that the area is saturated?
Blackburn:  Yes, and one could argue, and argue justifiably, that the SSRIs were 
a huge marketing success and rightly so. But at the end of the day they are 
efficacious and if you’ve sat at FDA meetings and listened to some of the patient 
groups, yes, they do work, however not for everyone. 
curzon:  One of the things we were asked to address was the general question of 
tensions and collaborations between scientists and industry. I have had a quite 
long and sometimes tense collaboration with Servier, the only drug company 
that I’ve had much of an involvement with. When I began this about 20 years 
ago, they seemed to tie me up with a formidable legal document but what can 
they do to me now anyway? 
They developed a novel antidepressant, tianeptine. What was novel about it 
was, unlike conventional antidepressants, in vitro studies suggested it didn’t 
increase extracellular 5-HT but decreased it. I said this seemed unlikely and 
furthermore that the new technique of in vivo dialysis could show whether they 
335 Omeprazole.
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were right or wrong. They offered a grant to study the question. It did indeed 
turn out that it decreased in vivo dialysate 5-HT, which pleased Servier, and a 
number of useful research grants followed, which was very nice for me.336
There was also something else that, as a laboratory scientist previously supported 
by public bodies, I’d never had generous travel expenses. I know clinicians are 
spoilt for choice in this kind of thing but that was not my situation. They gave 
me a list of the following year’s international meetings and told me to pick and 
choose whatever I wanted. 337 As it says in the Bible: ‘The devil had taken me up 
to a high place and showed me all the kingdoms of the world.’ I am a glutton 
for travel but I couldn’t help feeling a bit uneasy. 
The next thing was that Servier rang and asked me to speak at a series of 
meetings in Pakistan, a country I’d never been to: Karachi and Lahore, Multan. 
I hadn’t even heard of Multan. Also Peshawar, up on the North West Frontier. 
The meetings were to be entitled ‘Tianeptine: a new powerful antidepressant 
and anxiolytic drug.’ I said that I’d love to go to those far-away places, but I 
couldn’t accept because the evidence was against tianeptine being a powerful 
anxiolytic. ‘Oh, that’s alright,’ they said, ‘We won’t say anything about anxiety.’ 
However, at Karachi, I found myself standing in front of a big banner claiming 
tianeptine was a powerful anxiolytic, although this was not the case. Somewhat 
to my surprise, Servier still kept giving me research grants. A few weeks later the 
French licensing authorities told Servier they must no longer claim tianeptine 
was anxiolytic. I got a letter from a personal contact at Servier, whose name I’ve 
forgotten, with the words: ‘Strictly private and personal’ on the envelope saying, 
‘Unfortunately we are in the hands of our sales department.’
My other drug industry experience was also with Servier. Some 15 years ago 
they were supporting our work on the appetite suppressant d-fenfluramine, 
then thought to act by increasing extracellular 5-HT. However, while it 
certainly did increase it, as indicated by in vivo dialysis, its effect on feeding 
was the same in normal rats and rats previously treated with large doses of an 
inhibitor of 5-HT synthesis. This indicated its effect on feeding must be due to 
some other mechanism. I thought this was rather exciting, as it suggested the 
conventional wisdom was wrong, which is always interesting for a scientist. But 
Servier’s people could not have been less interested. They said the important 
336 Whitton et al. (1991). 
337 Professor Gerald Curzon wrote: ‘They also paid for my wife’s travel expenses (more than the MRC ever 
did).’ Note on draft transcript, 22 January 2013.
Drugs Affecting 5-HT Systems
131
thing was that d-fenfluramine had been given to many thousands of patients for 
many years and it did decrease feeding. It was as if Servier was one of those big 
battleships that took a long time to change its course. Anyway d-fenfluramine 
was soon withdrawn because its administration was reported ‘in a few patients’ 
to be followed by evidence of a defect of heart muscle. ‘A few patients’: was this 
sufficient evidence to totally withdraw an apparently successful drug?338 Both 
tianeptine and d-fenfluramine are now (as far as I know) therapeutic dead ends. 
However they did provide quite a bit of interesting work for my lab. I have no 
idea what’s happening with them at the moment. 
Hoyer:  I can answer this one: it was not a few patients.339 I think thousands of 
patients eventually had valvulopathies with d-fenfluramine and also with one of 
the follow-up compounds by the same company. It’s too long to go into details, 
but this is mediated by 5-HT
2B
 receptors, and has been perfectly well described 
and we have known this for about 15 years at least. It should have been stopped 
at the time.
curzon:  Why did it take so long, so many thousands of patients were given this 
drug and they never reported it?
Hoyer:  It’s not up to Servier to report it. Pharmacovigilance is implemented 
everywhere. The issue is that in France there are ways to manipulate things, 
as shown more recently; in other countries this has stopped, and very early 
on. D-fenfluramine was marketed by American Home Products in the United 
States; this was American Home’s end, the company got involved in thousands 
of lawsuits and that was it.340 So, it was reported very early on but depending 
on the country and depending on the company, it has had more or less effect. 
Servier was very resistant, we had a meeting in New York in 1989 and we were 
trying to make a point about the toxicity of 5-HT releasers and Servier had sent 
a whole range of competent medics and marketers there to tell us that this was 
no issue.341 Excuse me! 
338 For a review of fenfluramine, see Curzon and Gibson (1999).
339 Figures cited in SoRelle (1999) suggest that the drug was withdrawn after 177 patients reported valvular 
abnormalities. However compensation was paid to many thousands of patients who had been prescribed 
the drug.
340 In 1999 American Home Products settled lawsuits for billions of dollars for thousands of people who 
had taken the combination drug diet pill Fen-phen (fenfluramine and phentermine).For a summary, see 
SoRelle. (1999).
341 See Whitaker-Azmitia and Peroutka (eds) (1990) for the conference papers and discussions. The Institut 
de Recherches Internationales Servier is listed as one of the sponsors of this meeting.
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tyers:  I’ve been involved in setting up clinical trials with ondansetron in 
anxiety, in depression and in schizophrenia, both in America and in Europe. 
What’s apparent is that American psychiatrists have different diagnostic criteria 
for each of these three conditions compared with the other countries, including 
the UK. It makes it very difficult and extremely expensive doing meaningful 
comparisons and complicates clinical trial criteria.342 
Dourish:  I can expand on what Danny was saying on the d-fenfluramine issue. 
The main reason it didn’t get withdrawn sooner is that it never had been marketed 
in the US, which is clearly the biggest market for obesity. Servier did a deal with 
Wyeth, at the time I think they were owned by American Home Products, and 
when the compound was launched, it was projected to be a $1 billion-seller, so 
the sales within the first six months were way beyond anything that had been 
seen in Europe, where it was marketed in a limited number of countries. As a 
result, there were thousands and thousands more people exposed to the drug 
and therefore this huge increase in valvulopathy, which then led the FDA to 
withdraw the compound. After that Servier continued to market the drug in 
Europe for several months until eventually it was withdrawn worldwide.343
Hoyer:  The successor compound [Mediator], with the same mechanism of 
action, kept being prescribed until four years ago, when it had been stopped 
in all other countries. In 1997, the French Medicine Authority allowed two 
generics of the compound to be marketed at the time everyone knew that it was 
toxic. 
Dourish:  It’s probably also significant that, in the last year, Servier’s management 
has been in court, including Jacques Servier, the owner. This is due to withdrawal 
of the obesity and diabetes compound, Mediator, and they’re being charged with 
withholding of information about the drug from the regulatory authorities. So, 
there’s an alleged scandal around what Servier have done.344
Blackburn:  The interesting thing for me, after that New York Academy of 
Sciences meeting in 1989, where Servier were really pushing the compound, it 
was offered to SmithKline Beecham as an in-licensing opportunity. I was one of 
342 Dr Tyers wrote: ‘In fact it took Upjohn 11 clinical trials with Prozac to get the two positive trial results 
that were sufficient for FDA approval.’ Note on draft transcript, 20 December 2012.
343 D-fenfluramine was withdrawn worldwide in 1997.
344 Mediator was prescribed to up to 5 million patients between 1976 and 2009. It was withdrawn in Spain 
and Italy five years earlier and was never prescribed in the UK or US. It is believed to have caused between 
500 and 2000 deaths. See Mullard (2011).
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the people involved in the due diligence on the compound who turned it down. 
However, at the time the pressure from marketing people was intense with 
regard to in-licensing the compound, but thankfully we turned it down, largely 
based on the evidence presented at that New York Academy meeting, which 
showed neurodegeneration associated with the compound that was there for all 
to see, and which was completely ignored when the compound was eventually 
developed.
sanger:  Different countries do different things. Tegaserod was withdrawn 
worldwide some time ago, but a couple of weeks ago I talked to a German 
clinician whose patients were still getting tegaserod. They’d imported them 
from the Vatican [laughter], which is a separate state. So that led to a torrent of 
jokes about praying for safety and so on. 345 But you can get it anywhere.
curzon:  Something that I was rather uneasy about is the way Servier kept having 
clinical trials in exotic parts of the world. Were they deliberately choosing places 
where trial ethics were not as good as in Western Europe or the United States? 
Hunter:  I think I have to say something here. I can say this because I don’t 
actually work for big Pharma now, but whatever was able to go on 15 or 20 
years ago, there is no way these days that you would ever be able to run trials 
in that way, unless you were absolutely being completely and utterly illegal. 
In fact, what’s recently happened is that ten companies have come together to 
form a company called TransCelerate, which is trying to get common clinical 
standards across companies, in terms of clinical site approval and standards of 
trial conduction.346 So, I was a bit uncomfortable that it sounded like we were 
going down a ‘Pharma is being completely unethical’ route. Whatever happened 
345 The Vatican pharmacy, open to the public, ‘…is one of the only places people can buy – with a 
proper medical prescription – obscure, foreign or just-released pharmaceuticals that haven’t yet hit Italian 
drugstores. Brother Kattackal said Italian bureaucracy can hold up approval for a drug’s sale in Italy for 
months, or even years. But Vatican City State can purchase straight from international manufacturers drugs 
that have passed other nations’ standards and approval, he said, without dealing with Italian red tape.’ See 
www.catholicnews.com/data/stories/cns/0802820.htm (visited 9 July 2013).
346 TransCelerate Biopharma was founded in September 2012 as a non-profit making organization, whose 
aims are to ‘advance innovation in research and development (R&D), identify and solve common R&D 
challenges and further improve patient safety, with the goal of delivering more high quality medicines 
to patients. TransCelerate will seek to accomplish these objectives through its focus on identifying and 
capturing efficiencies in the clinical trial process, which will reduce costs, increase speed to market, and 
enhance quality, innovation and patient safety.’ See http://transceleratebiopharmainc.com (visited 11 
September 2013). The ten founder companies are: Abbvie, AstraZeneca, Boehringer Ingelheim, Bristol–
Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson and Johnson, Pfizer, Roche and Sanofi.
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20 years ago in the industry, and there may have been things, and you’ve seen 
there have certainly been issues in terms of selling and some marketing, I 
wouldn’t like to give the impression that Pharma companies can really get away 
with doing anything like that these days. It’s very, very heavily regulated and 
watched. So, for example, when you are doing a clinical trial in Brazil, you have 
to be doing your clinical trials in the sponsor country as well.347 They won’t let 
you just run clinical trials in Brazil. 
flower:  We wandered off message there but I think it was a very valid point. 
I am going to say a few words in summing up, but I just wondered if there’s 
anything else anyone urgently wants to say about the 5-HT area before we wind 
up. 
Aronson:  I have one comment about a clinical aspect of 5-HT that I don’t 
think we’ve discussed, and surprisingly it involves antipsychotic drugs. Many 
years ago, David Grahame-Smith was interested in the action of 5-HT in 
altering platelet aggregation in vitro. If you add 5-HT to a suspension of 
platelets they aggregate, but it’s transient in 90 per cent of cases. In a few cases 
it’s irreversible but most of the time it’s transient, whereas if you add ADP 
or other aggregating substances, it’s irreversible. What was reported was that 
chlorpromazine inhibited this aggregation in vitro.348 At that time, David was 
interested in finding markers for pharmacological actions that could be used to 
monitor progress in clinical conditions, and schizophrenia was clearly a difficult 
condition to monitor. He thought that this action of chlorpromazine might 
be helpful as an indicator of efficacy, and so he got a load of patients who 
had been given chlorpromazine and studied the platelet aggregation in vitro 
using their own plasma.349 Lo and behold, the aggregation was not reduced but 
it was markedly increased, for reasons that I think never really became clear, 
although presumably metabolites were involved. Whatever the reasons, that was 
the outcome and there’s more to say about it. Some years later Hershel Jick from 
the Boston Collaborative Surveillance Program published a paper in the Lancet 
347 The WHO International Clinical Trials Registry Platform was developed to ‘to ensure that a complete 
view of research is accessible to all those involved in health care decision making. This will improve research 
transparency and will ultimately strengthen the validity and value of the scientific evidence base.’ See www.
who.int/ictrp/en (visited 30 April 2013). Clinical trials sponsored by organizations such as the MRC and 
the Wellcome Trust are required to register on the metaRegister of the International Standard Randomised 
Controlled Trial Number Register.
348 Boullin et al. (1975a).
349 Boullin et al. (1975b).
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showing that there is an increased risk of thromboembolism in patients taking 
classical phenothiazines.350 We did wonder whether this aggregatory effect of 
chlorpromazine on platelets, perhaps through 5-HT, was the mechanism. 
Blackburn:  I did a clinical study with the compound ICI 170,809 on platelet 
response and showed a very marked antagonist activity on platelet aggregation.351 
At that time we were thinking it was through the S2 (5-HT
2A
) receptor. Sitting 
here and thinking of people like Jimmy Black, who worked on 5-HT for a while, 
it would be interesting to have heard some of his comments on the complexity 
of this area with his background in H
1
, H
2
, β1, β2 receptors.352 Also we just 
touched a little on the work of John Vane, who made a major contribution with 
the bioassay system.353 These are contributions where it would have been nice 
to hear the thoughts from some of these guys. 
marsden:  At the beginning of this discussion we talked a lot about Maurice 
Rapport, who was essential in the elucidation of what 5-HT. He died fairly 
recently and his family have, through the Serotonin Club, asked us to look 
after his papers related to this period of his research. The suggestion is that they 
should be lodged with the Wellcome Library. I would hope that that could be 
arranged through this event.
Bakhle:  Is plasma 5-HT increased in people who take SSRIs?
cowen:  I don’t think there’s much 5-HT in the plasma, so what you get with 
SSRIs is a profound lowering of platelet 5-HT and some people think that could 
tie in with a possible protective effect of SSRIs against myocardial infarction. 
Also there is more bleeding during surgical operations. If you have an operation 
and take SSRIs, you’re more likely to need a blood transfusion.
Bakhle:  But why does the platelet 5-HT fall if you block uptake because you’ve 
got no metabolism in there, have you? There isn’t a metabolizing enzyme, MAO 
within the platelet.
marsden:  We actually did this with paroxetine in one of the very initial clinical 
trials and looked at platelet 5-HT, which drops very rapidly on the start of 
350 Zornberg and Jick (2000).
351 Blackburn et al. (1990).
352 Black, Fisher and Smith (1958). 
353 John Vane developed the technique of cascade superfusion bioassay; Vane (1964). For Vane’s work, see 
also note 9.
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treatment. The reason is because all the 5-HT in the platelets gets there through 
the uptake site. The platelets can’t make 5-HT. So if you block uptake, you don’t 
get any 5-HT in there and so it can’t be stored there.354
flower:  Well, it’s been a terrific day. One of the good things about these 
meetings is that it’s like travelling through the entire history of a discipline 
by time machine. We started off this morning talking about substances of 
unknown structure found in clotted blood and we finished tonight with SSRIs, 
triptans and a whole swathe of 5-HT
3
 antagonists, all of which are very useful 
medicines. Along the way we’ve learnt how important those defining meetings, 
such as the ‘Birmingham meeting’, were, and the significance of the Serotonin 
Club, and also the role of the BPS in fostering a sense of community between 
people working in this field. We’ve heard several times today how nice you all 
are – and I’m sure it’s not just that – but for whatever reason, this field seems to 
have come together very well in terms of industry–academia collaborations. The 
fact that you’re all so ‘nice’ may be that you’ve been brought up in a culture that 
encourages collegial collaborations and I think that’s one thing that groups like 
the Serotonin Club and the BPS try to encourage. So an important lesson for all 
collaborations is that you need to have this sense of community. We also have 
heard how molecular biology had both a positive and a negative effect on drug 
development and also the importance of discussions with our clinical colleagues 
to discover what they know about diseases. We didn’t really touch upon things 
like different disease pathotypes, which we could have discussed for a long time. 
We then wandered into rather philosophical territory when we tried to put the 
world to rights by identifying what was wrong with drug discovery today. Well, 
I’ve been to several of these meetings, and we always wind up at that point and 
that’s one of the reasons why I thought it might be a good time to stop. You’ve 
been a terrific audience and a terrific group to work with. 
tansey:  Thanks very much, Rod. I would like to add my thanks to you all 
for coming and sharing your experiences. I’m a lapsed neuroscientist and I 
did my PhD on catecholamine and 5-HT distribution in Octopus brain and 
I still remember the excitement of looking at that yellow fluorescence down 
the microscope, so it’s been particularly nice to hear some of the stories about 
people whose papers I quoted so long ago. When I decided several years later 
to become an historian, I did a PhD on Henry Dale and his work, so again 
there’s been a lot of resonance this afternoon and I’m delighted to have learnt 
so much about the continuation of some of that work. Obviously I’d like to 
354 Marsden et al. (1987). 
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follow up the point that Charles made about the Rapport papers and also the 
Serotonin Club papers. I think these would fit in very clearly with the Wellcome 
Library’s collection strategy at the moment, which is emphasizing neuroscience 
and genetics. The archives of the Wellcome Library include the BPS archives 
and papers of people such as Marthe Vogt, Edith Bülbring and Bill Paton. So 
there is already a very good pharmacological collection in the Wellcome Library 
and I am sure they would fit very well. I’d like to say a particular thank you to 
Rod for chairing this meeting so ably. This is the third meeting that he’s chaired 
and I’m delighted he allowed me to persuade him to chair this one. So, Rod, 
thank you very much indeed. 
figure 25: Participants at the Witness seminar.
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Appendix 1255
Pioneering research by smithkline Beecham: 5-Ht
3
 receptor 
antagonism and anti-emetic activity, by Professor gareth sanger256
Our dissection of the different pharmacological properties of metoclopramide 
laid the foundation for the characterization of the ‘prokinetic’ 5-HT
4
 receptor and 
identified a relationship between the relatively low affinity of metoclopramide 
for the 5-HT
3
 receptor and the need to use high doses of the drug to prevent 
cytotoxic-evoked emesis. After successfully testing our pioneering analysis, we 
identified, developed and now market granisetron as the first 5-HT
3
 receptor 
antagonist designed as an anti-emetic drug. We also patented the use of 5-HT
3 
receptor antagonists for the control of emesis. Included in the patent was the 
world’s first data on the anti-emetic properties of ondansetron, a compound 
identified by Glaxo for the treatment of schizophrenia and anxiety. Our 
discovery dominates the early 5-HT
3
/emesis scientific literature.
 
Kytril: The link between the 5-HT
3
 receptor and the mechanisms of 
emesis: significant publication history. 
Prior to publishing in peer-review journals, we introduced the novel concept 
that high-dose metoclopramide might not prevent emesis via antagonism at the 
dopamine receptor.
255 SmithKline Beecham was formed in 1989 from the merger of SmithKline Beckman and the Beecham 
Group.  Several of the pharmaceutical companies mentioned in the text have merged, and briefly these 
changes were: Allen and Hanburys research laboratories at Ware were absorbed into Glaxo (1958); 
SmithKline and French merged with Beckman Inc to become SmithKline Beckman (1982); SmithKline 
Beckman and the Beecham Group merged to form SmithKline Beecham (1989); Glaxo and Wellcome 
merged to form Glaxo Wellcome (1995); Glaxo Wellcome and SmithKline Beecham merged to form 
GlaxoSmithKline (2000). 
256 Professor Gareth Sanger wrote: ‘This was prepared as an internal document (SmithKline Beecham) to 
support our successful patent claim over the use of the Glaxo drug ondansetron (Zofran) for anti-emetic 
control, and then subsequently in 1998, to support the PhARMA award. It emphasizes the fact that in the 
discovery of the involvement of the 5-HT
3
 receptor in the mechanisms of nausea and vomiting, our research 
led the way.’ Email to Ms Caroline Overy, 7 August 2013. See also the discussion on pages 56–60 and note 
190 by Professor Sanger.
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In 1984 we concluded: ‘However, additional factors may also be involved, since 
unlike other dopamine antagonists, high-dose intravenous metoclopramide 
successfully prevents emesis caused by strongly emetic cancer chemotherapeutic 
agents.’ (McRitchie et al. (1984), page 297).
In 1986 we stated: ‘The results with Domperidone and BRL 24924 suggest 
that dopamine antagonism is not essential for the inhibition of cisplatin emesis 
in the ferret. The efficacy of metoclopramide and BRL 24924 may therefore 
involve other properties, such as 5-HT M-receptor (5-HT
3
) antagonism and/or 
effects on gut motility.’ (Miner, Sanger and Turner (1986), page 374P).
In 1986 we also began to submit our work for peer review. Firstly we concluded 
that 5-HT
3
 receptor antagonism prevented cytotoxic drug-evoked emesis. This 
appeared as a Rapid Communication in the British Journal of Pharmacology and 
has now received several hundred citations (Miner and Sanger (1986)).
In 1987 we developed our discovery by including a range of cytotoxic therapies. 
Significantly, we published in the British Journal of Cancer and thereby directly 
addressed the oncology community (Sanger, Miner and Turner (1987)).
In 1988 we again published in the British Journal of Cancer, describing the 
efficacy of the highly selective 5-HT
3
 receptor antagonist BRL 43694, later 
known as granisetron or Kytril (Bermudez et al. (1988)).
The development of Kytril was a superb team effort within SmithKline Beecham. 
Its discovery was the product of a highly productive association between 
Medicinal Chemistry, led by Dr F King, and Discovery Biology.  The discovery 
of the link between the 5-HT
3
 receptor and the mechanism of emesis, primarily 
involved three people:  Dr G J Sanger, the late Mrs Christine McClelland and 
Mr W D Miner.
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Professor Paul Andrews 
PhD (b.1953) studied physiology 
at undergraduate and postgraduate 
levels at the University of Sheffield 
prior to obtaining lectureships at 
the University of Edinburgh and 
St George’s, University of London, 
where he is Emeritus Professor 
of Comparative Physiology. His 
research over the past 30 years 
has focused on the pre-clinical 
neuropharmacology of emesis, 
with particular emphasis on anti-
cancer chemotherapy and the role 
of the vagus nerve. He has worked 
on the site(s) of action of 5-HT
3
 
and NK1 receptor antagonists in 
conjunction with colleagues in 
industry and is currently working 
on mechanisms of nausea and non-
animal methodologies to investigate 
emetic liability of new drugs. 
Dr Jeffrey Aronson
DPhil FRCP FBPharmacolS FFPM 
(b. 1947) trained in the University 
of Glasgow (1964–73) and the 
Medical Research Council Unit 
and University Department of 
Clinical Pharmacology, Oxford, 
under the late Professor David 
Grahame-Smith. He is currently 
Reader in Clinical Pharmacology 
at the University of Oxford and 
Honorary Consultant Physician in 
the Oxford University Hospitals 
Trust. He was President of the 
British Pharmacological Society 
(2008/9) and is now Emeritus 
President. He was Vice-chairman 
of the Medicines Commission 
(2002–2005) and Editor-in-chief 
of the British Journal of Clinical 
Pharmacology (2003–07). He has 
been Chairman of the British 
Pharmacopoeia Commission’s 
Expert Advisory Group on 
Nomenclature since 2006. He 
was a member of the Formulary 
Committees of the British National 
Formulary from 2006 and the 
British National Formulary for 
Children from 2003, and is now 
a member of the Advisory Board 
of the British National Formulary. 
For further details, see www.phc.
ox.ac.uk/jeffrey-aronson (visited 9 
September 2013).
Dr Julius Axelrod
PhD (1912–2004) obtained a 
degree in chemistry and biology in 
1933 at the City College of New 
York and an MSc in chemistry 
at New York University in 1941. 
After working as a laboratory 
assistant and a chemist, in 1949 
Biographical notes*
* Contributors are asked to supply details; other entries are compiled from conventional 
biographical sources.
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he was appointed to the National 
Heart Institute, part of the NIH 
in Bethesda. There he worked 
with Bernard Brodie on anti-
malarial drugs and their research 
into acetaminophen led to the 
development of the new pain 
relief drug, tylenol /paracetamol. 
In 1955 he completed his PhD 
and was appointed as head of the 
section of pharmacology in the 
Laboratory of Clinical Science at 
the National Institute of Mental 
Health, where he remained until 
his retirement in 1984. His research 
focused on the neurotransmission 
of catecholamine, adrenaline and 
noradrenaline. In 1970, he was 
jointly awarded (with Bernard 
Katz and Ulf von Euler) the Nobel 
Prize for Physiology or Medicine 
‘for their discoveries concerning 
the humoral transmitters in 
the nerve terminals and the 
mechanism for their storage, release 
and inactivation.’ For further 
biographical details and details 
of Axelrod’s research, see Iversen 
(2006b) and his interview in Healy 
(1996), pages 29–49.
Dr y s (mick) Bakhle
DPhil DSc (b. 1936) read 
chemistry, took chemical 
pharmacology as a supplementary 
subject and went on to do his 
DPhil in the Department of 
Pharmacology at Oxford; in 1993 
he received a DSc. After two 
post-doctoral years as a Fulbright 
Fellow at Yale, he joined the 
Department of Pharmacology at 
the Royal College of Surgeons 
(RCS) in London in 1965, 
working with John Vane and was 
appointed Reader in Biochemical 
Pharmacology in 1980.  After 
nearly 30 years at the RCS, he 
moved to the National Heart and 
Lung Institute at Imperial College, 
where he is a Senior Research 
Fellow. For five years (2001-2006), 
he was a senior editor of the British 
Journal of Pharmacology and has 
been Press Editor for the last six 
years. 
Professor sir James Black
Kt OM FRCP FRS (1924–2010) 
was Professor and Head of the 
Department of Pharmacology, 
University College London, 
(1973–1977), Director of 
Therapeutic Research at Wellcome 
Research Laboratories (1978–1984); 
and Professor of Analytical 
Pharmacology at King’s College 
Hospital Medical School, London 
(1984–1993). He was chancellor of 
Dundee University (1992–1996). 
He shared the 1988 Nobel Prize 
for Physiology or Medicine (with 
George Hitchings and Gertrude 
Elion) for ‘discoveries of important 
principles for drug treatment’. 
He was knighted in 1981 and 
appointed to the Order of Merit 
in 2000. See the special issue of 
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the British Journal of Pharmacology 
celebrating his life and work 
(McGrath, Bond and MacKie (eds) 
(2010)).
Dr tom Blackburn
MPhil PhD DSc FBPharmacolS 
(b. 1949) received his degrees 
from Nottingham and Manchester 
Universities. He has held C-level 
executive and senior management 
positions at ICI Pharmaceuticals 
PLC, Beecham Pharmaceuticals 
PLC and SmithKline Beecham 
in the UK and with two biotech 
companies in the US, Synaptic 
Pharmaceutical Corporation and 
Helicon Therapeutics Inc. He 
has led companies, departments, 
and project teams that identified 
and developed novel therapeutics, 
including several 5-HT receptor 
subtype antagonists (5-HT
2A
, 
5-HT
2B
, 5-HT
2C
 & 5-HT
3
), 
Galanin R3 and the SSRI 
antidepressant, Seroxat/Paxil. His 
passion, based on an extensive 
knowledge of pre-clinical and 
clinical drug development and 
marketing is helping to define 
strategies and positioning of 
pharmaceutical products for 
biotech startup companies. He 
has authored over 100 peer-
reviewed scientific papers, review 
articles and book chapters and is 
an inventor on 22 patents. He is 
President Emeritus of the British 
Pharmacological Society and a 
member of the American College 
of Neuropsychopharmacology. He 
is also a non-executive Director 
for Motac Neuroscience Ltd., 
a neuroscience biotechnology 
company specializing in Parkinson’s 
disease and neurodegenerative 
disorders.
Professor Bernard Brodie
PhD (1907–1989) graduated from 
McGill University in 1931. He 
was awarded his PhD in organic 
chemistry in 1935 from New 
York University and was then 
appointed Associate Professor in 
the Physiology Department. After 
carrying out research into anti-
malarial therapy at the Goldwater 
Research Service at NY University 
from 1941 until 1949, he moved 
to the National Heart Institute in 
Bethesda, MD, where he headed 
the Laboratory of Chemical 
Pharmacology until his retirement 
in 1970. His research pioneered 
developments in drug metabolism, 
neuropsychopharmacology and 
toxicology. See Bickel (1989); 
Costa et al. (1989). 
Professor David clarke
PhD FBPharmacolS (b. 1936) 
obtained his undergraduate degree 
at the University of London and his 
PhD at the University of Bradford, 
where he was an Assistant Lecturer 
and then Lecturer in Pharmacology 
(1961–1969). He was Associate 
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Professor of Pharmacology, 
University of Pittsburgh (1969–
1973); Professor and Chairman of 
the Department of Pharmacology, 
University of Houston (1973–
1989); Distinguished Scientist at 
Syntex, and later Roche, Palo Alto, 
CA (1989–1996).  Subsequently, he 
has worked as a freelance consultant 
for pre-clinical and clinical drug 
discovery and development, 
while serving on the Board of 
Pharmovation Ltd.  Currently, he is 
engaged as the Principal Consultant 
for Recordati (Milan, Italy) and 
Afferent Pharmaceuticals (San 
Mateo, CA. USA). 
Dr Alec coppen
DSc FRCP FRCPsych (b. 1923) 
trained in medicine at Bristol 
University after military service 
during the Second World War. 
He went on to the Institute of 
Psychiatry and the Maudsley 
Hospital and in 1960 became 
Clinical Director of the  MRC’s 
Neuropsychiatric Research 
Institute and was Head of the 
WHO-designated Centre for 
Biological Psychiatry in the UK. 
His research focused on 5-HT 
and mood disorders and was the 
first to propose a 5-HT theory for 
depression. For a discussion of his 
research, see his interview in Healy 
(1996), pages 265–86.
Professor Brenda costall 
PhD DSc (b. 1947) worked 
at the University of Bradford 
as Lecturer in Pharmacology 
(1973–1979), Senior Lecturer 
in Pharmacology (1979–1983), 
Reader in Neuropharmacology 
(1983–1985), and Professor 
of Neuropharmacology since 
1985 and Head of the School of 
Pharmacy (1998–2004). She retired 
in 2007.
Professor Philip cowen
MD FRCPsych (b. 1951) trained 
in medicine at University College 
Hospital, London, and then 
in psychiatry at King’s College 
Hospital, London.  He went to 
Oxford to work in the MRC 
Unit of Clinical Pharmacology 
under David Grahame-Smith 
and Richard Green.  Since 1983 
he has been an MRC Clinical 
Scientist and Honorary Consultant 
Psychiatrist in the Department 
of Psychiatry in Oxford.  He 
was elected to a personal chair 
in Psychopharmacology in the 
University of Oxford in 1997 and 
the Academy of Medical Sciences 
in 2001. His main interests are in 
the biochemistry and treatment of 
mood disorders, particularly the 
pharmacological management of 
resistant depression.
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Professor Helen cox
PhD (b. 1957) completed her PhD 
at University of Southampton 
and post-doctoral research at 
University of Cambridge, and has 
been interested in peptide receptor 
signalling. Her current research 
focuses on how the intestine senses 
nutrients and signals their presence 
locally to alter gut function, and 
acts as an interface that regulates 
energy homeostasis. 5-HT has a 
role in these sensing mechanisms.  
She has been Professor of 
Pharmacology at King’s College 
London since 2004 and has served 
on an IUPHAR subcommittee for 
nomenclature of NPY receptors, 
on the editorial board of the British 
Journal of Pharmacology and other 
pharmacological journals, on the 
British Pharmacological Society 
Council, as well as the finance and 
executive committees. 
Professor gerald curzon   
PhD DSc (b. 1928) was educated 
in Leeds at state schools and Leeds 
University (BSc Chemistry, PhD 
Biochemistry.)  He spent most 
of his career at the Institute of 
Neurology, University College, 
London, and received a DSc in 
neurochemistry. He has broad 
historical interests and spent a 
period of time as historian and 
archivist of the International 
Society for Neurochemistry.  
Dr colin Dourish
PhD DSc (b. 1955) received a 
BSc in Psychology (1977) and 
a PhD (1980) and DSc (1993) 
in psychopharmacology from 
Queen’s University, Belfast and 
carried out post-doctoral research 
at the University of Saskatchewan 
in Canada and at the Institute 
of Neurology, London.  He is 
Chief Executive Officer of the 
clinical research organization 
P1vital Limited.  Prior to co-
founding P1vital, he was Senior 
Vice President Research and CSO 
of Vernalis Group plc, Research 
Director and co-founder of 
Cerebrus Limited, Director of 
Neuropharmacology at Wyeth 
Research and Section Head at 
Merck & Co.  He is an Honorary 
Fellow of the Department of 
Psychiatry at the University of 
Oxford and formerly a William 
Pitt Fellow of Pembroke College, 
Cambridge, Visiting Professor 
of Psychopharmacology at the 
University of Durham and Visiting 
Professor of Neuroscience and 
Psychological Medicine at Imperial 
College of Science, Technology and 
Medicine, London.
Professor Vittorio erspamer 
(1909–1999) graduated in 
medicine and surgery in 1935 
and after a short appointment as 
Assistant Professor of Anatomy 
and Physiology at the University 
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of Pavia, he went to the Institute 
of Pharmacology at the University 
of Berlin. In 1939 he became 
Professor of Pharmacology in 
Rome and in 1947, Professor of 
Pharmacology at the University of 
Bari, a post that he held until 1955 
when he moved to the University 
of Parma. Much of his research 
focused on marine organisms 
and amphibians, isolating and 
identifying more than 60 new 
chemical compounds; later in his 
career he concentrated on peptides. 
In 1935 he identified an extract 
from the enterochromaffin cells 
contained an amine, which he 
named ‘enteramine’, which was 
later shown to be the same as 5-HT. 
Professor roderick flower
PhD DSc FMedSci FRS (b. 
1945) trained as a physiologist at 
Sheffield University, subsequently 
receiving a PhD in experimental 
pharmacology from the University 
of London and a DSc in 1985. 
After 12 years working in industry 
at the Wellcome Foundation, 
he left to take the Chair of 
Pharmacology at the University of 
Bath in 1985. In 1990 he returned 
to London to establish a new unit 
at the William Harvey Research 
Institute, Barts and The London 
School of Medicine and Dentistry. 
During this time he was Head, on 
a part-time basis, of the Clinical 
Pharmacology Department, 
and was President of the British 
Pharmacological Society (2000–
2003).
Dr John fozard
PhD, studied pharmacy at the 
University of London and received 
his PhD in Pharmacology from 
the University of Bradford in 
1968. After a lectureship and 
senior lectureship at the University 
of Manchester and a year at the 
University of Mainz, he was 
appointed Head of Pharmacology 
at the Merrell-Dow Research 
Institute in Strasbourg France in 
1977 where he remained for ten 
years. He was subsequently Head 
of Hypertension Research and 
then Head of Asthma Research 
at Sandoz in Basle.  In 1996 he 
became Head of Respiratory 
Disease Research at Novartis 
and after three years a Novartis 
Distinguished Scientist in the 
Respiratory Disease Research 
section of the Novartis Institutes 
for BioMedical Research. He retired 
in 2005. See the biographical 
information submitted by Professor 
Daniel Hoyer to the Serotonin 
Club Newsletter, Autumn 2005 to 
mark Fozard’s retirement, at http://
serotoninclub.org/newsletters/
Nwsltr66.pdf (visited 15 July 
2013).
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Dr ray fuller 
PhD (1935–1996) studied at 
Southern Illinois University, 
graduating in chemistry in 1957 
and gaining a Master’s degree in 
microbiology in 1958. He went on 
to receive a PhD in biochemistry 
from Purdue University in 1961. 
In 1963 he was appointed a 
Senior Pharmacologist at the 
pharmaceutical company Eli Lilly 
and Co. in Indianapolis. His 
research with David Wong and 
Bryan Molloy on antidepressants 
led to their discovery of fluoxetine, 
the first SSRI, which from 1988 
was marketed as ‘Prozac’.
Professor sir John gaddum 
Kt FRS FRSE (1900–65) went 
to Trinity College Cambridge in 
1919 on an entrance scholarship 
for mathematics and in 1922 
became a medical student at 
University College Hospital, 
London. He worked at the 
Wellcome Physiological Research 
Laboratories, London, in 1925; at 
the National Institute for Medical 
Research, London (1928–1934); 
and was Professor of Pharmacology 
at the University of Cairo (1934). 
In 1935 he was appointed Professor 
of Pharmacology at University 
College, London and in 1938 
took the Chair at the School of 
Pharmacy, University of London. 
During the Second World War he 
worked at the Chemical Defence 
Research Station, Porton, and in 
1942 was appointed Professor 
of Materia Medica at Edinburgh 
University. In 1958 he became 
Director of the Institute of Animal 
Physiology, Babraham, Cambridge. 
See Feldberg (1967).
Professor David grahame-smith 
CBE FRCP (1933–2011) was 
Rhodes Professor of Clinical 
Pharmacology,  University of 
Oxford (1972–2000), Honorary 
Director of the MRC Clinical 
Pharmacology Unit, Oxford (1972–
1992), Honorary Director of the 
Oxford University SmithKline 
Beecham Centre for Applied 
Neuropsychobiology (1989–1999), 
and Honorary Consultant in 
Clinical Pharmacology and General 
Internal Medicine to the Oxford 
Radcliffe Hospitals (1972–2000). 
See Aronson (2011b).
Dr Arda green
MD (1999–1958) studied 
chemistry and philosophy at the 
University of California, Berkeley, 
and went on to receive an MD 
from Johns Hopkins School of 
Medicine in 1927. Following 
research at Harvard Medical School 
and Radcliffe College she went to 
Washington University as Research 
Associate and Assistant Professor 
and worked with Carl and Gerty 
Cori, who went on to be jointly 
awarded the 1947 Nobel Prize 
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in Physiology or Medicine. In 
1945, Green was invited to join 
the research staff at the Cleveland 
Clinic, where she worked with 
Irvine Page and Maurice Rapport 
on 5-HT. She remained there until 
1953 when she was appointed to 
the McCollum-Pratt Institute of 
Johns Hopkins, where her research 
focused on biolumiscence. See 
Colowick (1958).
Professor richard green
PhD DSc (b 1944) completed 
his PhD (1969) with Gerald 
Curzon and following two years 
at National Institute of Mental 
Health (NIMH), Washington, 
DC, with Erminio Costa, he 
joined David Grahame-Smith at 
the MRC Clinical Pharmacology 
Unit in Oxford becoming Assistant 
Unit Director in 1981.  In 1986 
he was appointed Director of 
the new Astra Neuroscience 
Research Unit in London.  In 
1996 he was appointed Director, 
Global Discovery CNS & Pain 
Control, for Astra. After retiring 
from AstraZeneca in 2007 he has 
continued psychopharmacology 
research in Nottingham, and is 
currently Honorary Professor 
of Neuropharmacology at 
Nottingham University.  He was 
awarded the DSc by London 
University in 1988 and in 2010 was 
given the Lifetime Achievement 
Award by the British Association 
for Psychopharmacology. He is a 
President Emeritus of the BPS and 
a former President of the Serotonin 
Club. 
Professor Daniel Hoyer
PhD DSc FBPharmacolS 
(b. 1954) received his PhD in 
Pharmacology (1981 Strasbourg) 
DSc (1986 Strasbourg), was a 
post-doctoral fellow (University 
of Pennsylvania, Philadelphia), 
Cardiovascular Research Sandoz 
(Basel, 1983), and Neuroscience 
Research (1989-2012, Sandoz/
Novartis). He worked on 
catecholamine, serotonin, 
neuropeptide receptors and 
ligand-gated channels; genomics 
of depression and schizophrenia; 
epilepsy, sleep disorders, RNAi 
and epigenetics of neuropsychiatric 
disorders, and published more 
than 300 papers/articles. He 
is a member of the British 
and German Pharmacological 
Societies, European College of 
Neuropsychopharmacology, Society 
for Neurosciences, scientific council 
of the Institut Pasteur, Council/
Director of the BPS. He is past 
editor of European Journal of 
Pharmacology, Neuropharmacology, 
Current Opinions in Pharmacology, 
Current Drugs, Drug Discovery 
Today, Journal of Receptors and 
Signal Transduction, Pharmacology 
and Therapeutics, and is currently a 
senior editor of Psychopharmacology, 
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Naunyn Schmiedeberg’s Archives 
of Pharmacology, Encyclopedia of 
Psychopharmacology and British 
Journal of Pharmacology.  He 
chaired the Serotonin and 
the Somatostatin Receptor 
Nomenclature subcommittees 
(NC IUPHAR), and was President 
of the Serotonin Club and the 
European Neuropeptide Club. He 
was Novartis Leading Scientist 
(1998), Professor adjunct, MIND, 
the Scripps Research Institute, La 
Jolla, CA (2004), Fellow of the BPS 
(2005); he was in the top ten most 
cited researchers in pharmacology 
(see www.in-cites.com/scientists/
pha-10-aug2003.html, visited 9 
September 2013), with to date 
more than 22,000 citations and 
an H index of 75. He is Professor, 
Chair and Head, Department 
of Pharmacology, School of 
Medicine, University of Melbourne 
(December 2012), and Honorary 
Professorial Fellow, Florey Institute, 
Melbourne (March 2013).
Dr Patrick Humphrey 
OBE DSc PhD  
FBPharmacolS (Hon) (b. 1946) 
was born in South Africa and 
graduated from the School of 
Pharmacy, University of London, 
in 1968, with a strong interest 
in drug receptor theory. After 
obtaining a PhD in pharmacology 
at St Mary’s Hospital Medical 
School and briefly working as a 
Lecturer in the Department of 
Physiology, he joined Allen & 
Hanburys at Ware to initiate a 
project on migraine. His work 
on cerebrovascular pharmacology 
led directly to the development 
of sumatriptan, the prototype of 
a new drug class (the triptans) for 
the treatment of migraine.  During 
this time, he became the overall 
Director of the Glaxo Division of 
Pharmacology that was not only 
instrumental in the discovery of 
sumatriptan, but also naratriptan, 
alosetron, ondansetron, vapiprost 
and salmeterol, covering a broad 
spectrum of therapeutic areas. 
He has received many important 
academic honours, including an 
honorary Professorship from the 
University of Cambridge, as well 
as the Royal Society’s Mullard 
medal.  In 1999, he was awarded 
the OBE for ‘services to migraine 
research’.  He maintains a passion 
for research aimed at drug discovery 
and was latterly the successful 
Head of Research and Executive 
Vice President at Theravance in 
San Francisco, CA, from 2001 to 
2008. He has over 300 published 
scientific papers and book chapters 
to his name and was ranked 
fourth in the list of total literature 
citations in Pharmacology and 
Toxicology from 1994 to 2004. He 
is currently consulting for a number 
of new, innovative pharmaceutical 
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companies and is a non-executive 
Director on the board of Verona 
Pharma plc.
Dr Jackie Hunter 
PhD FBPharmacolS gained a BSc 
in physiology and psychology 
in 1977 and a PhD in animal 
behaviour at the University of 
London in 1980. Subsequently she 
undertook a Wellcome Trust post-
doctoral fellowship at St George’s 
Hospital Medical School, London, 
in behavioural pharmacology. She 
has been a senior leader in the 
pharmaceutical industry for over 
25 years and more recently has 
become widely recognized as an 
expert in the application of open 
innovation in healthcare.  In terms 
of research and development, 
she was responsible for both 
clinical and non-clinical portfolios 
at GlaxoSmithKline (GSK), 
primarily within the neuroscience 
therapeutic area, taking compounds 
from early research to late phase 
development.  She was also a non-
Executive director for Proximagen 
plc, a neuroscience biotechnology 
company, prior to its acquisition 
by Upshire Smith in 2012. She has 
extensive international experience 
in industry and academic 
collaborations and alliances and 
has served on the boards of large 
public private initiatives such as 
the Innovative Medicines Initiative.  
She has also held numerous 
other positions on academic and 
industry advisory boards as well 
as committees for funding bodies 
and charities. After leaving GSK, 
she formed OI Pharma Partners 
Ltd, which helps companies and 
institutions across the life sciences 
apply open innovation principles 
effectively within their businesses.  
She has received several awards 
including Women of Achievement 
in Science, Engineering and 
Technology and a CBE for Services 
to the Pharmaceutical Industry. 
In 2013 she was appointed the 
new CEO for the Biotechnology 
and Biological Sciences Research 
Council.
Professor Leslie iversen
CBE PhD FRS (b.1937) studied 
biochemistry and pharmacology 
at Trinity College, Cambridge. 
After post-doctoral fellowships at 
the NIH, Harvard Medical School 
and Trinity College, Cambridge, 
he became Locke Research 
Fellow of the Royal Society in the 
Department of Pharmacology, 
University of Cambridge in 1967. 
In 1971 he was appointed Director 
of the MRC Neurochemical 
Pharmacology Unit, Cambridge, 
until 1983, when he became 
Director of Merck, Sharp & 
Dohme Neuroscience Research 
Centre in Harlow. From 1995 
he was visiting Professor of 
Pharmacology at Oxford University 
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was Professor of Pharmacology and 
Director of the Wolfson Centre 
for Age-related Diseases, Kings 
College, London, from 1999 
to 2004 and has been Emeritus 
Professor of Pharmacology at the 
University of Oxford since 2007.  
sir David Jack
KT CBE PhD FRS FRSE 
(1924–2011) studied pharmacy 
and pharmacology at Glasgow 
University where he became 
Assistant Lecturer before National 
Service. After working in the 
pharmacy research department 
at Glaxo (Greenford) and at the 
pharmaceutical company Menley 
and James (later part of Smith Kline 
and French), completing a part-
time PhD at London University, he 
was appointed Head of Research 
at Glaxo (Allen & Hanburys) 
at Ware in 1961, becoming 
Research and Development 
Director from 1978 to 1987 when 
he retired. He pioneered major 
developments in the treatment of 
asthma (salbutamol), gastric ulcers 
(ranitidine), migraine (sumatriptan) 
and cancer therapy-induced emesis 
(ondansetron) He was awarded 
the CBE in 1982 and knighted in 
1993. For further details, see Watts 
(2012); Barnes and Breckenridge 
(2012).
Paul Janssen
(1926–2003) trained in medicine 
in Leuven and Ghent and 
after military service studied 
pharmacology and chemistry at 
Cologne University. After several 
years of teaching and study 
trips, he turned to independent 
research and founded his own 
research laboratory in 1953. In 
1961 the company merged with 
the American company Johnson 
and Johnson, but retained its 
own identity and independence, 
and in 1964 the company was 
renamed Janssen Pharmaceutica 
N V (formerly N V Research 
Laboratorium C Janssen, after his 
father, Constant Janssen). By the 
time of his death, Paul Janssen held 
over 100 patents, had published 
more than 850 papers, and received 
numerous awards. See Watson 
(2003).
Professor Alberto kaumann
MD (b. 1936) trained in medicine 
at the University of Buenos Aires, 
receiving his MD in 1961. He 
devoted his research to drug 
receptor pharmacology and cardiac 
arrhythmias. Between 1961 and 
1965 he carried out research at 
the Centro de Investigaciones 
Cardiologicas in Buenos Aires, 
finding that the β-blocker sotalol 
prevented ventricular fibrillation 
and death after coronary artery 
ligation through a mechanism 
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independent of blockage of 
β-adrenoceptors. From 1966 
to 1968 he was Instructor in 
Pharmacology at the Department 
of Pharmacology of Harvard 
University, discovering (with 
Camille Olson) that sotalol acted 
through a novel antiarrhythmic 
mechanism. From 1969 to 1971 
he was a Fellow and Research 
Associate at the Mayo Clinic 
(US), uncovering atypical agonist 
properties of some β-blockers, 
which culminated with the 
concept of a low-affinity site of 
the β1-adrenoceptor in 1999. He 
was an Assistant in Physiology 
at the University of Dusseldorf 
(1975–1985), and obtained an 
MD and Professorship, describing 
(with Horst Lemoine) a selective 
coupling of β2-adrenoceptors to 
Gs protein. After 1985 he worked 
in the UK as a scientist at Imperial 
Chemical Industries (1985–1986), 
SmithKline Beecham (1987–
1992), the Babraham Institute 
in Cambridge (1992–1999) and 
until 2012 in the Departments 
of Clinical Pharmacology and 
Physiology of the University of 
Cambridge.
Professor charles marsden
PhD DSc (b. 1943) read zoology 
at the University of London 
before going to Southampton 
University where he obtained an 
MSc in biochemical pharmacology 
(1967), a PhD in invertebrate 
neuropharmacology (1969) and a 
DSc in 1986. Following his PhD, 
he went to the University of Bergen 
(Norway) for three years (1969–
1972) before going to the Institute 
of Neurology, London to work 
with Professor Gerald Curzon.  In 
1978 he moved to the Department 
of Physiology and Pharmacology 
at the University of Nottingham, 
where in 1981 he obtained a 
Wellcome Trust Senior Lectureship 
and subsequently a Professorship in 
Neuropharmacology (1986).  From 
2002 to 2008 he was co-director 
of the Institute of Neuroscience 
at Nottingham. During this time 
he was President of the British 
Association of Psychopharmacology 
(2000–2002) and of the Serotonin 
Club (2008).  He was awarded 
the J R Vane medal by the 
British Pharmacological Society 
(2002) for his contribution to 
neuropharmacology. In 2012 he 
was made an honorary member of 
the Serotonin Club and in 2013 
was given a Life Time Achievement 
Award by the British Association 
for Psychopharmacology. 
mr Wesley miner
BSc (b. 1948) is a graduate in 
physiology from the University 
of Edinburgh.  From 1982 to 
1986 he worked at Beecham 
Pharmaceuticals (GlaxoSmithKline 
since 2000) with Gareth Sanger.  
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During this time, Miner and 
Sanger discovered, and were 
the first to publish that 5-HT
3
 
antagonists were extremely 
efficacious pharmacological 
agents for preventing and treating 
anti-cancer therapy (chemo and 
radiation) induced nausea and 
vomiting (Miner and Sanger 
(1986)). This seminal experimental 
work translated very well to the 
clinic when granisetron (Kytril) was 
shown to be highly efficacious in 
human patients (see Appendix 1).  
Importantly, this discovery became 
one of a very select few where 
research into 5-HT mechanisms 
actually culminated in a marketable 
drug that markedly improved 
the quality of life for patients.  
Following this groundbreaking 
research at Beecham, he relocated 
to another major international 
pharmaceutical company and 
became a key member of the 
biology team that discovered 
darifenacin (M3 selective 
antimuscarinic), which is now 
indicated and marketed for Over 
Active Bladder (OAB) and urinary 
incontinence. 
Professor robert naylor 
PhD DSc FRPharmS (b. 1943) 
graduated from Bradford in 
1967 and undertook a doctoral 
neuropharmacology research 
programme under the supervision 
of J E Olley. With Brenda Costall, 
he subsequently established the 
Bradford Neuropharmacology 
Research Group, becoming 
Lecturer, Senior Lecturer, Reader 
and Professor of Pharmacology, 
with a Personal Chair in 
Neuropharmacology and Head 
of the School of Pharmacy at 
Bradford. He investigated the 
functional role of brain dopamine 
systems in motor control and the 
detection of atypical antipsychotic 
drug action, and anti-Parkinson 
treatments. Concomitant 
investigations of the role of 5-HT 
in central and peripheral systems 
revealed the anti-emetic actions of 
the 5-HT
3
 receptor antagonists in 
animal models.
Dr irvine Page
PhD (1901–1991) trained in 
medicine at Cornell University. 
After carrying out research in 
physical chemistry in New York 
and at the Kaiser Wilhelm Institute 
in Munich, between 1931 and 
1937 he worked at the Rockefeller 
Institute in New York. In 1937 
he was appointed Director of the 
Laboratory for Clinical Research 
at the Eli Lilly Research Unit at 
the City Hospital in Indianapolis, 
IN, and in 1945 established a new 
Research Division at the Cleveland 
Clinic.  He remained chairman 
of the division until 1966 and 
Senior Consultant and Emeritus 
Consultant until 1978. As well 
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as his identification of 5-HT, he 
is remembered for his pioneering 
research into hypertension. See 
Gifford (1987); Frohlich, Dustan 
and Bumpus (1991).
Professor maurice rapport
PhD (1919–2011), studied 
chemistry at City College, New 
York and received his PhD in 
organic chemistry from California 
Institute of Technology in 1946. 
He then went to work with Irvine 
Page at the Cleveland Clinic. With 
Page and Arda Green, in 1948 
he isolated 5-HT and in 1949, 
determined its structure. Following 
research in Rome, Columbia, the 
Sloan-Ketting Institute for Cancer 
Research, New York, and the Albert 
Einstein College of Medicine, New 
York, in 1968 he was appointed 
to the New York Psychiatric 
Institute as Chief of Pharmacy 
and Professor of Biochemistry, 
and in 1969 established the 
division of neuroscience. He 
remained there until 1985 when 
he moved to the Albert Einstein 
College of Medicine, and retired 
in 1986. His research led to major 
contributions in cardiovascular 
disease, connective tissue diseases, 
cancer and demyelinating diseases.  
For further details, see his 
obituary in the New York Times, 
available online at www.nytimes.
com/2011/09/03/health/03rapport.
html (visited 16 July 2013). 
Professor gavin reynolds 
PhD (b. 1952) studied chemistry 
at the University of York and 
received a PhD in biochemistry 
from the University of London. 
His post-doctoral work in 
London and Vienna established 
his long-standing interests in the 
neurochemistry and pharmacology 
of schizophrenia and other 
neuropsychiatric disorders. He 
developed these research interests 
further while ‘brain-banking’ 
with the MRC in Cambridge 
and following an appointment 
in 1985 as Wellcome Lecturer at 
the University of Nottingham.  In 
1990 he moved to the University 
of Sheffield and in 2004 took 
up the Chair of Neuroscience at 
Queen’s University Belfast.  He 
is now Honorary Professor in the 
Biomedical Research Centre at 
Sheffield Hallam University and 
Professor Emeritus at Queen’s 
University Belfast. He was 
President of the British Association 
for Psychopharmacology (2008-
2010).   
Professor merton sandler
MD FRCP FRCPath FRCPsych 
(b. 1926) trained in medicine 
at Manchester University, and 
held various house and registrar 
jobs leading to a Lectureship in 
Chemical Pathology at the Royal 
Free Hospital Medical School. 
He was Professor of Chemical 
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Pathology, University of London, 
from 1973 to 1991. He was 
President of the British Association 
for Psychopharmacology 
(1980–1982). He has received 
various international honours 
and awards, including the CINP 
(Collegium Internationale 
Neuro-Psychopharmacologicum) 
Lifetime Award for contribution 
to monoamine studies in human 
health and disease. For an interview 
with Merton Sandler, see Healy 
(1996), pages 381–400.
Professor gareth sanger
PhD DSc FBPharmacolS (b. 
1953) received his BSc and PhD 
degrees in physiology from the 
Universities of Newcastle-upon-
Tyne and Manchester (1974 
and 1977), later returning to 
Manchester to be awarded his DSc 
in 1998.  He worked as a post-
doctoral fellow at King’s College 
Hospital Medical School, London, 
where he was among the first to 
examine the functions of some of 
the newly discovered prostanoids 
on the human isolated gut.  A 
move to industrial research led 
to his identification of a novel 
5-HT receptor-mediated function 
in the gut, later named by others 
as the 5-HT
4
 receptor.  Parallel 
research led to the identification 
of the role of the 5-HT
3
 receptor 
in the mechanisms of emesis 
and to new drugs to treat severe 
emesis, for which he was jointly 
awarded the 1998 Discoverers 
Award by the Pharmaceutical 
Research and Manufacturers 
of America (PhRMA).  Within 
industry he then explored several 
research areas, helped place 
several novel compounds into 
development, published more 
than 110 original research papers, 
served on editorial boards and 
taught on MSc courses (Palliative 
Medicine, Gastroenterology).  In 
2008 he was elected Fellow of the 
British Pharmacology Society and 
in 2009 he joined Queen Mary, 
University of London as Professor 
of Neuropharmacology within the 
Neurogastroenterology Group.  
His current research focus is on 
the use of human gastrointestinal 
tissues to undertake translational 
neuropharmacology and investigate 
functional changes during advanced 
age and different conditions 
associated with gastrointestinal 
neurodegeneration. His first paper 
won a ‘highly commended’ award 
from NC3Rs for promoting a 
culture shift in the use of human 
tissues for functional research.
Professor tilli tansey
PhD PhD DSc HonMRCP 
HonFRCP FMedSci (b. 1953) 
graduated in zoology from the 
University of Sheffield in 1974, 
and obtained her PhD in Octopus 
neurochemistry in 1978. She 
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worked as a neuroscientist in the 
Stazione Zoologica Naples, the 
Marine Laboratory in Plymouth, 
the MRC Brain Metabolism Unit 
Edinburgh, and was a Multiple 
Sclerosis Society Research Fellow 
at St Thomas’ Hospital, London 
(1983–1986). After a short 
sabbatical break at the Wellcome 
Institute for the History of 
Medicine (WIHM), she took a 
second PhD in medical history 
on the career of Sir Henry Dale, 
and became a member of the 
academic staff of the WIHM, later 
the Wellcome Trust Centre for the 
History of Medicine at UCL. She 
became Professor of the History 
of Modern Medical Sciences 
at UCL in 2007 and moved to 
Queen Mary, University of London 
(QMUL), with the same title, in 
2010. With the late Sir Christopher 
Booth she created the History 
of Twentieth Century Medicine 
Group in the early 1990s, now the 
History of Modern Biomedicine 
Research Group at QMUL.  
Dr mike tyers
PhD DSc (b. 1946) obtained his 
first degree in pharmacology at 
Chelsea College, London. His 
industrial career started at Allen 
& Hanburys Ltd, Ware, (now 
part of GlaxoSmithKline), where 
he undertook his PhD studies 
on nicotinic receptor blocking 
drugs under the supervision of the 
late Sir David Jack and Dr Roy 
Brittain. This early work included 
the discovery of fazadinium, a 
muscle relaxant that was used 
clinically for a few years. He later 
undertook research in the field 
of opioid, neurokinin and 5-HT 
receptors, aiming to identify novel 
analgesic drugs.  After several 
senior roles in Glaxo, he became 
Director of Pharmacology at 
Ware in 1992. Moving to new 
laboratories in Stevenage in 
1996, he then undertook a role 
as Group Director of Therapeutic 
Research, providing oversight of all 
therapeutic areas internationally.  
His greatest recognition came from 
the discovery of ondansetron, a  
5-HT
3
 receptor antagonist. His 
investigation of the functional 
role of 5-HT
3
 receptors led to 
early clinical studies in migraine, 
and emesis associated with 
cancer chemotherapy. In 1990 
ondansetron (Zofran) was launched 
as an anti-emetic And was awarded 
the European Prix Galien Award 
for best drug introduced that year, 
and in 1998, Mike was jointly 
awarded the Discoverers Award 
by the Pharmaceutical Research 
and Manufacturers of America 
(PhRMA)for his contribution 
to the launch of Zofran in the 
US. Also that year, together with 
colleagues, he was awarded the 
Royal Society Mullard Medal 
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in recognition of their work in 
the field of 5-HT therapeutics. 
He received a DSc in 1994 in 
recognition of his research into 
drug receptor subtypes.
Dr sydney udenfriend 
PhD (1918–1999) graduated in 
chemistry at City College, New 
York, in 1939 and then went on to 
receive his Master’s degree and his 
PhD in biochemistry from New 
York University in 1948. After 
post-doctoral studies, he joined 
Bernard Brodie at the National 
Heart Institute, Bethesda, in 1950, 
where he collaborated with Julius 
Axelrod and Al Sjoerdsma on 
malignant carcinoid. He set up a 
laboratory of clinical biochemistry 
focused on the biochemistry 
of 5-HT, biogenic amines and 
collagen biosynthesis. In 1968 he 
was appointed Founding Director 
of the Roche Institute of Molecular 
Biology, Nutley, New Jersey, 
where he developed a fluorescent 
technique for peptide and protein 
chemistry. He remained until the 
closure of the laboratory in 1996, 
afterwards becoming Director 
of the Charles A. Dana Research 
Institute for Scientists Emeriti at 
Drew University until 1999.  For 
full details of his research, see 
Weissbach and Witkop (2003).
Professor sir John Vane 
Kt DPhil DSc FRS (1927–2004), 
pharmacologist, discovered the role 
of prostaglandins in the human 
body in response to illness and 
stress and later demonstrated 
aspirin’s mechanism of action. He 
shared the 1982 Nobel Prize for 
Physiology or Medicine (with Sune 
Bergström and Bengt Samuelsson). 
A student in Professor J H Burn’s 
laboratory at the University 
of Oxford, he gained a BSc in 
pharmacology in 1949, followed by 
a DPhil with Dr Geoffrey Dawes at 
the Nuffield Institute for Medical 
Research, Oxford, and later 
held the Royal Society’s Stothert 
Research Fellowship. He was 
Assistant Professor of Pharmacology 
at Yale University, Newhaven, CT, 
from 1953 to 1955, moving to 
work with Professor Sir William 
Paton at the Royal College of 
Surgeons’ Institute of Basic Medical 
Sciences, London, in 1955, first 
as Senior Lecturer, Reader and 
as Professor from 1966 to 1973. 
He became Group Research and 
Development Director at the 
Wellcome Foundation, Beckenham, 
Kent, from 1973 to 1985, moving 
to the William Harvey Research 
Institute as Director in 1986 and 
Chairman from 1990 until his 
death. He was also Professor of 
Pharmacology and Medicine at 
the New York Medical College 
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(1986–2004). See Moncada 
(2006). See also http://nobelprize.
org/medicine/laureates/1982/
vane-autobio.html (visited 24 July 
2013).
Professor David Wallis
PhD HonFBPharmacolS (b. 
1934) trained as a zoologist at the 
University of Cambridge, and was a 
Research Fellow at the University of 
Pennsylvania, Philadelphia (1959–
1961) and in the department 
of Physiology, University 
of Aberdeen (1961–1967), 
working with Hans Kosterlitz 
and Gordon Lees. In 1967 he 
moved to Cardiff with main 
interests in neuropharmacology 
and neurophysiology. He was 
on the editorial board of the 
British Journal of Pharmacology 
(1982–1988) and was Chairman 
of the British Pharmacological 
Society committee. He is Emeritus 
Professor of Physiology at Cardiff 
University.
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